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O-001
The Expression of Estrogen Receptor-, Progesterone Recep-
tor, HER-2, Aromatase and Epidermal Growth Factor Receptor
Mutation in Postoperative Non-Small Cell Lung Cancer
Si-Yu Wang, Hai-Bo Sun, Wei Ou, Qin Fang, Peng Li Department of
Thoracic Surgery, Cancer Center , Sun Yet-Sen University, China
Introduction: The aim of this study was to investigate the correlation
between estrogen receptor- (ER-), progesterone receptor (PR), HER-2 and
aromatase expression and clinicophathologic factors and EGFR mutations in
non small cell lung cancer (NSCLC).
Methods:We evaluated 316 resected NSCLC specimens for ER, PR, HER-2
and aromatase (n272) expression using immunohistochemistry. EGFR
mutations were evaluated with TaqMan polymerase chain reaction (PCR).
Results: ER- and PR were detected in the nuclei of 36.1% and 45.0% of all
patients respectively. Aromatase was detected in the cytoplasm of 64.0% of
patients. We did not detect significant HER-2 expression. Only 24 (7.6%) of
tumors exhibited weak, incomplete HER-2 staining (1). ER- expression
was significantly associated with female gender (P.004) and smaller
diameter (3cm) of the tumor (P.001). The expression of PR was signif-
icantly associated with N status, pathologic stage, differentiation of the tumor
and menstruation status (P.008 to .032). ER- expression showed a
positive correlation with PR (r.275, P.001), HER-2 (r.183, P.001),
and aromatase (r.244, P.001) expression levels. EGFR mutation was
independently associated with the female gender (odds ratio [OR]2.975;
95% CI, 1.550 to 5.721; P.001), negative expression of PR (OR3.906;
95% CI, 1.996 to 7.692; P.001) and negative expression of aromatase
(OR2.092; 95% CI, 1.089 to 4.016; P.027).
Conclusion: The expression of ER- and PR distinguish a subset of NSCLC
that has defined clinicopathologic features. Negative expression of PR and
aromatase correlate with EGFR mutation.
O-002
Which Is Superior Prognostic Factor of Total Number or Ana-
tomical Location of Involved Lymph-Nodes (LNS) in Non-Small
Cell Lung Cancer (NSCLC)? : A Single Institutional Analysis
Hisashi Saji1, Tatsuya Inoue1, Gaku Yamaguchi1, Masaharu Nomura2, Ma-
satoshi Kakihana1, Jistuo Usuda1, Masahiro Kajiwara1, Osamu Uchida1,
Tatsuo Ohira1, Norihiko Ikeda1 1Department of Thoracic Surgery, Tokyo
Medical University, Japan, 2Department of Pathology, Tokyo Medical Uni-
versity, Japan
Introduction: Total number of involved lymph-nodes (LNs) has superior to
proven prognosis in colorectal, head & neck and bladder cancer compared
with anatomical location of involved LNs. We previously reported survival
impact of total number of resected and involved LNs on NSCLC
(ASCO2009, #7514). We analyzed which is more reliable prognostic factor
of total number or anatomical location of involved LNs in NSCLC.
Methods: A series of 928 consecutive NSCLC pts who underwent complete
resection at least lobectomy with systematic nodal dissection at Tokyo
Medical University (2000-2007) was eligible. Log rank and Cox proportional
hazard model was used to estimate survival rates and relative risks.
Results: Pts demographics are as follows: median age: 65.0, sex: 547 males and
381 females, median follow-up time: 3.5 yrs, c-stage: 765 I, 84 II and 76 III,
histology: 684 adenocarcinoma, 182 squamous cell carcinoma, and 62 others,
mean number of resected LNs: 15 (1-49), mean number of involved LNs: 0.9
(0-22). We observed a statistically significant increasing trend in overall survival
(OS) between 0-3 and 4 and more of number of involved LNs (P0.001). Four
and more number of involved LNs in only pN1 Pts (n13) are trend to worse
prognosis than 0-3 involved LNs in pN2 Pts (n27) (P0.1).
Conclusion: Total number of involved LNs might prefer to demonstrate
prognosis of NSCLC compared with anatomical location of involved LNs in
our series. Further validation study using different series is warrant.
O-003
Wnt1/-catenin Expression Is an Independent Poor Prognostic
Marker of Non-Small Cell Lung Cancer after Surgery
Xianhua Xu1, Ping-Li Sun2, Sanghoon Jheon2, Choon-Taek Lee3, Jin-Haeng
Chung1 1Department of Pathology, Seoul National University Bundang Hos-
pital, Seoul National University College of Medicine, Republic of Korea,
2Department of Thoracic and Cardiovascular Surgery, Seoul National Univer-
sity Bundang Hospital, Seoul National University College of Medicine, Republic
of Korea, 3Department of Internal Medicine, Seoul National University Bundang
Hospital, Seoul National University College of Medicine, Republic of Korea
Introduction:Wnt signaling pathway plays a major role in development and
is involved in cancer development. As a novel anticancer drug can be
developed using inhibitors of this pathway, we investigated Wnt signaling
pathway molecules in non-small-cell lung cancer (NSCLC).
Methods: Immunohistochemical analysis of a tissue microarray (TMA) with
262 resected NSCLC specimens was performed to study the expression and
subcellular localization of Wnt1 in relation to downstream molecules includ-
ing GSK3, -catenin, Cyclin D1, c-Myc and p53. These results were
correlated with other clinicopathologic features.
Results: Cytoplasmic Wnt1 expression was detected in 36.6% (96/262)
NSCLC and significantly associated with adenocarcinoma (ADC) histology
(p0.001). The majority of tumors retained some degree of -catenin
membranous staining, whereas decreased membranous expression and al-
tered cytoplasmic or nuclear expression were identified in 76% (199/262) of
NSCLC.There were significant association between Wnt1 expression and
altered expression of -catenin (p0.034), overexpression of c-Myc
(p0.001) or Cyclin D1 (p0.018). While there was no significant associ-
ation between Wnt1 or -catenin and stage, the 5-year survival was signif-
icantly lower in patients with Wnt1 and -catenin positive NSCLCs than
negative NSCLCs (p0.05, respectively). In multivariate analysis, stage and
Wnt1/ -cateninexpression were independently predictive of overall
survival (p0.001 and p0.010 respectively).
Conclusion: These findings support that Wnt1 overexpression is a possible
mechanism of the activation of canonical Wnt/-catenin signaling pathway
in NSCLC, and Wnt1 and altered -catenin expression are poor prognostic
markers independent of stage.
O-004
Use of Peptide Nucleic Acid (PNA)-Mediated PCR Clamping
Based Method for Detection EGFR Mutation in Patients with
Non-Small Cell Lung Cancer
Kye Young Lee1, Hee Joung Kim1, Young-Chul Kim2, Kyu-Sik Kim2, Sung
Yong Lee3, Tae Won Jang4, Min Ki Lee5, Kyeong-Cheol Shin6, Gwan Ho
Lee6, Jae Chol Lee7, Jeong Eun Lee8, Sun Young Kim8 1Department of
Internal Medicine, Konkuk University School of Medicine, Republic of
Korea, 2Department of Internal Medicine, Chonnam National University
Medical School, Hwasun Hospital, Republic of Korea, 3Department of
Internal Medicine, Guro Hospital, Korea University Medical School, Repub-
lic of Korea, 4Department of Internal Medicine, Kosin University Medical
College, Republic of Korea, 5Department of Internal Medicine, Pusan
National University College of Medicine, Republic of Korea, 6Department of
Internal Medicine, Yeungnam University College of Medicine, Republic of
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Korea, 7Department of Internal Medicine, Korea Cancer Center Hospital,
Republic of Korea, 8Department of Internal Medicine, Choongnam National
University Hospital and Cancer Research Institute, Republic of Korea
Introduction: Although the gold standard method for research trials for
EGFR mutations has been direct sequencing, this approach is expensive and
time-consuming. Low sensitivity is often concerned in clinical setting. The
aim of this study was to develop a simple and sensitive method for screening
of EGFR mutations.
Methods: Clinical specimens from 188 NSCLC patients were analyzed for
EGFR mutations in exons 18, 19, 20 and 21. All clinical data and tumor
specimens were obtained from 8 centers of Korean Molecular Lung Cancer
Group (KMLCG). After genomic DNA extracted from paraffin-embedded
tissue specimens, both PNA-mediated PCR clamping and direct sequencing
were performed. The results and clinical response to EGFR-TKIs were
compared.
Results: Sequencing revealed a total of 35 (22.9 %) mutations: 8 missense
mutations in exon 21 and 26 deletion mutations in exon 19. PNA-mediated
PCR clamping showed the presence of genomic alterations in 45 (28.3%)
samples, including the 32 identified by sequencing plus 13 additional
samples (6 in exon 19 and 7 in exon 21).
Conclusion: PNA-mediated PCR clamping is a simple and rapid, as well as
a more sensitive method for screening of genomic alterations in EGFR gene
compared to direct sequencing. This data suggests that PNA-mediated PCR
clamping should be implemented as a useful screening tool for detection of
EGFR mutations in clinical setting.
NON-SMALL-CELL LUNG CANCER –
ADVANCED DISEASE
O-005
A Phase II Study of S-1 (S) Plus Cisplatin (P) with Concurrent
Thoracic Radiotherapy (TRT) for Locally Advanced Non-Small
Cell Lung Cancer (LA-NSCLC): West Japan Oncology Group
(WJOG) 3706 Trial
Nobuyuki Katakami1, Masaki Kokubo1, Toshiyuki Sawa2, Masahiro
Tanaka3, Takashi Seto4, Tomonari Sasaki5, Takeharu Yamanaka6, Yukito
Ichinose4, Yasumasa Nishimura7, Kazuhiko Nakagawa8 1Department of
Integrated Oncology, Institute of Biomedical Research and Innovation,
Japan, 2Department of Pulmonary Medicine, Gifu City Hospital, Japan,
3Department of Clinical Oncology, Osaka City General Hospital, Japan,
4Department of Thoracic Oncology, National Kyusyu Cancer Center, Japan,
5Department of Pulmonary Medicine, University of Kumamoto School of
Medicine, Japan, 6Department of Clinical Trial, National Kyusyu Cancer
Center, Japan, 7Department of Radiation Oncology, Kinki University School
of Medicine, Japan, 8Department of Medical Oncology, Kinki University
School of Medicine, Japan
Introduction: Standard treatment of LA-NSCLC is platinum-based chemo-
therapy with concurrent TRT. S is an oral 5-FU derivative which has shown
promising efficacy in combination with P for advanced NSCLC and produces
synergistic effect with radiation.
Methods: Pts with stage III NSCLC, 20-74 years in age, PS 0-1, and no prior
chemotherapy were eligible. Chemotherapy consisted of P, 60 mg/m2, day 1 and
S, 40 mg/m2/dose b.i.d., days 1-14, every 4 weeks for 2 cycles. Beginning on day
1, TRT (60 Gy/30 fractions over 6 weeks) was delivered. After chemoradio-
therapy, pts received 2 cycles of same chemotherapy. The primary endpoint was
objective response rate (ORR) and the planned sample size was 55 based on
exact binomial test (P060%, P180%, 0.025, 0.1).
Results: of 55 pts registered from 18 centers between Nov 2006 and Dec
2007, 50 were evaluable for efficacy analysis. The median age was 64;
male/female: 40/10; PS 0/1: 21/29; clinical stage IIIA/IIIB 26/24; and
histology ad/sq/others: 20/24/6. The median progression-free survival was 20
months and the median overall survival was 37 months. The 1- and 2-year
overall survival rates were 88% (95%CI, 75–94%) and 70% (95%CI,
55–81%), respectively. Common toxicities included grade 3/4 neutropenia
(30%), grade 3/4 anemia (20%), grade 3/4 thrombocytopenia (13%), grade
3/4 febrile neutropenia (9%), and grade 3 esophagitis (9%). Grade 3 pneu-
monitis was observed in one patient. Two treatment-related deaths were
reported.
Conclusion: Chemoradiotherapy of S plus P with concurrent TRT is en-
couraging for LA-NCSLC with acceptable toxicity.
O-006
A Randomized Trial of 1st Line Docetaxel and Cisplatin at 75/60
Vs 60/60 mg/m2 for Patients with Stage IIIB or IV Non-Small
Cell Lung Cancer
Young-Chul Kim1, Kyu-Sik Kim1, In-Jae Oh1, Hee-Jung Ban1, Sang-Yun
Song1, Manaljav Ish Tesden2, Kook-Joo Na1, Sung-Ja Ahn1, Song Choi1,
Yoo-Duk Choi1 1Department of Medicine, Chonnam National University
Hwasun Hospital, Republic of Korea, 2Department of The Brain Korea 21
Project, Center for Biomedical Human Resources, Chonnam National Uni-
versity, Republic of Korea
Introduction: The primary objective of this study was to compare response
rates between two different dosages of docetaxel(D), in other words, to test
whether the response rate of D 60mg/m2 is non-inferior to D 75mg/m2 in
combination with Cisplatin(P, 60mg/m2) as a first line treatment for NSCLC.
Methods: Patients were stratified according to ECOG PS 0,1 vs 2, weight
loss in the previous 6 months5% vs5% and Stage IIIB vs IV or Relapsed.
The non-inferiority margin was set at -15%. A total of 264 patients was
required to provide the study with 80% power with a 5% type 1 one-sided
error rate. Secondary objectives included time to progression and safety.
Results: 132 patients were enrolled. After a pre-planned interim analysis,
this study was closed early as it met primary end point. The patients were
randomly assigned to 75/60 (n65) or to 60/60 (n67). Response rates were
38.5% in 75/60 group and 40.3% in 60/60 group. The 95% CI for the
difference in response rate was -14.9%18.5%. There was no significant
difference in number of cycles (3.42 vs. 3.57), time to progression (4.9 vs.
4.7m) between the two groups. However, the dose reduction rate (53.8% vs
22.4% p0.01), incidences of grade 3-4 leukopenia and neutropenia were
significantly higher in 75/60 compared to 60/60 group.
Conclusion: We conclude that D 60mg/m2 in combination with P 60mg/m2
was non-inferior to D 75mg/m2 with P 60mg/m2 in response rate and time
to progression, while providing patients with a better safety profile in Korean
population.
O-007
Changes in Pulmonary Function in Patients with Lung Cancer
Receiving Chemotherapy
Jick-Hwan Ha, Chin-Kook Rhee, Ji-Young Kang, Hyeon-Hui Kang, Sung-
Kyoung Kim, Sang-Haak Lee, Hwa-Sik Moon Department of Internal
Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, De-
partment of Internal Medicine, The Catholic University of Korea, Republic
of Korea
Introduction: Chemotherapy for lung cancer may affect directly to lung
function. However, there have been only few studies for pulmonary function
of lung cancer patients who received chemotherapy.
Methods: A retrospective review of a prospective database of patients with
non–small cell lung cancer(NSCLC) who underwent chemotherapy and had
pulmonary function tests(PFT) was performed. Pulmonary function has been
evaluated with spirometry, lung volume and diffusing capacity of the lung
for carbon monoxide(DLCO).
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Results: Fifty-seven patients were eligible for analysis. They underwent total
317 cycles of chemotherapy and 173 PFTs. Chemotherapy regimens in-
cluded gemcitabine/cisplatin(27 cycles), gemcitabine/carboplatin(166 cy-
cles), gemcitabine alone(6 cycles), docetaxel/cisplatin(3 cycles), docetaxel/
carboplatin(28 cycles), docetaxel alone(1 cycle), paclitaxel/carboplatin(13
cycles) and other others(73 cycles). There were no significant differences in
spirometry, lung volume. However, DLCO decreased by 7.979%(P0.001)
after chemotherapy. No statistically significant differences were found be-
tween taxane and gemcitabine-based chemotherapy. Patients who underwent
combination chemotherapy with platinum showed greater reduction in
DLCO than taxane or gemcitabine alone(P0.05).
Conclusion: A decline of DLCO is evident in patients with NSCLC
receiving chemotherapy. Combination of chemotherapy with platinum may
exacerbate decline of DLCO.
O-008
Efficacy of Pemetrexed Maintenance in East-Asian Patients:
Subgroup Analysis of a Phase III Study Comparing Pemetrexed
versus Placebo in Non-Small Cell Lung Cancer (NSCLC) Fol-
lowing Platinum-Based Induction Chemotherapy
Chandra P Belani1, Yi-Long Wu2, Yuh-Min Chen3, Joo-Hang Kim4, Sung-
Hyun Yang5, Li Zhang6, Patrick Peterson7, Mauro Orlando8 1Department of
Penn State Hershey Cancer Institute, Penn State College of Medicine, United
States of America, 2Department of Guangdong Lung Cancer Institute,
Guangdong General Hospital, Guangdong Academy of Medical Sciences,
China, 3Department of Chest, Taipei Veterans General Hospital, School of
Medicine, National Yang-Ming University, Taiwan, China, 4Department of
Yonsei Cancer Center, Yonsei University Health System, Republic of Korea,
5Department of Hemato-Oncology, Korea Cancer Center Hospital, Republic
of Korea, 6Department of Medical Oncology Cancer Center, Sun Yat-Sen
University, Guangzhou, China, 7Department of Corporate Center, Eli Lilly
& Co, United States of America, 8Department of Medical, Eli Lilly Inter-
ame´rica Inc., Buenos Aires, Argentina
Introduction: Pemetrexed maintenance therapy prolonged progression-free
survival (PFS) and overall survival (OS) for patients with advanced NSCLC,
with greater benefit in patients with non-squamous histology, according to a
study by Ciuleanu and colleagues (2009) in the Lancet. East-Asian ethnicity
is a recognized favorable prognostic factor in NSCLC treatment. This subset
analysis describes characteristics of East-Asian patients enrolled in the study
and assessed efficacy outcomes according to histology.
Methods: This retrospective analysis of a global phase III study compares
patient outcomes from East- Asians (Korean, Chinese and Taiwanese) to
Non-East Asians. For PFS and OS, a Cox model was used to estimate hazard
ratios and 95% confidence intervals (CI). Medians were estimated using the
Kaplan-Meier method.
Results: In total, 663 patients were enrolled; 481 had non-squamous histol-
ogy (129 East-Asians, 352 Non-East Asians). There were more females and
never-smokers among East-Asians, but other baseline characteristics were
similar in both subgroups. The Median PFS (95%CI) was significantly
greater with premetrexed versus placebo treatment (4.1 [2.9-5.7] versus 1.8
[1.5-3.0] months; hazard ratio [95%CI]0.54 [0.35-0.83]; p.004) in East-
Asian non-squamous NSCLC patients, consistent with non-East Asian pa-
tient results. The OS numerical trend was also consistent between the
subgroups (19.7 vs 16.4 months). No statistical differences between pem-
etrexed and placebo in grade 3 or 4 toxicities or serious adverse events were
reported in East-Asian patients.
Conclusion: This analysis indicates improved efficacy outcomes and toler-
ability for advanced, non-squamous NSCLC East-Asian patients treated with
maintenance pemetrexed compared to placebo, consistent with previous
global population observations.
O-009
Expression of the MAGE-A3 Gene in Tumors from Stage IB-
IIIA Non-Small Cell Lung Cancer Patients: Preliminary Results
of the Eligibility Screening of Patients for the MAGRIT Trial
Joo-Hang Kim1, Byoung Chul Cho1, Oleg Gladkov2, Sebastian Gallen-
berger3, Erich Stoelben4, Melanie Mackean5, Haruhiko Kondo6, Tatsuo
Ohira7, Aung Myo8, Channa Debruyne9, Debois Muriel9, Chih-Yi Chen10
1Department of Internal Medicine, Yonsei Cancer Center, Yonsei University
College of Medicine, Seoul, Republic of Korea, 2Department of Oncology,
Chelyabinsk Regional Clinical Oncology Center, Russian Federation, 3De-
partment of Oncology, Medizinische Hochschule, Hannover, Germany, 4De-
partment of Oncology, Metropolitan Hospital of Cologne, Germany, 5De-
partment of Oncology, Edinburgh Cancer Centre, United Kingdom,
6Department of Oncology, Shizuoka Cancer Center, Japan, 7Department of
Thoracic Surgery, Tokyo Medical University, Japan, 8Department of Oncol-
ogy, Glaxosmithkline Biologicals, Singapore, 9Department of Clinical On-
cology, Glaxosmithkline Biologicals, Belgium, 10Department of Cancer Cen-
ter, China Medical University Hospital, Taiwan, China
Introduction: The MAGE-A3 Antigen-Specific Cancer Immunotherapeutic
(ASCI) combines the recombinant tumor-specific antigen MAGE-A3 with a
potent immunostimulant AS15. Clinical activity was reported in two proof-
of-concept studies in metastatic melanoma and Non-Small Cell Lung Cancer
(NSCLC), the MAGE-A3 ASCI is now under investigation as adjuvant
treatment for patients with completely resected MAGE-A3 positive stage IB,
II, IIIA NSCLC.
Methods: Formalin Fixed Paraffin-Embedded (FFPE) tumor tissue from
surgical samples is tested for MAGE-A3 expression by quantitative Reverse
Transcription Polymerase Chain Reaction (RT-PCR).
Results: 34% of the 5737 NSCLC valid tumor samples expressed the
MAGE-A3 gene (on APR 14, 2010). The expression of the MAGE-A3 gene
does not seem related to tumor stage (34% in stage IB, 36% in stage II and
33% in stage IIIA) but rather to histology (squamous cell carcinoma 48%
versus adenocarcinoma 24%). In adenocarcinoma, MAGE-A3 expression is
related to primary tumor size (20% when  3 cm, 24% when3 cm to 5 cm
and 34% when5 cm). MAGE-A3 gene expression is less frequent in
females (27% vs 37% in males) and in East Asian population (28% vs 35%
in other populations)
Conclusion: MAGE-A3 expression is 34% in stage IB-IIIA NSCLC. The
MAGE-A3 expression appears similar in stage IB, II, IIIA, but higher in
males and squamous cell carcinoma. It is less frequent in East Asian
population, in females and in small adenocarcinoma tumors.
O-010
First-Line Erlotinib vs Gemcitabine/Carboplatin (GC) in Acti-
vating EGFRMutation-Positive Advanced Non-Small Cell Lung
Cancer (NSCLC): Efficacy and Safety Results from Phase III
OPTIMAL Study in Chinese Patients (pts)
Chang-Li Wang1, Caicun Zhou2, Yi-Long Wu3, Shun Lu4, Li Zhang5,
Yiping Zhang6, Ming Ye7, Jun Ma8, Jianan Huang9, Quingyu Xiu10 1De-
partment of Medical Oncology, Tianjin Cancer Hospital, China, 2Depart-
ment of Oncology, Shanghai Pulmonary Hospital, China, 3Department of
Lung Cancer, Guangdung General Hospital, China, 4Department of Lung
Cancer, Shanghai Lung Cancer Center, China, 5Department of Medical
Oncology, Cancer Center of Sun Yat-Sen University, China, 6Department of
Lung Cancer, Zhejiang Cancer Hospital, China, 7Department of Medical
Oncology, Renji Hospital, Affiliated to Shanghai Jiao Tong University
School of Medicine, Shanghai, China, 8Department of Medical Oncology,
Harbin Institute of Hematology and Oncology, China, 9Department of
Medical Oncology, The First Affiliated Hospital of Suzhou University, China,
10Department of Lung Cancer, Changzhen Hospital, The Second Military
Medical University, Shanghai, China
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Introduction: Epidermal growth factor receptor tyrosine-kinase inhibitors
(EGFR TKIs) such as erlotinib are particularly effective in NSCLC pts
whose tumours have activating EGFR mutations (mut). OPTIMAL is a
prospective phase III study evaluating first-line erlotinib vs GC in Chinese
pts with advanced mutNSCLC.
Methods: Eligibility criteria included: untreated, measurable advanced
NSCLC; ECOG PS 0–2, confirmed mutations in exon 19 or 21 of EGFR. Pts
were randomised (1:1; no cross-over) to receive erlotinib (150mg/d) or
gemcitabine (1000mg/m2, d1d8) plus carboplatin (AUC5, d1), q3w for
up to 4 cycles, until progression or unacceptable toxicity. The primary
endpoint was progression-free survival (PFS); secondary endpoints included
overall survival (OS), safety, quality of life, and additional biomarker
analyses.
Results: 549 pts were screened; 186 had activating EGFR mutdisease, of
whom 165 were randomised to erlotinib (n83) or GC (n82). No unex-
pected adverse events (AEs) were reported in either arm (n155). Overall,
treatment-related AEs and serious AEs (all grades) were lower with erlotinib
(n83; 79.5% & 2.4%, respectively) vs GC (n72; 94.4% & 13.9%,
respectively). Considerably lower incidences of haematological AEs (all
grades) were seen with erlotinib vs GC. As expected, treatment-related rash
and diarrhoea were more common with erlotinib vs GC (rash 67.5% vs
19.4%; diarrhoea 24.1% vs 2.8%, respectively), but most events were grade
2. No interstitial lung disease-like events were observed. Full efficacy
analyses will be presented.
Conclusion: First-line erlotinib (150mg/d) has a favourable safety profile vs
chemotherapy in pts with advanced mutNSCLC; efficacy outcomes will be
assessed.
O-011
Gemcitabine/CisplatinSorafenib for the First-Line Treatment
of Chemonaive Chinese Patients with Advanced, Nonsquamous
Non–Small Cell Lung Cancer (NSCLC): Subgroup Analysis of
the Phase III NExUS Trial
Meilin Liao1, Li Zhang2, Yan Sun3, Shiying Yu4, Hongming Pan5, Caicun
Zhou6, Anastasia Jiang7, Elaine Montegriffo8, Teng Jin Ong9, Ulrich Gatze-
meier10 1Department of Pulmonary Oncology, Clinical Medical Centre of
Lung Tumor, Shanghai Chest Hospital, China, 2Department of Oncology,
Sun Yat-Sen University Cancer Center, China, 3Department of Oncology,
Tongji Hospital, China, 4Department of Oncology, Tongji Hospital, China,
5Department of Oncology, Sir Run Run Shaw Hospital, China, 6Department
of Oncology, Pulmonary Hospital, China, 7Department of Medical Affairs,
Oncology, Bayer Healthcare, China, 8Department of Biostatistics, Bayer
Schering Pharma, United Kingdom, 9Department of Global Clinical Devel-
opment, Bayer Healthcare, United States of America, 10Department of
Thoracic Oncology, Hospital Grosshansdorf, Germany
Introduction: The phase III multinational, randomized, double-blind, placebo-
controlled NSCLC Research Experience Utilizing Sorafenib (NExUS) study
evaluated gemcitabine/cisplatinsorafenib in a large sample of patients with
Stage IIIB/IV, nonsquamous NCSLC who had at least one measurable lesion.
Given the high prevalence of NSCLC and NSCLC-related mortality in the AP
region and the heightened need for effective therapy in this population, we
performed an exploratory analysis of NExUS data in a subset of patients from
China to evaluate whether any differences in outcome occurred in this subgroup
and to explore potential reasons for the observations.
Methods: Baseline and demographic characteristics were summarized for
the Chinese cohort by treatment group for all randomized patients with
nonsquamous NSCLC. Exploratory assessments in the Chinese subpopula-
tion included overall survival (OS), progression-free survival (PFS), and
safety. The primary population for efficacy analysis was the intent-to-treat
(ITT) population, which was defined as all randomized patients with
nonsquamous histology. Tumor response and disease progression were
evaluated based on RECIST. For the subset analysis of efficacy, the two
treatment groups were compared using a stratified log-rank test with one-
sided alpha of 0.025. All patients who received at least one dose of study
drug were included in the safety analysis. Adverse events were graded
according to NCI CTCAE version 3.0.
Results: The NExUS Chinese subpopulation was comprised of 185 random-
ized non-squamous patients, 93 of whom were treated with sorafenib and 92
of whom received placebo.
Conclusion: Data will be presented.
O-012
Randomized Phase III Study of Carboplatin Plus S-1 Compared
with Carboplatin Plus Paclitaxel as First-Line Treatment in
Advanced Non-Small-Cell Lung Cancer (WJTOG3605)
Chiyoe Kitagawa1, Satoshi Morita2, Hiroshige Yoshioka3, Koji Takedea4,
Fumihiko Hirai5, Nobuyuki Yamamoto6, Masahiko Ando7, Isamu Oka-
moto8, Masahiro Fukuoka9, Kazuhiko Nakagawa10 1Department of Medical
Oncology, National Hospital Organization Nagoya Medical Center, Japan,
2Department of Biostatistics and Epidemiology, Yokohama City University,
Japan, 3Department of Respiratory Medicine, Kurashiki Central Hospital,
Japan, 4Department of Clinical Oncology, Osaka City General Hospital,
Japan, 5Department of Thoracic Oncology, National Kyushu Cancer Center,
Japan, 6Department of Thoracic Oncology, Shizuoka Cancer Center, Japan,
7Department of Preventive Services, Kyoto University School of Public
Health, Japan, 8Department of Medical Oncology, Kinki University School
of Medicine, Japan, 9Department of Medical Oncology, Izumi Municipal
Hospital, Japan, 10Department of Medical Oncology, Kinki University Fac-
ulty of Medicine, Japan
Introduction: S-1 is an oral fluorinated pyrimidine conjugate. Single-agent
S-1 and Phase II studies of S-1 plus platinum compounds have shown
promising activities in advanced NSCLC.
Methods: Chemotherapy-naı¨ve patients with advanced (IIIB/ IV) NSCLC,
ECOG PS of 0-1, and adequate organ functions were randomly assigned to
either carboplatin AUC 5 mg/ml/min on day 1 plus oral S-1 80 mg/m2/day
on days 1 to 14 or carboplatin AUC 6 mg/ml/min plus paclitaxel 200 mg/m2
on day 1 every 21 days. The primary endpoint was to compare overall
survival to demonstrate noninferiority of carboplatin/S-1 (CbS) relative to
carboplatin/paclitaxel (CbP); secondary endpoints included progression-free
survival (PFS), response rate, safety, and quality of life.
Results: 563 eligible patients were enrolled from August 2006 to May 2008.
Demographic factors were well balanced. At the interim analysis, with 61%
of events available, the study passed the O’Brien-Fleming boundary at 0.006
for positive results, and noninferiority of CbS compared with CbP was
confirmed for overall survival (hazard ratio [HR], 0.928; 95% CI, 0.730 to
1.179, meeting the predefined criterion [upper CI limit for HR1.33];
median survival 15.3 vs 13.3 months). There was no significant difference in
PFS (CbS, 4.1 months; CbP, 4.8 months; P0.998). For CbS, grade 3/4
leukopenia, neutropenia, and febrile neutropenia (P.001) were significantly
lower, whereas grade 3/4 thrombocytopenia (P.001) was more common.
Nonhematologic toxicities were acceptable.
Conclusion: Oral S-1 with carboplatin provides similar efficacy but better
tolerability and more convenient administration than carboplatin/paclitaxel
as a first-line treatment for advanced NSCLC.
O-013
Randomized, Double-Blind, Placebo-Controlled Phase II Study
of Vandetanib Maintenance for Advanced or Metastatic Non-
Small-Cell Lung Cancer (NSCLC) Following 1st-Line Platinum-
Doublet Chemotherapy
Myung-Ju Ahn1, Keunchil Park1, Jin Seok Ahn1, Eun Kyung Cho2, Gyeong
Won Lee4, Jin-Hyoung Kang5, Sang-We Kim3, Dae Ho Lee3, Jong-Seok
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Introduction: Vandetanib (VAN) is a once-daily oral inhibitor of VEGFR,
EGFR and RET signaling. Several studies have shown the efficacy and
tolerability of vandetanib in NSCLC. This study assessed VAN maintenance
therapy in NSCLC.
Methods: Patients (Pts) who had not progressed after 4 cycles of platinum-
based chemotherapy were randomized to VAN 300 mg/day or placebo (P).
The primary endpoint was to evaluate progression-free survival (PFS) at 3
months. An interim analysis was conducted upon accrual of 24 pts in each
arm evaluable for PFS. The primary analysis at 3 months was planned if 63
evaluable pts were enrolled.
Results: A total of 79 pts were randomized to VAN (39) or P (42). Following
the interim analysis, 37 more pts were assigned to the VAN arm. The
intention-to-treat (ITT) analysis comprised 117 pts (75, VAN; 42, P).The
median duration of follow-up was 5.9 months. The interim analysis showed
that PFS at 3 months was 30% with P (29%) leading this arm to be stopped;
PFS at 3 months with VAN was 37.5%, allowing this arm to proceed to the
second stage. The ITT analysis showed 37.3% of pts in the VAN arm
achieved PFS at 3 months. Overall, the most common adverse events in pts
receiving VAN were rash (12% grade 3/4), diarrhoea, pruritus, and anorexia.
Conclusion: In this study of pts with advanced NSCLC, VAN maintenance
therapy demonstrated 37% PFS at 3 months with acceptable toxicities. Based
on these results, VAN maintenance therapy should be considered for further
study.
O-014
Risk of Pneumonectomy or Bilobectomy after Neoadjuvant
Concurrent Chemoradiotherapy for Stage IIIA-N2 Non-Small
Cell Lung Cancer
Jong Ho Cho1, Yong Soo Choi1, Young Mog Shim1, Kwhanmien Kim1,
Jhingook Kim1, Keunchil Park3, Yong Chan Ahn2 1Department of Thoracic
Surgery, Samsung Medical Center, Sungkyunkwan University School of
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Introduction: The role of surgical resection in patients with stage IIIA-N2
non-small cell lung cancer is controversial. The aim of this study was to
evaluate the outcomes of surgical resection, especially bilobectomy and
pneumonectomy, after chemoradiation therapy.
Methods: Retrospective analyses were performed of all patients who under-
went surgical resection after neoadjuvant chemoradiation therapy for stage
IIIA-N2 non-small cell lung cancer from 1998 to 2007. The chemotherapy
regimens consisted of weekly paclitaxel plus cisplatin or weekly paclitaxel
plus carboplatin for 5 weeks. Concurrent thoracic radiotherapy dose was 45
Gy over 5 weeks. Surgical resection was planned at around 4 weeks
following the completion of neoadjuvant therapy.
Results: of 186 patients who underwent neoadjuvant therapy, 28 pneumo-
nectomies, 23 bilobectomies, and 135 lobectomies were performed. Early
postoperative mortality rate (within 30 days after operation) was 7.1%, 8.7%,
and 1.5% in pneumonectomy, bilobectomy, and lobectomy, respectively.
The 5-year overall survival rate was 25%, 25%, and 43% after pneumonec-
tomy, bilobectomy, and lobectomy, respectively. The 5-year disease-free
survival rate was 18%, 21%, and 30% after pneumonecromy, bilobectomy,
and lobectomy, respectively. The 5-year overall survival rate were higher in
lobectomy than in pneumonectomy (p0.0251) and bilobectomy
(p0.0409), but there was no statistical difference between pneumonectomy
and bilobectomy (p0.9092). The 5-year disease-free survival rate were
higher in lobectomy than in pneumonectomy (p0.0337) but there were no
statistical differences between pneumonectomy and bilobectomy (p0.5401)
or between lobectomy and bilobectomy (p0.2363).
Conclusion: Pneumonectomy or bilobectomy carries high operative mortal-
ity and poor longterm survival after neoadjuvant concurrent chemoradiother-
apy for stage IIIA-N2 non-small cell lung cancer.
O-015
Sunitinib in Combination with Erlotinib for the Treatment of
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Introduction: Angiogenesis and EGFR signaling pathways are important
pathogenic mechanisms in NSCLC. Preclinical data suggest adding
sunitinib, a multitargeted TKI of VEGFR and PDGFR, to erlotinib enhanced
antitumor activity vs. either alone. Phase II data suggest inhibiting angio-
genesis further improves outcome in NSCLC patients treated with erlotinib.
This phase III trial evaluated sunitiniberlotinib vs. placeboerlotinib in
patients with recurrent NSCLC.
Methods: Patients (18 yrs; ECOG PS 0/1; previously treated with 1 or 2
chemotherapy regimens) with recurrent NSCLC were randomized (1:1) to
sunitinib 37.5 mg/derlotinib 150 mg/d, or placeboerlotinib 150 mg/d,
stratified by prior bevacizumab use, smoking history, and EGFR expression.
The primary endpoint was OS (734 events); secondary endpoints included
progression-free survival (PFS), objective response rate (ORR) and safety.
Results: 960 patients were randomized; baseline characteristics included
adenocarcinoma (52.7%) and squamous cell carcinoma (28.1%) histologies,
median age: 61 yrs, male: 60.5%, never smokers: 19.4%. Median OS was 9.0
months for sunitiniberlotinib vs. 8.5 months for placeboerlotinib (HR
[95%CI]: 0.922 [0.797–1.067]; p0.1388, 1-sided, stratified log-rank). Me-
dian PFS was in favour of sunitiniberlotinib: 15.5 weeks vs. 8.7 weeks for
placeboerlotinib (HR [95%CI]: 0.807 [0.695–0.937]; p0.0023, 1-sided,
stratified log-rank) and ORR was 10.6% vs. 6.9% (p0.0471, 2-sided),
respectively. Common treatment-related adverse events (Grade3) included
diarrhea, rash, decreased appetite, fatigue, and nausea in both arms.
Conclusion: Addition of sunitinib to erlotinib significantly improved PFS
but not OS in recurrent NSCLC. Additional analyses will be presented.
O-016
Survival According to the Results of Repeat Mediastinoscopy
after Induction Therapy for Patients with Pathologically Proven
N2 Non-Small Cell Lung Cancer
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Introduction: There are few reports specifically studying survival according
to the results of repeat mediastinoscopy (reMS). The objective of this study
is to analyse the survival of patients who underwent induction chemotherapy
or chemoradiotherapy for pathologically proven stage III-N2 non-small cell
lung cancer (NSCLC) whose objective tumour response was assessed by
reMS.
Methods: From July 1992 to February 2009, 81 patients (76 men; median
age: 59 years), underwent 84 reMS (three patients required a second reMS)
for restaging after induction therapy for pathologically proven N2 disease.
Patients with positive reMS underwent definitive chemotherapy or chemo-
radiotherapy. Patients in whom reMS was negative underwent thoracotomy
for lung resection and systematic nodal dissection. Systematic nodal dissec-
tion was the gold standard to compare the negative results of reMS.
Follow-up data were completed in January2010 and survival analysis was
performed by the Kaplan-Meier method.
Results: Median survival time in patients with true negative reMS was 51.5
months (95% CI 0- 112); with a positive reMS, it was 12 months (95% CI
6.8-17.3); and with a false negative reMS, it was 7 months (95% CI 4.7-9.3).
In the combined group of patients with positive and false-negative reMS,
median survival time was 11 months (95% CI 7.6- 14.1) (p0.0001).
Conclusion: Persistent mediastinal lymph node involvement after induction
therapy is associated with poor prognosis, and lung resection in this group of
patients does not add any survival benefit. Therefore, techniques providing
cyto-histological evidence of nodal dowstaging are advisable to avoid un-
necessary thoracotomies.
O-017
The Association between SNP of EGFR and Response to EGFR-
TKIs According to EGFR Mutation in Non-Small Cell Lung
Cancer
Eun Kyoung Jeon1, Jung-Young Shin2, Eun Kyung Cho3, Jin-Hyoung Kang1
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Introduction: Some NSCLC patients having wild type EGFR have favor-
able response to EGFR TKIs. Accordingly, we formulated hypothesis that
toxicities and clinical outcome of EGFR TKIs might be related with single
nucleotide polymorphism (SNP) of EGFR and undertook the study to
analyze the association between genotype of SNP and clinical response
according to the status of EGFR mutation.
Methods: We investigated EGFR mutation, clinical response and 6 different
SNPs of EGFR in the patients (pts) receiving gefitinib or erlotinib for
inoperable NSCLCs.; axon 191CA, axon 216 GT, CA repeat number,
exon13 R497K, axon 20 (2607GA), and axon 25 D994D.
Results: A total of 117 pts was eligible. Analysis for EGFR mutation was
available in 57 pts; 29 (50.9%) were positive. Objective response rate (ORR)
was 37.6%.; 3 pts (2.6%) had CR, 41 (25.0%), PR, and 37 (31.6%), SD.
Median TTP was 4.3 months (95% CI 2.87-5.80). In exon 216, GG genotype
was detected in 101 pts (86.3%). The pts having either haplotype of CA
repeat including 20, 21, 22, or 23 and more than 38 of total number were 68
(58.1%). In exon 13, wild type was analyzed in 30 (25.6%), heterozygote
variant in 44 (34.6%), and homozygote variant in 40 (34.2%). In exon20, 94
pts (80.3%) had wild type, 19 (16.2%) had heterogygote. In exon25 D994D,
GG, AG and AA genotypes were detected in 52 (44.4%), 53 (45.3%), and 9
(7.7%) pts, respectively.
Conclusion: The association between SNP of EGFR and clinical response
are under the analyzed and will be open in APLCC.
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Introduction: PF299804 is an orally bioavailable, irreversible inhibitor of
human epidermal growth factor receptor (HER)-1/EGFR, -2, and -4 tyrosine
kinases with antitumor activity in Western patients with NSCLC at a dose of
45 mg once daily (QD). Updated Phase 2 data are presented from a Phase
1/2, multicenter, open-label study in Asian patients with KRAS wild-type
NSCLC of adenocarcinoma histology refractory to 1 chemotherapy and
gefitinib or erlotinib.
Methods: Patients received 45 mg QD (21-day cycles). The primary end-
point was progression-free survival at 4 months (PFS4m). The null hypoth-
esis, PFS4m 25%, was tested at 10% significance level using a single-stage
Fleming design. Secondary endpoints included overall survival (OS), objec-
tive response rate (ORR), safety, and patient-reported outcomes (PROs).
Results: 43 patients enrolled. Since observed PFS4m was 47% (95% CI 32%,
61%), the study concluded that the true PFS4m exceeded 25% with 1-sided
p-value0.0008. Observed median PFS was 15.4 (9.7, 17.6) weeks; OS6m
was 81% (63%, 90%); median OS was 45.1 (32.3, not reached) weeks. ORR
was 17.1% (7.2%, 32.1%); clinical benefit rate (partial responsestable
disease 24 weeks) was 26.8% (14.2%, 42.9%). PRO data for NSCLC
symptoms ‘cough’ and ‘pain’ improved over the first 4 cycles of PF299804.
Common treatment-related AEs were diarrhea (grade 1/2/3: 44.2%/23.3%/
14.0%), dermatitis acneiform (32.6%/44.2%/4.7%), and paronychia (32.6%/
25.6%/9.3%). No patients discontinued due to treatment-related AEs.
Conclusion: In Asian patients with advanced NSCLC, PF299804 treatment
demonstrated antitumor activity, was generally well tolerated, and, for this group
of patients with refractory NSCLC, observed median OS was 45 weeks.
O-042
A Phase II Study of Afatinib (BIBW 2992) in Patients with
Adenocarcinoma of the Lung and Activating EGFR/HER1 Mu-
tations (LUX-Lung 2)
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Introduction: NSCLC patients whose tumours harbour EGFR/HER1 muta-
tions represent a subpopulation with unparalleled responsiveness to EGFR
tyrosine kinase inhibitors (TKIs). A Phase II study of afatinib – an oral,
potent irreversible inhibitor of EGFR/HER1 and HER2 – was conducted in
Taiwan and the US to assess its efficacy and safety in this patient population.
Methods: Patients with stage IIIB/IV or recurrent lung adenocarcinoma and
EGFR mutations in exons 18–21 (direct sequencing), 1 line of prior
chemotherapy, no previous EGFR-TKI, received 50 or 40 mg of afatinib qd
until progression. Primary endpoint was objective response rate (ORR);
secondary endpoints included progression-free survival (PFS) and overall
survival (OS), among others.
Results: 461 patients were screened for EGFR mutations; 129 received 1
dose of afatinib. Among the 129 patients, investigators reported an ORR of
67% (confirmed ORR 60%; disease control rate (DCR) of 86%, median PFS
of 14 months, and median OS of 24 months. We observed a similar
confirmed ORR, DCR and median PFS in patients with L858R mutations
(59%, 83%, and 16.1 months) and del19 mutations (63%, 90%, and 13.7
months). The most common drug-related AEs were diarrhoea and rash/acne
in 95% and 91% of patients, respectively, with CTCAE Grade 3 in 19% and
21% of patients, respectively.
Conclusion: Afatinib treatment resulted in similarly high ORR, DCR and
PFS in NSCLC patients with del19 or L858R mutations. Gastrointestinal and
skin disorders were the most frequently observed AEs. A further update on
PFS and OS will be presented.
CANCER CONTROL AND EPIDEMIOLOGY
O-019
Clinicopathiologic Characteristics and Survival Outcomes Com-
parisons between Japan-Born and US-Born Japanese Non-
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Introduction: We compared the clinicopathologic characteristics and sur-
vival outcome between Japan-born and US-born Japanese non-small cell
lung cancer (NSCLC) patients in the US.
Methods: Retrospective population-based analysis and comparison of Japan-
born and US-born Japanese NSCLC patients from California Cancer Regis-
try between 1991 and 2006.
Results: 1178 Japanese NSCLC patients born in US or Japan were analyzed.
The majority of Japan-born patients were female while the majority of
US-born patients were male. US-born patients were significantly older than
Japan-born NSCLC patient regardless of gender or major histologies. Japan-
born patients with stage IV disease were diagnosed with a significant higher
proportion of adenocarcinoma compared to US-born patients (49.7% vs.
45.0%; p0.0412). There was a significant age difference between stage IV
US-born who received chemotherapy versus those who did not (p0.0020)
but not between stage IV Japan-born patients (p0.1482). Significantly more
US-born patients died from lung cancer than Japan-born (69.3% vs. 62.6%;
p0.0204). Univariate analysis revealed Japan-born patients had signifi-
cantly improved lung cancer-specific survival (LCSS) (HR0.863;
p0.0486) when compared to US-born patients especially among stage IV
patients (HR0.759; p0.0206). Nativity was not an independent prognos-
tic factor for LCSS or OS by multivariate analysis.
Conclusion: There are differences between Japan-born and US-born Japa-
nese NSCLC by median age of diagnosis and lung-cancer specific survival.
The potential differences indicate the role of environmental influence in the
pathogenesis of NSCLC.
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Introduction: This study was conducted to determine the impact of a
functional tandem repeat minisatellite (MNS16A) polymorphism in the
telomerase reverse transcriptase (TERT) gene on the risk of lung cancer, as
well as on survival of patients with non-small cell lung cancer (NSCLC).
Methods: The effect of the MNS16A variable number of tandem repeat
(VNTR) polymorphism on the risk of lung cancer was evaluated in a
case-control study that consisted of 937 lung cancer patients and 943 healthy
controls. The effect of the polymorphism on survival outcome was evaluated
in 703 patients with surgically-resected NSCLC.
Results: As compared to the VNTR-302 allele, the VNTR-243 allele was
associated with a significantly increased risk of lung cancer (adjusted odds
ratio, 1.55; 95% confidence interval [CI], 1.07-2.25; P0.02). In addition,
the genotypes carrying at least one VNTR-243 allele were associated with a
significantly increased risk of lung cancer as compared to the genotypes with
no VNTR-243 allele (adjusted odds ratio, 1.61; 95% CI, 1.09-2.38; P0.02).
By contrast to the effect of the polymorphism on the risk of lung cancer, the
genotypes carrying at least one VNTR-243 allele were associated with a
significantly better overall survival in patients with surgically-resected
NSCLC (adjusted hazard ratio, 0.51; 95% CI, 0.28-0.93; P0.03).
Conclusion: These findings suggest that the MNS16A VNTR polymorphism
in the TERT gene has dual, conflicting roles in lung carcinogenesis. This
polymorphism may increase the risk of lung cancer development, and may
improve survival in lung cancer patients.
O-021
Occupational Lung Cancer Surveillance in South Korea
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Dong Mug Kang13, Yun-Chul Hong14 1Department of Occupational and
Environment Medicine, Inha University Hospital, Republic of Korea, 2De-
partment of Internal Medicine, Inha University Hospital, Republic of Korea,
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Introduction: As South Korea has experienced rapid industrialization and
urbanization during the last 50 years, many other changes have occurred such
as the westernization of eating habits and increased driving rates. These
changes have affected the pattern of cancer incidence and mortality in South
Korea. The lung cancer mortality in Korea has increased remarkably during
the last 20 years, and has been the first leading cause of cancer-related deaths
since 2000. The aim of the current study was to examine the time trends of
occupational lung cancer and carcinogens exposure during the period 2006-
2009 in South Korea, by assessing the proportion of occupational burden.
Methods: We defined occupational lung cancer for surveillance, and devel-
oped a reporting protocol and reporting website for the surveillance of
occupational lung cancer. The study patients were chosen from 9 participat-
ing university hospitals in the following 7 areas: Seoul, Incheon, Wonju,
Daejeon, Daegu, Busan, and Kwangju.
Results: The combined proportion of definite and probable occupational
lung cancer among all lung cancers investigated in this study was 10.0%,
8.6%, 10.7%, and 15.8% in the years 2006 to 2009, respectively, with an
average of 11.7% over the four-year study period. The main carcinogens
were asbestos, crystalline silica, radon, polyaromatic hydrocarbons (PAHs),
diesel exhaust particles, chromium, and nickel.
Conclusion: We estimated that about 11.7% of the incident lung cancer was
preventable. This reveals the potential to considerably reduce lung cancer by
intervention in occupational fields.
EARLY DETECTION AND CHEMOPREVENTION
O-022
Diagnosis and Treatment Outcomes of Early Central Lung
Cancer
Hidetoshi Honda, Kentaro Iwasaki, Yojiro Makino, Gaku Yamaguchi, Keishi
Otani, Takamoto Saijo, Seisuke Nagase, Jitsuo Usuda, Tatsuo Ohira, Nori-
hiko Ikeda Department of Thoracic Surgery, Tokyo Medical University,
Japan
Introduction: Diagnosis of early central lung cancer enables highly invasive
surgery to be avoided and successful treatment to be achieved by photody-
namic therapy. We report herein the diagnosis and treatment outcomes of
early central lung cancer at our institution.
Methods: Using Autofluorescence bronchoscopy, we investigated 440 cases
and performed biopsy on all regions even in the case of abnormality. Optical
coherence tomography was additionally performed in patients in whom lung
cancer was suspected following autofluorescence bronchoscopy. For patients
diagnosed with early central lung cancer on both techniques, photodynamic
diagnosis using autofluorescence bronchoscopy was performed, the superfi-
cial invasion range of the focus was more clearly determined, and photody-
namic therapy was applied.
Results: Reduced autofluorescence was observed in 91 regions of 75 patients
diagnosed with lung cancer. Through combined use of optical coherence
tomography, 69 regions of 65 of these patients were diagnosed as early
central lung cancer. Photodynamic diagnosis was positive in 64 of these
patients. The complete response rate for photodynamic therapy was 94%
(tumor size 1.0 cm).
Conclusion: At our institution, the complete response rate to photodynamic
therapy is 94% and outcomes are favorable. Autofluorescence bronchoscopy
is useful for localization of early central lung cancer; however, as it is only
indicated for diagnosis in the bronchial surface, it should be used in
conjunction with techniques such as optical coherence tomography for
diagnosis of invasion depth. Combined use of autofluorescence bronchos-
copy, optical coherence tomography and photodynamic diagnosis can lead to
more accurate diagnosis and treatment of central type early stage lung
cancer.
O-023
Potential Diagnostic Markers in Bronchial Fluid of Small Cell
Lung Cancer (SCLC)
Sergio Carrera Revilla1, Rafael Zalacain2, Guillermo Lopez Vivanco1,
Aintzane Sancho Gutierrez1, Itziar Rubio Etxebarria1, Alberto Mun˜oz
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Introduction: Lung cancer is a major cause of mortality. An early diagnosis
could improve survival among these patients. The aim of this study was to
identify protein markers obtained from bronchial fluids of SCLC patients
which may differ from non-pathological bronchoscopy samples.
Methods: We have included 43 patients with SCLC diagnosed using
bronchoscopy and 49 consecutive patients with non pathological bronchos-
copy. Bronchial fluid was obtained from each patient and potential markers
were studied. After being centrifuged, supernatant proteins were analysed
using bidimensional electrophoresis with poliacrilamid gel stained with
silver nitrate. Gel was scanned and analysed with Progenesis PG6220
program, which measures intensity of each spot. Resultant intensities in each
group of patients (SCLC/non pathological bronchoscopy) were compared
using T-Student. We selected as potential markers those spots with a p value
of less than 0.05. We calculated “fold change” of each spot as the ratio
between mean intensity in SCLC samples and non pathological samples.
Results: Optimal bidimensional gels of each sample were obtained. Among
300 comparable spots, 10 of them were expressed with a different intensity
in both groups of patients; 6 of these potential markers were overexpressed
in SCLC samples, whereas 4 of them were underexpressed. The “fold
change” of these 10 spots ranges from 1.5 to 8.67.
Conclusion: Different protein markers can be detected in bronchial fluid
obtained from SCLC samples. Significant differences in expression of these
biomarkers were detected between SCLC patients and non pathological
bronchoscopy patients. The development of an early diagnostic test using
these proteins must be validated.
PATHOLOGY
O-024
Epithelial-Mesenchymal Transition EMT in Non-Small Cell
Lung Cancers: Clinicopathologic Correlation and Prognostic
Significance of EMT Related Protein
Hyojin Kim1, Xianhua Xu2, Hyun Ju Lee2, Jin-Haeng Chung2 1Department of
Pathology, Seoul National University Hospital, Republic of Korea, 2Department of
Pathology, Seoul National University Bundang Hospital, Republic of Korea
Introduction: Epithelial-mesenchymal transition (EMT) is a mechanism for
epithelial cells to overcome the physical constraints imposed on them by
intercellular junctions and adopt a motile phenotype. EMT is important to
acquisition of invasiveness and progression as well as chemoresistance in cancer
cells. We investigated EMT phenomenon in non-small cell lung cancer (NSCLC).
Methods: Surgically resected 383 NSCLC samples including 225 adenocarci-
nomas (ADCs) and 138 squamous cell carcinomas (SCCs) were analyzed for the
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expression of six EMT related proteins (E-cadherin, , -catenin, -catenin,
vimentin, matrix-metalloprotein (MMP) 2, snail1) by immunohistochemistry (IHC).
Results: Loss of epithelial markers (E-cadherin and -catenin) was related
with pleural invasion and new TNM stage in ADC. In particular, loss of
E-cadherin was associated poor prognosis (p0.0049 for progression free
survival, p0.04 for cancer specific survival) and proportional to loss of
-catenin (p0.035) and increased mesenchymal markers such as MMP2
(p0.002) and snail expression. Expression of mesenchymal proteins (vi-
mentin, MMP2 and snail1) was also related with lymphatic and vascular
invasion in ADC. Expression of vimentin was significantly associated with
poor prognosis (p0.01 for cancer specific survival).
Conclusion: Expression of EMT related proteins (loss and/or decreased
epithelial markers and increased mesenchymal markers) was associated
tumor progression, invasiveness and poor prognosis in lung ADC. These
results suggest a novel anticancer therapeutic agent can be developed using
inhibitors of EMT pathways.
O-025
Screening of Potential Patient Group with Benefit from ALK
Inhibitors by Immunohistochemistry in Non-Small Cell Lung Cancer
Jin Haeng Chung1, Jin Ho Paik1, Gheeyoung Choe1, Hyojin Kim1, Jiyoung
Choe1, Sanghoon Jheon2, Choon-Taek Lee3, Jong-Seok Lee3 1Department of
Pathology, Seoul National University Bundang Hospital, Republic of Korea,
2Department of Thoracic Surgery, Seoul National University Bundang Hos-
pital, Republic of Korea, 3Department of Internal Medicine, Seoul National
University Bundang Hospital, Seoul National University College of Medi-
cine, Republic of Korea
Introduction: There are no universally accepted, evidence-based guidelines for
how to screen the ALK gene rearrangement by immunohistochemistry (IHC).
Methods: We retrospectively reviewed 465 resected cases of NSCLC using
tissue microarray (TMA) and compared protein expression of ALK by IHC
and fluorescence in situ hybridization (FISH). The ALK immunoreactivity
was scored as 0-3, for comparison with FISH results. Based on the TMA
results, 187 consecutive lung adenocarcinomas (ADCs) were investigated for
ALK status, prospectively.
Results: ALK protein expression consisted of IHC 1(14/465, 3.0%),
2(10/465, 2.2%) and 3(16/465, 3.4%), while 20 cases (20/453, 4.4%)
were FISH-positive. All 20 FISH-positive cases were either IHC 2or 3.
Four of 10 (40%) IHC 2cases and all 16 IHC 3cases (100%) were
FISH-positive. None of IHC 0/1cases (0/427) was FISH-positive, as none
of IHC 3cases (0/16) was FISH-negative. Regarding 187 consecutive ADCs,
ALK protein expression was detected in the 14 cases (2 cases of IHC 1, 6 IHC
2and 6 IHC 3), of which 10 cases (10/187, 5.3%) were FISH-positive. All
two IHC 1cases were FISH-negative and all six IHC 3cases FISH-positive.
Among 6 IHC 2tumors, four cases (4/6, 67%) were FISH-positive.
Conclusion: These data support an algorithmic guideline in which FISH
testing is restricted to IHC 2tumors. ALK IHC 0/1and IHC 3were
highly compatible with FISH results with an overall concordance of 100%.
The lower level of concordance between IHC 2and FISH results raises the
necessity of FISH analysis in those cases.
NON-SMALL-CELL LUNG CANCER - EARLY
DISEASE
O-026
Is Mediastinal Lymph Node Dissection Necessary in Patients
with Clinical Stage IA Non-Small Cell Lung Cancer?
Sung Ryong Kim1, Dong Kwan Kim1, Seung-Il Park1, Yong Hee Kim1,
Hyeong Ryul Kim1, Dong Gon Yoo2, Do Kyun Kang1, Ju Ri Chung1
1Department of Thoracic and Cardiovascular Surgery, Asan Medical Center,
Republic of Korea, 2Department of Thoracic and Cardovascular Surgery,
Gang Neung Asan Hospital, Republic of Korea
Introduction: To determine if systematic mediastinal lymph node dissection
is mandatory in patients with clinical stage IA NSCLC
Methods: 586 clinical stage IA NSCLC patients who were underwent
surgical resection and systematic mediastinal lymph node dissection between
January 2001 and December 2009 were reviewed. The preoperative staging
was based on the seventh edition of the TNM classification
Results: Among 586 patients, patients with pN0 was 495(84.5%), pN1
38(6.5%), pN2 53(9%). The average number of dissected lymph nodes was
25.810.2. In 477 patients with adenocarcinoma, 28(5.9%) were turned out
pN1, 44(9.2%) pN2. In 90 squamous cell carcinoma, 8(8.9%) pN1, 8(8.9%)
pN2. The difference in mediastinal lymph node metastasis between two were not
significant (p0.919). As well, no significant difference in mediastinal lymph
node metastasis in relation to the location of primary tumor were found
(p0.696). 349 patients were in T1a and 237 in T1b. The difference in
mediastinal lymph node metastasis between T1a and T1b were not significant
(p0.646). Also, 52 patients with GGO lesion on preoperative chest CT finding
were identified. There was no lymph node metastasis in these patients. The
difference in lymph node metastasis between GGO pattern and non GGO pattern
were significant (p0.001).
Conclusion: In 586 patients with clinical stage IA NSCLC performed
systematic mediastinal lymph node dissection, mediastinal lymph node
metastasis occurred with relatively high frequency. Therefore systematic
mediastinal lymph node dissection is necessary for all resectable clinical
stage IA NSCLC patients. But, if primary tumor is pure GGO lesion,
omission of mediastinal lymph node dissection can be considered.
SURGERY
O-027
Prediction of Acute Pulmonary Complications after Resection of
Lung Cancer in Patients with Pre-Existing Interstitial Lung Disease
Joon Suk Park, Hong Kwan Kim, Kwhanmien Kim, Jhingook Kim, Young
Mog Shim, Yong Soo Choi Department of Thoracic Surgery, Samsung
Medical Center, Republic of Korea
Introduction: Interstitial lung disease (ILD) is associated with a high
morbidity from acute pulmonary complications, such as acute lung injury
(ALI) or acute respiratory distress syndrome (ARDS), after pulmonary
resection. This study attempts to uncover risk factors for postoperative
ALI/ARDS in lung cancer patients with ILD.
Methods: We retrospectively reviewed 100 patients with ILD who underwent
curative lung resection for lung cancer, from January 2000 to December 2008.
Results:Among the 100 patients, 91 were male, and 9 were female. The median
age was 66 years old. Fifty-eight patients underwent a preoperative carbon
monoxide diffusing capacity test (DLCo). Twelve pneumonectomies and 88
lobectomies were performed. Acute pulmonary complications were observed in
28 patients (13 with ALI and 15 with ARDS). Operative mortality was 14%.
Cause of death was due to respiratory failure from ALI/ARDS in all patients,
except in one patient who died due to complications of ARF. For all 100 patients,
univariate analysis revealed that pre-existing co-morbidities, such as ischemic
heart disease, renal failure, COPD, and neoadjuvant treatment for lung cancer
were risk factors for development of postoperative ALI/ARDS. For the 58
patients who underwent preoperative DLCo testing, significant univariate risk
factors included pre-existing co-morbidities and decreased DLCo. Multivariate
analysis did not show any significant risk factors for ALI/ARDS.
Conclusion: Pre-existing co-morbidities and decreased preoperative DLCo
were most significant risk factors for the development of acute pulmonary
complications after pulmonary resection in patients with lung cancer and ILD.
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O-028
The Role of Surgery for T4 and/or M1 Non-Small Cell Lung Cancer
Byung Su Yoo1, Young Tae Kim1, Yeon Bum Lee2, Se Hoon Choi1, Chang
Hyun Kang1, Sook Whan Sung1, Joo Hyun Kim1 1Department of Thoracic
and Cardiovascular Surgery, Seoul National University Hospital, Republic
of Korea, 2Department of Cancer Research Institute, Seoul National Uni-
versity, Republic of Korea
Introduction: The purpose of this study was to clarify a role of surgical
resection in patient with T4 and/or M1 non-small cell lung cancer (NSCLC).
Methods: During a period of 15 years between January 1995 and March
2010, 258 patients were diagnosed as either T4 and/or M1 NSCLC. There
were 181 males and 77 females. The mean age was 58.710.6 years. Major
pulmonary resection larger than wedge resection was performed in
119(36.1%) patients. Most common pathologic cell type was adenocarcino-
ma(53.9%) followed by squamous cell carcinoma(38.4%). One hundred and
thirty patients had T4M0, 91 had T1-3M1, and the remaining 37 patients had
T4M1. The patients withT4M0 were subdivided according to their patho-
logic N status; N0 in 73, N1 in 20, N2 in 35 and N3 in 2 patients. We did a
retrospective analysis using various clinical prognostic variables.
Results: The overall survival was 33% at 5 years. In T4M0 patients, the
5-year survival rate was as high as 54%. Two clinical variables, younger age
(65, p0.022) and surgical resection(p0.002) were analyzed as signifi-
cant prognostic factors for long-term survival in multivariable analysis.
When further analyzed according to the pathologic N status, performing
surgical resection influenced favorably on survival in T4N0M0 (p0.013)
and T4N1M0 (p0.017) patients, whereas it did not affect in T4N2M0.
Surgical resection adversely affected on survival in M1 (p0.045) patients.
Conclusion: Surgical resection can provide an improved long-term survival
in selected patients with T4N0M0 or T4N1M0 NSCLC. However, it does not
provide any beneficial effect for T4N2M0 and can affect detrimentally in
patients with M1 lesions.
ENDOSCOPY AND INTERVENTION
BRONCHOSCOPY
O-029
Prognostic Factors for Airway Intervention in Patients with
Malignant Upper Airway Obstruction
Jae-Uk Song, Sang-Won Um, Gee Young Suh, Man Pyo Chung, O Jung
Kwon, Hojoong Kim Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Republic of Korea
Introduction: Bronchoscopic intervention have showed an effective role in
patients with malignant airway obstruction, providing emergency rescue
form suffocation, improvement of general condition, as well as a bridge to
allow time for definitive therapeutic modalities such as surgery, radiation,
and chemotherapy. To access the prognostic factors influencing survival after
bronchoscopic intervention, retrospective review was investigated.
Methods: One hundred eight patients (median age, 61 years; male 81) who
underwent airway intervention for malignant airway obstruction were included.
Clinical parameters were analyzed to find favorable prognostic factor.
Results: Bronchoscopic intervention, such as mechanical debridement
(n43), stenting (n51), laser (n52), and balloning (n24) was carried
out in intraluminal mass (n90), extrinsic compression (n13), and com-
bined lesion (n5). Initial palliation was achieved in 94% of patients. After
rigid bronchoscopic procedure, additional definitive treatment was per-
formed in 70 patients (65%), including resection of primary tumor (n14),
radiation (n37), chemotherapy (n12), chemoradiotherapy (n3), and
photodynamic therapy (n4). Overall one year survival was 38% (median
survival 7.0 months; range 3.0 to 17.2). Four variables were independently
associated with survival: age (odds ratio, 1.021; 95% confidence interval,
1.002-1.040), intraluminal lesion (OR, 3.296; CI 1.731-6.276), immediate
success of intervention (OR, 3.065; CI 1.316-7.137), and additional defini-
tive therapy (OR 2.047; CI 1.464-3.957).
Conclusion: In patients with malignant airway obstruction, bronchosopic
intervention could prolong survival, when patients are in young age, lesions
are intraluminal mass, intervention shows immediate successful outcome and
additional definitive therapy is available.
O-030
The Role of Endobronchial Ultrasound-Transbronchial Needle
Aspiration in the Diagnosis of Recurrent Non-Small Cell Lung
Cancer
Seo Goo Han, Kyeongman Jeon, Won-Jung Koh, Gee Young Suh, Man Pyo
Chung, Hojoong Kim, O Jung Kwon, Sang-Won Um Department of Medi-
cine, Samsung Medical Center, Sungkyunkwan University School of Medi-
cine, Republic of Korea
Introduction: In the patients who were suspicious for recurrent lung cancer,
accurate histopathological diagnosis is mandatory for optimal treatment.
However, the role of EBUS-TBNA is not well known for the diagnosis of
recurrent lung cancer. The purpose of this retrospective study was to
investigate the usefulness of EBUS-TBNA in the diagnosis of recurrent
non-small cell lung cancer (NSCLC).
Methods: Consecutive patients who underwent convex probe EBUS-TBNA
for mediastinal or hilar lymph nodes and peribronchial lung parenchymal
lesions between May 2009 and June 2010 were included in this study.
Diagnostic sensitivity, specificity, accuracy, positive predictive value (PPV),
and negative predictive value (NPV) were calculated on a per lesion and a
per patient basis, respectively.
Results: Twenty-six patients who were suspicious for recurrent NSCLC
underwent EBUS-TBNA for 35 mediastinal and hilar lymph nodes and 4
peribronchial lung parenchymal lesions. Among 39 lesions, recurrence of
malignancy was confirmed in 21 lesions by EBUS-TBNA (18 for lymph
nodes and 3 for peribronchial lung lesions). On a per lesion basis, diagnostic
sensitivity, specificity, accuracy, PPV, and NPV of EBUS-TBNA for con-
firmation of recurrence were 91.3%, 100%, 93.8%, 100%, and 81.8%,
respectively. On a per person basis, diagnostic sensitivity, specificity, accu-
racy, PPV, and NPV were 90.0%, 100%, 91.3%, 100%, and 60%, respec-
tively. There were no serious complications related to procedures.
Conclusion: Convex probe EBUS-TBNA is sensitive method for the diag-
nosis of recurrent NSCLC in the lymph nodes and peribronchial lung
parenchymal lesions. Therefore, EBUS-TBNA can impact on patient man-
agement in this clinical setting.
O-031
Aberrant Expression of Let-7a Mirna in Blood of Non-Small
Cell Lung Cancer Patients
Hye Cheol Jeong Department of Internal Medicine, Cha University, Republic
of Korea
Introduction: Abnormal expression of let-7a microRNA (miRNA) in non-
small cell lung cancer (NSCLC) cells and tissue has been reported. This
study was conducted to investigate aberrant expression of let-7a miRNA in
blood of NSCLC patients.
Methods: Using real-time PCR (RT-PCR), we analyzed let-7a miRNA in
archived whole blood from 65 participants, 35 of whom did and 30 of whom
did not have NSCLC. Using RT-PCR, we also investigated expression of
let-7a miRNA in NSCLC cell lines (A549, HCC 1588), a normal human lung
fibroblast cell line (WI-38), and 40 human NSCLC tissues.
Results: The 2-ddCt of let-7a miRNA in blood of normal subjects and those
with NSCLC were 3242.49355.28 and 747.85177.74, respectively. Rel-
ative expression of let-7a miRNA in A549 and HCC 1588 cancer cell lines
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was about 0.3 and 0.35 when compared with WI-38 cells. The 2-ddCt of
let-7a miRNA in normal human lung tissues and human NSCLC tissues were
42.303.98 and 27.733.86, respectively.
Conclusion: Let-7a miRNAs in blood of NSCLC patients, as well as
NSCLC cells and NSCLC tissues, were under-expressed compared with
those of normal controls. The possibility of using let-7a miRNA as a
serologic marker for lung cancer warrants further studies.
RADIOTHERAPY
O-032
Postoperative Radiotherapy Prolongs Disease Free Survivalin
Completely Resected Stage II or III Thymoma-20Years’ Expe-
rience
Ji Hyun Chang1, Hong-Gyun Wu1, Charn Il Park3, Young Tae Kim2, Joo
Hyun Kim2 1Department of Radiation Oncology and Cancer Research
Institute, Seoul National University College of Medicine, Republic of Korea,
2Department of Thoracic and Cardiovascular Surgery, Seoul National Uni-
versity College of Medicine, Republic of Korea, 3Department of Radiation
Oncology, Asia Cancer Center, Republic of Korea
Introduction: We assessed the efficacy of adjuvant radiotherapy in patients
with stage II or III thymoma and evaluated prognostic factors.
Methods: Records of 76 patients with surgically resected stage II (n65) or
III (n11) thymoma treated at a single institution from November 1988 to
February 2009 were retrospectively reviewed. Seventeen patients were
treated with surgery only (Group A) and 59 patients received adjuvant
radiotherapy after surgery (Group B). The median radiation dose was 50 Gy
(range, 43.2 - 66 Gy). The median follow-up time was 58.5 months (range,
3 - 231 months).
Results: The 5 and 10-year overall survival rates (OS) were 95.3% and
83.8%, respectively. The 5 and 10-year disease-free survival rates (DFS)
were 91.5% (80% for group A vs. 97.8% for group B) and 82.5% (70% for
group A vs. 92.7% for group B), respectively. The median time to recurrence
was 36.9 months (37.4 months for group A and 50.6 months for group B). In
the univariate analysis the 5-year DFS was associated with the largest
diameter of tumor (8cm, 95.2%;  8cm, 85.1%, p0.023). Masaoka
staging and adjuvant radiotherapy were statistically marginally significant
prognostic factors in univariate analysis, but were statistically significant
prognostic factors in multivariate analysis after adjusting for age and size
(p0.006 and p0.039, respectively).
Conclusion: Masaoka staging and adjuvant radiotherapy were related to
DFS in surgically resected stage II or III thymoma. Based on this study,
postoperative radiotherapy would be beneficial in this clinical setting.
O-033
Predictive Implications of KRAS and EGFR Gene Mutations in
Non-Small Cell Lung Cancer Treated with Radiation Therapy
James Welsh1, Anna Likhacheva1, Edward Kim2, Pamela Allen1, Roy
Herbst2, James Cox1, Ritusko Komaki1 1Department of Radiation Oncol-
ogy, Md Anderson Cancer Center, United States of America, 2Department of
Medical Oncology, Md Anderson Cancer Center, United States of America
Introduction: EGFR and KRAS are the most commonly mutated proto-
oncogenes in non-small cell lung carcinoma (NSCLC); KRAS mutations
have been shown to be prognostic for worse survival, and EGFR mutations
prognostic for improved survival and predictive for response and progres-
sion-free survival with EGFR tyrosine kinase inhibitor treatment. In this
study, we analyzed the KRAS and EGFR biomarker status and clinical
outcomes of patients with NSCLC who underwent definitive radiation
therapy.
Methods: We retrospectively analyzed 59 specimens from 47 patients with
NSCLC who underwent definitive radiation therapy as primary or adjuvant
therapy, the median follow up was 18 months (range 2-59 months). DNA
was extracted from paraffin-embedded tissues and tested for KRAS and
EGFR mutations.
Results: Fifteen tumors harbored KRAS mutations and six tumors had
EGFR mutations. Response to radiation was associated with the presence of
KRAS mutations, with 100% (15/15) of patients with KRAS mutations
having a complete response compared with 32% (14/44) of patients with
wild-type KRAS (p0.001). KRAS mutations were associated with im-
proved progression-free survival (p0.018) and improved local-regional
control (p0.03) but not with metastasis-free survival (p0.0881); the
median survival time was not reached. The presence of EGFR exon 19
mutations was associated with higher local recurrence rates (100% 2⁄2 vs.
22% 13⁄57, p0.014).
Conclusion: KRAS mutations have been linked with poor survival our
findings suggest that patients with NSCLC and KRAS mutations may
preferentially benefit from radiation therapy. To our knowledge this is the
first study to show an association between KRAS mutation status and
outcome after definitive radiation therapy.
O-034
Results of a Phase I Dose Escalation Trial (WJOG3305) Using
Accelerated Hyperfractionated 3D Conformal Radiation Ther-
apy (AHF-3DCRT) and Concurrent Chemotherapy for Unre-
sectable Stage III Non-Small Cell Lung Cancer (NSCLC).
Kayoko Tsujino1, Takuhito Tada2, Haruyuki Fukuda3, Yasumasa Nish-
imura4, Masaki Kokubo5, Toshinori Soejima1, Yoshie Takada2, Tatsuyuki
Nishikawa4, Kazuhiko Nakagawa6 1Department of Radiation Oncology,
Hyogo Cancer Center, Japan, 2Department of Radiology, Osaka City Uni-
versity, Japan, 3Department of Radiology, Osaka Prefectural Medical Cen-
ter for Respiratory and Allergic Disease, Japan, 4Department of Radiation
Oncology, Kinki University School of Medicine, Japan, 5Department of
Image-Based Medicine, Division of Radiation Oncology, Institute of Bio-
medical Research and Innovation, Japan, 6Department of Medical Oncol-
ogy, Kinki University School of Medicine, Japan
Introduction: The purpose of this study is to establish the maximum
tolerated dose (MTD) of radiotherapy using AHF-3DCRT and concurrent
chemotherapy.
Methods: Eligibility included patients with unresectable stage III
NSCLC, PS0-1, ages under 75, and lung V20  35%. Concurrent
chemotherapy consisted of Carboplatin (AUC2) and paclitaxel (40mg/
m2) given weekly. Radiotherapy consisted of 1.5Gy twice -daily to an
initial dose of 54Gy/36fr (level 1), and the dose was increased in 6Gy
increments up to 72Gy/48fr (level 4) or until determining the MTD. Three
dimensional techniques were used without elective nodal irradiation. The
dose-limiting toxicities (DLTs), defined as  grade 4 esophagitis and
neutropenic fever, and  grade 3 other non-hematologic toxicities, were
evaluated for 90 days.
Results: Twenty-six patients were enrolled and 24 patients were assessable.
The incidence of the DLT was 1/6, 0/7, 2/7 and 0/4 in levels 1 to 4
respectively. As none experienced the DLT in level 4, MTD was not reached
in this trial. The DLTs included grade 3 neuropathy (n2) and grade 3
appetite loss (n1). One grade 5 radiation pneumonitis occurred in level 1
was not counted as DLT because it developed after the observation term of
90 days. The median overall survival and late toxicities will be presented.
Conclusion: The MTD was not reached in the setting of AHF-3DCRT up to
72Gy/48fr. Acute toxicities were relatively mild. However, in consideration
of late toxicity, we determined 66Gy/44fr (level 3) as the recommended dose
for the next phase II study.
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NOVEL THERAPEUTICS AND MODALITIES
O-035
Comparison of Crizotinib (PF-02341066) Pharmacokinetics be-
tween Asian and Non-Asian Patients with Advanced Malignancies
Sai-Hong Ignatius Ou1, Ravi Salgia2, Jeffrey Clark3, Eunice L Kwak3, David
Ross Camidge4, Robert Maki5, Yung-Jue Bang6, Ben Solomon7, Weiwei
Tan8, Geoffrey I Shapiro9 1Department of Medicine-Hematology/Oncology,
Chao Family Comprehensive Cancer Center, University of California Irvine
Medical Center, United States of America, 2Department of Medicine-Hematol-
ogy/Oncology, University of Chicago Medical Center, United States of America,
3Department of Medicine-Hematology/Oncology, Massachusetts General Hos-
pital, United States of America, 4Department of Medicine-Hematology/Oncol-
ogy, Anchultz Cancer Center, University of Colorado Medical Center, United
States of America, 5Department of Medicine-Hematology/Oncology, Memorial
Sloan Kettering Cancer Center, United States of America, 6Department of
Medicine-Hematology/Oncology, Seoul National University Medical Center,
Republic of Korea, 7Department of Medicine-Hematology/Oncology, Peter
Maccallum Cancer Center, Australia, 8Department of Clinical Pharmacology,
Pfizer Oncology, United States of America, 9Department of Medicine-Hematol-
ogy/Oncology, Dana Farber Cancer Institute, United States of America
Introduction: Crizotinib is a potent, selective, ATP-competitive, orally bio-
available anaplastic lymphoma kinase (ALK) inhibitor. Patients with advanced
malignancies were enrolled in an expansion cohort of the first-in-human study
using the recommended phase 2 dose to characterize clinical activity, safety, and
pharmacokinetics of crizotinib. We compared these parameters between Asian
and non-Asian patients in the expansion cohort.
Methods: Crizotinib 250 mg twice daily was orally administered to patients
under fasting conditions in continuous 28-day cycles. Preliminary single- and
multiple-dose pharmacokinetic data were collected for 95 patients with
advanced malignancies (82 with ALK-fusion-gene-positive (ALK)
NSCLC). Ethnic differences were evaluated by comparing crizotinib phar-
macokinetics between Asian (n32) and non-Asian (n63) patients. Safety
and response were also compared by race in patients with ALKNSCLC.
Results: After repeated crizotinib dosing, mean AUCtau,ss and Cmax,ss
were respectively 56% and 70% higher in Asian than non-Asian patients
(body weight adjustment accounted for30% of the difference), with median
trough concentrations 41–59% (median 50%) higher. No effects of gender or
age on crizotinib pharmacokinetics were observed. Asian versus non-Asian
patients with ALKNSCLC tended to have a higher response rate (76%
versus 47%) and higher incidences of low-grade adverse events (e.g. gas-
trointestinal, visual impairment) but lower incidences of high-grade adverse
events (e.g. cough, ALT increase).
Conclusion: Steady-state crizotinib pharmacokinetics indicate higher crizotinib
exposure in Asian versus non-Asian patients. The mechanism of pharmacokinetic
differences is under investigation. Current efficacy and safety results support con-
tinuing use of the same dose regimen in Asian and non-Asian patients.
O-036
Immunotherapy with Adenocarcinoma Cells Transfected with
HLA A1 and gp96-Ig Heat Shock Protein in Advanced Non-
Small Cell Lung Cancer (NSCLC) Patients
Luis E Raez, Eva Fisher, Jorge Gomez, Gail Walker, Paulette Baldie,
Edgardo Santos, Eckard Podack Department of Hematology/Oncology, Uni-
versity of Miami, United States of America
Introduction: Phase I clinical trial to determine the safety, immunogenicity,
and clinical response to our allogeneic gp96-Ig tumor vaccine for NSCLC
patients (pts) with advanced disease who have failed standard chemotherapy and
erlotinib.
Methods: Allogeneic, cultured lung adenocarcinoma cells transfected with
HLA A1 and gp96-Ig were irradiated and injected intradermall. Three
dose-schedule combinations were considered (total of 4.5 ? 107 cells admin-
istered by 9 biweekly (DS1), 18 weekly (DS2), or 36 twice weekly (DS3)
injections). Immune response to vaccination was measured by determining
adenocarcinoma-specific CD8 CTL frequencies in ELI-spot assays for inter-
feron- (IFN-) and by measuring the frequency of FoxP3CD4Tregs. If
pts had a clinical response: (CR, PR, or SD), they continued with the next
course of vaccinations for up to 3 courses.
Results: 19 pts have been enrolled. Median age was 65 years; most of the pts
were Hispanic females. Data is available from 17 pts: 12 pts were treated in
DS1 cohort, three in DS2 and two in DS3. None of the pts experienced
serious adverse events (SAE) related to vaccine. Grade I: rash, skin indura-
tion and skin erythema were the most common AEs in the 3 cohorts. There
was no increase of AEs with the increase in the frequency of vaccinations.
Five pts have achieved disease stabilization (SD). Most of the pts had an
immunological response (CD8 CTL) determined by ELI-spot, and the
frequency of FoxP3CD4Treg decreased.
Conclusion: Minimal toxicity and immunologic response has been seen so
far in this very advanced population of NSCLC pts.
SMALL CELL LUNG CANCER
O-037
Quality of Life and Cigarette Smoking of Small Cell Lung
Cancer (SCLC) Patients
Jun Chen1, Yingwei Qi2, Jason Wampfler3, Aminah Jatoi4, Yolanda I
Garces5, Allan Busta3, Sumithra Mandrekar3, Ping Yang3 1Department of
Medical Oncology, The First Affiliated Hospital, China Medical University,
China, 2Department of Cancer Center Statistics, Mayo Clinic, United States
of America, 3Department of Health Sciences Research, Mayo Clinic, United
States of America, 4Department of Medical Oncology, Mayo Clinic, United
States of America, 5Department of Radiation Oncology, Mayo Clinic, United
States of America
Introduction: In this prospective study of 223 SCLC patients, we evaluated
self-reported QOL profile (overall QOL, ECOG performance status, and
selected symptoms-pain, fatigue, coughing, dyspnea, and reduced appetite)
and the impact of smoking cessation.
Methods: SCLC cases were diagnosed at Mayo Clinic, 1997-2008, and
followed for 5years. 334 matched controls (age, sex, and smoking status)
were non-cancer patients who had a CT/PFT. Descriptive and comparative
analyses were conducted on demographic, clinical, and QOL variables
(0-100, worst-best).
Results: Of the 223 cases, 54% were male and 38% had extensive disease at
diagnosis; 3% were never smokers and 53% were current smokers; 43% of
the cases quit smoking more than one year before diagnosis and 14% never
quit smoking. Compared to the matched controls, except for pain, SCLC
patients consistently showed statistically significant worse QOL profile:
fatigue and dyspnea were poor (mean scores ranging 48.5 to 59.0) and
coughing was moderate (66.4). Never smokers reported the best QOL profile;
individuals who quit after one year post diagnosis or never quitters reported
the worst. To assess the longitudinal changes over time, we compared QOL
profile reported within one year and after 2 years of diagnosis in 42 cases
with complete information; 19 patients who had quit at or within one year of
diagnosis showed significantly higher improvement and/or lower decline in
QOL profile than the other 23 patients.
Conclusion: Quitting smoking within one year (either before or after) of SCLC
diagnosis showed positive impact on patients’ overall QOL and major symptoms.
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BASIC SCIENCE
O-038
Somatic Mutations in Epidermal Growth Factor Receptor Sig-
naling Pathway Genes in Non-Small Cell Lung Cancers
Shin Yup Lee1, Guang Jin2, Jin Eun Choi2, Hyo Sung Jeon2, Ji Young Park3,
Sukki Cho4, Eung Bae Lee4, Seung Ick Cha1, Tae In Park3, Chang Ho Kim1,
Tae Hoon Jung1, Jae Yong Park1 1Department of Internal Medicine, Kyung-
pook National University, School of Medicine, Republic of Korea, 2Department
of Biochemistry, Kyungpook National University, School of Medicine, Republic
of Korea, 3Department of Pathology, Kyungpook National University, School of
Medicine, Republic of Korea, 4Department of Thoracic Surgery, Kyungpook
National University, School of Medicine, Republic of Korea
Introduction: Epidermal growth factor receptor (EGFR) signaling pathway
plays a crucial role in the development and progression of lung cancer. We
searched for mutations of EGFR pathway genes in non-small cell lung cancers
(NSCLCs) and analyzed their relationship with clinicopathologic features.
Methods: Mutations of EGFR, ERBB2, ERBB3, ERBB4, KRAS, NRAS,
BRAF, PTEN, PIK3CA, LKB1, and AKT1 genes were determined by direct
sequencing in 173 surgically resected NSCLCs - 56 squamous cell carcino-
mas (SCCs) and 117 adenocarcinomas (ACs).
Results: Of the 173 NSCLCs, a total of 65 mutations were detected in 63
(36.4%) tumors - 10 (17.9%) in SCCs and 53 (45.3%) in ACs. Mutations in
EGFR pathway genes were significantly more frequent in females and ACs
than in males and SCCs (P0.02 and P0.001, respectively). The mutations
occurred in a mutually exclusive pattern. When the genes were divided into
3 subgroups according to their roles in the signaling cascade, mutations in the
EGFR/ERBB2 and KRAS/BRAF genes were more frequent in ACs than in
SCCs (P0.001 and P0.01, respectively). In marked contrast, mutations in
the PIK3CA/PTEN were more frequent in SCCs than in ACs (P0.002).
Furthermore, mutations in the PIK3CA/PTEN genes were more frequent in
smokers (P0.04).
Conclusion: Our study demonstrates that mutations in each part of the EGFR
pathway were associated with different clinicopathologic features in patients
with NSCLCs.
TRANSLATIONAL RESEARCH
O-039
Over-Expression of Proto-Oncogene BCL11A in Non-Small Cell
Lung Cancer Is Driven by Genomic Gains and Inactivation of
miR-30a and is Associated with Better Outcome of Early Stage
Patients
Benyuan Jiang1, Xuchao Zhang2, Jian Su2, Xuning Yang1, Jinji Yang1, Qing
Zhou1, Shiliang Chen2, Honghong Yan2, Xiaolin Zhang3, Yilong Wu1
1Department of Pulmonary Oncology, Guangdong Lung Cancer Institute,
China, 2Department of Medical Research Center, Guangdong General
Hospital, China, 3Department of Innovation Center China Joint Laboratory,
Guangdong General Hospital-Astrazeneca, China
Introduction: This study aimed to investigate the expression pattern and
clinicopathologic significance of BCL11A in patients with non-small cell
lung cancer as well as possible genomic aberrations.
Methods: Gene and microRNA expression profiling was conducted in a
cohort of NSCLC patients; profiling results were further validated by
RT-PCR. BCL11A protein expression was evaluated by immunohistochem-
istry (n113). Data of array-based Comparative Genomic Hybridization
(aCGH) and microRNA transfection experiments were integrated to explore
the potential molecular mechanisms of abnormal BCL11A expression in
NSCLC.
Results: BCL11A expression levels were up-regulated in NSCLC tissues
both at mRNA level (P0.004) and protein level (P0.001). The patients
with high BCL11A protein expression had a longer disease free survival
(P0.0004) and overall survival (P0.051). Multivariate analysis demon-
strated that in early stage NSCLC (IA-IIB), BCL11A protein was not only an
independent prognostic factor for disease free survival [P0.001,
HR0.239, 95% CI 0.115-0.497], but also for overall survival [P0.003,
HR0.232, 95% CI 0.089-0.608]. BCL11A mRNA levels correlated with
copy number variations (CNV) in squamous cell carcinoma (rs0.347,
P0.041). Functionally using luciferase reporter system in vitro, in H460
cells co-transfected with microRNA-30a expression vector, reporter intensity
with BCL11A 3’UTR sequence could be significantly suppressed (P0.013).
Conclusion: BCL11A proto-oncogene was dysregulated in NSCLC tis-
sues. High level of BCL11A expression predicted a better overall survival
and disease free survival of early stage (IA-IIB) NSCLC. Genomic copy
number gain (CNG) might be causative for BCL11A over-expression in
squamous cell carcinoma. In addition, miR-30a inactivation might be
another potential mechanism responsible for the over-expression of
BCL11A proto-oncogene.
O-040
Reciprocal and Complementary Relationship between Epider-
mal Growth Factor Receptor T790M Mutation and MET Am-
plification in Acquired Resistance to Kinase Inhibitors in Lung
Adenocarcinoma
Kenichi Suda1, Isao Murakami2, Tatsuya Katayama1, Kenji Tomizawa1,
Hirotaka Osada3, Yoshitaka Sekido3, Yasushi Yatabe4, Tetsuya Mitsudomi1
1Department of Thoracic Surgery, Aichi Cancer Center Hospital, Japan,
2Department of Respiratory Medicine, Higashihiroshima Medical Center,
Japan, 3Department of Molecular Oncology, Aichi Cancer Center Research
Institute, Japan, 4Department of Pathology and Molecular Diagnostics,
Aichi Cancer Center Hospital, Japan
Introduction: In the epidermal growth factor receptor (EGFR)-tyrosine
kinase inhibitor (TKI) therapy, acquired resistance develops almost inevita-
bly, despite dramatic initial responses, and this limits the improvement in
patient outcomes. EGFR T790M mutation and MET amplification are the
two main mechanisms underlying this resistance, however the relationship
between these two mechanisms are unclear.
Methods: Erlotinib-resistant HCC827 (HCC827ER) cells were developed by
chronic exposure to erlotinib at increasing concentrations. Erlotinib/PHA-
665,752 (a MET-TKI)-resistant HCC827 (HCC827EPR) cells were also
developed by chronic exposure to erlotinib at increasing concentrations in the
presence of 1 M PHA-665,752. TKI resistant mechanisms of these resistant
cells and 33 autopsy samples from six lung adenocarcinoma patients who
responded to gefitinib monotherapy and experienced disease progression
while on continuous treatment with gefitinib were analyzed.
Results: HCC827ER developed MET amplification and clinically rele-
vant resistance occurred at a four-fold MET gene copy number gain
(CNG) or greater. By contrast, HCC827EPR developed T790M without
MET CNG. Of six patients harboring multiple gefitinib-refractory tu-
mors, three exhibited T790M only, one exhibited MET amplification
only, and the other two exhibited T790M and/or MET amplification
depending on the lesion sites. In these gefitinib-refractory tumors, T790M
developed in 93% (14/15) of tumors without MET gene CNGs, in 80%
(4/5) of tumors with moderate MET gene CNGs (less than four-fold), and
in only 8% (1/13) of tumors with MET amplification (four-fold or
greater).
Conclusion: These results indicate a reciprocal and complementary relation-
ship between T790M and MET amplification and the necessity of concurrent
inhibition of both for improving patient outcomes further.
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O-041
Quantification of Anti-Angiogenic Effect of Epidermal Growth
Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) with
Dynamic Contrast-Enhanced MR Imaging (DCE-MRI) in Patients
with Non-Small Cell Lung Cancer (NSCLC): Feasibility Study
Chin A Yi1, Ju Won Lee2, Jae-Hun Kim1, Keunchil Park3, Myung-Ju Ahn3,
Seonwoo Kim4, Kyung Soo Lee1, Ho Yun Lee1 1Department of Radiology,
Samsung Medical Center, Sungkyunkwan University School of Medicine,
Republic of Korea, 2Department of Radiology, Inha University School of
Medicine, Republic of Korea, 3Department of Oncology, Samsung Medical
Center, Sungkyunkwan University School of Medicine, Republic of Korea,
4Department of Statistics, Samsung Medical Center, Sungkyunkwan Univer-
sity School of Medicine, Republic of Korea
Introduction: We quantified anti-angiogenic effect of EGFR TKIs using
pharmacokinetic parameters from DCE-MRI in patients with NSCLC.
Methods: The prospective study included five patients with pathologically
proven stage IV NSCLC and underwent EGFR TKI treatment with gefitinib
or erlotinib. DCE-MRI was performed at D-1, D7, and D28. D0 is the
date of starting chemotherapy. Pharmacokinetic parameters were calculated
for each pixel of the whole primary mass using two-compartment model;
volume transfer constant[Ktrans], volutme of extravascular extracellular
space (EES) per unit volume of tissue[ve], flux rate constant between EES
and plasma [kep]. Time-concentration curves were analyzed; enhancement
amplitude [EA], time of half rising [T1⁄2max], and maximal slope [MS].
Longitudinal changes of anti-angiogenic effect were quantified and these
parameters were compared with the Response Evaluation Criteria in Solid
Tumors (RECIST) results at each follow-up time point.
Results: The Ktrans, ve, EA, and MS were significantly decreased at D7 after
EGFR TKI treatment (p0.05), suggesting anti-angiogenic effect with de-
creased permeability and EES volume and alleviation of strong and fast en-
hancement pattern in lung cancer. On 7th day of follow-up after EGFR TKI
treatment, more than 30% change of pharmacokinetic parameters was seen in
Ktrans (4/5 pts.), ve (5/5 pts.), EA (3/5 pts), and MS (5/5 pts.). But, no patients
showed complete remission or partial response with more than 30% change in
the longest diameter based on RECIST at D7.
Conclusion: Pharmacokinetic parameters from DCE-MRI can be quantified
and may be an early indicator for response evaluation of target agent
treatment in NSCLC.
POSTER DISCUSSION ABSTRACTS
PROGNOSTIC AND PREDICTIVE MARKERS
PD-001
Detection of STK11 Mutations in Early Stage NSCLC Patients
Using High Resolution Melting Analysis
Hongdo Do1, Guenaelle Levallet2, Martine Antoine2, Benjamin Solomon3,
Stephen Fox1, Ge´rard Zalcman2, Alexander Dobrovic1 1Department of
Pathology, University of Melbourne, Australia, 2Department of Thoracic
Oncology, Intergroupe Francophone De Cance´rologie Thoracique, France,
3Department of Division of Haematology and Medical Oncology, Peter
Maccallum Cancer Centre, Australia
Introduction: Germline mutations in the tumour suppressor gene
STK11 (also known as LKB1) cause Peutz–Jeghers syndrome which is
characterised by mucocutaneous pigmentation, intestinal hamartomas
and increased risk of developing cancers. In lung cancer, STK11 plays
a crucial role in pulmonary tumorigenesis, controlling initiation, differ-
entiation, and metastasis. In contrast to other cancers, the STK11 gene is
frequently inactivated by somatic mutations in non-small cell lung cancer.
Methods: A total of 14 HRM assays were developed covering and
flanking the coding region. The mutation status of STK11 was
assessed in 195 stage I and II NSCLC samples. All HRM positive
samples were then characterised by Sanger sequencing.
Results: A total of 30 STK11 mutations, comprising 27 non-
synonymous mutations and 3 synonymous changes were detected,
giving a mutation frequency of 15%. The non-synonymous muta-
tions consisted of 9 nonsense, 5 frameshift, 6 missense, and 7 splice
site variants. STK11 muations were detected in all coding exons
except for exon 7 and were not recurrent except with exceptions of
a nonsense mutation (K191X) and a splice site variant (c.291-
1GT), which were each found in two tumours. Single base sub-
stitutions (25/30, 83%) were more common than small insertions/
deletions (5/30, 17%) and the size of insertions/deletions were less
than 20 base pairs. The majority of mutations (28/30, 93%) were
present in the kinase domain and the two remaining changes were
located in the C-terminal regulatory domain.
Conclusion: In conclusion, these results demonstrate the utility of
HRM analysis for the cost efficient detection of somatic STK11
mutations in clinical NSCLC samples.
PD-002
Reduced Disease-Free Survival Associated with Anaplastic
Lymphoma Kinase Translocation (ALK) in Lung Adenocar-
cinoma Patients with No Cigarette Smoking History
Ping Yang1, Andre Oliveira2, Jason Wampfler1, Jennifer M Boland2, Shawn
M Stoddard1, Michele R Ericison-Johnson2, Hui Tang1, Kimary Kulig3,
Eunhee S Yi2 1Department of Health Sciences Research, Mayo Clinic,
United States of America, 2Department of Laboratory Medicine and Pathol-
ogy, Mayo Clinic, United States of America, 3Department of Health Sciences
Research, Mayo Clinic, United States of America
Introduction: To define the natural history of ALK and NSCLC clinical
outcome, we designed a nested case-case study using the ongoing Mayo
Clinic Lung Cancer Cohort to evaluate clinical outcomes of never-smoking
lung adenocarcinoma patients with respect to ALK translocation status.
Methods:We employed IHC (Dako clone ALK1 with ADVANCE detection
chemistry, Carpinteria, CA) and FISH with dual color break-apart probe
(Vysis, Des Plaines, IL) on formalin-fixed paraffin-embedded tissue to test
for ALKand analyzed disease-free survival (DFS). We considered
ALKif FISHor IHC scored 23, ALK- if FISH- or IHC scored 0. To
control for known prognostic indicators of lung cancer survival, matching
criteria (age, sex, and stage) were used to create comparable sets of
ALKvs. ALK- cases. To date, Set 1 includes 10 FISHand 10 FISH- cases
(age/ 10 years, stage III , IIIIV); Set 2 includes 7 FISHand 7
FISH-cases (age/ 5 years, stage III, IIIIV).
Results: For Set 1, median DFS is 30.3 months for ALKvs. 57.4 months
for ALK- cases; for Set 2, median DFS is 26.5 months vs. 63.4 months. The
multivariable Cox model revealed a hazard ratio of 1.93 (p0.09) for DFS
for ALKvs. ALK- cases by FISH test, and a hazard ratio of 1.87 p0.06
by IHC test.
Conclusion: Our preliminary analysis suggests a trend of worse outcome, as
measured by DFS, in patients with ALKtumors. Our continued screening
for ALK status in this cohort will allow more robust analyses and results.
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NON-SMALL-CELL LUNG CANCER –
ADVANCED DISEASE
PD-003
A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial
of BMS-690514 versus Erlotinib in Previous Chemotherapy-
Treated Non-Small Cell Lung Cancer (NSCLC) Patients: A
Safety Review
Eric Sbar5, Benjamin Besse1, Enriqueta Felip2, Alice Shaw3, Myung-Ju
Ahn4, Mark Salvati5, Prabhu Bhagavatheeswaran5, Jean-Charles Soria1 1De-
partment of Medicine, Institut Gustave Roussy, France, 2Department of
Medical Oncology, Hospital Vall D’Hebron, Spain, 3Department of Medi-
cine, Massachusetts General Hospital, United States of America, 4Depart-
ment of Medicine, Samsung Medical Center, Sungkyunkwan University,
Republic of Korea, 5Department of Oncology, Bristol-Myers Squibb Com-
pany, United States of America
Introduction: BMS-690514 is a potent, reversible oral inhibitor of EGFR,
ErbB2, HER4, and VEGFR1-3 in development for NSCLC based on the
rationale that balanced inhibition of ErbB and VEGFR provides increased
benefit over EGFR-alone. In CA187002, NSCLC patients with multiple prior
treatment (N61) had a DCR of 43% in erlotinib-naı¨ve and 23% in
erlotinib-exposed patients. The objective of this study is to explore whether
PFS with BMS-690514 is superior to PFS with erlotinib. Here, we present
safety data; efficacy will be presented later.
Methods: BMS-690514 (200mg) was compared with erlotinib (150mg) in
patients with progressive NSCLC after 1-2 previous cytotoxic chemotherapy
regimens (i.e. erlotinib-eligible per label). Endpoints included PFS, ORR,
OS, PFS rate, change in tumor size at 6 weeks, safety, and tolerability. Safety
was assessed as per standard practice with additional note of those known to
result from VEGFR and EGFR inhibition.
Results: 141 subjects (41 women, 100 men) were randomized to receive
either BMS-690514 or erlotinib. Patient characteristics included: 22 current,
99 previous and 19 never smokers; 79 adenocarcinoma, 35 squamous cell, 16
large cell, and 2 bronchoaveolar carcinoma. BMS-690514 AEs will be
compared to those known to occur at high incidences with erlotinib including
but not limited to: rash, diarrhea, fatigue and hypertension.
Conclusion: AEs BMS-690514-related were target-specific (EGFR, HER2,
and VEGFR) but similar to erlotinib. These data indicate that observed AEs
with BMS-690514 were not “additive” or higher than with VEGFR and
EGFR inhibitors administered as monotherapy. AEs were manageable and
reversible with concurrent medications and dose modification.
PD-005
A Randomized Phase II Study of Gefitinib Plus Simvastatin
versus Gefitinib Alone in Previously Treated Patients with Ad-
vanced Non-Small Cell Lung Cancer
Young-Woong Won1, Ji-Youn Han2, Soo-Hyun Lee2, Nam Jin Yoo2, Suk
Hyung Lee2, Yoon Joo Moon2, Tak Yun2, Heung Tae Kim2, Jin Soo Lee2
1Department of Center for Clinical Trials, National Cancer Center, Republic
of Korea, 2Department of Center for Lung Cancer, National Cancer Center,
Republic of Korea
Introduction: To evaluate the efficacy and safety of gefitinib plus simva-
statin (GS) versus gefitinib (G) alone in previously treated patients with
advanced non-small cell lung cancer (NSCLC).
Methods: Between May 2006 and September 2008, 106 patients (51% male,
75% adenocarcinoma, 50% never-smoker, 54% more than two prior regi-
mens) were randomly assigned to gefitinib alone (250 mg/d, n54) or
gefitinib plus simvastatin (250mg/d and 40 mg/d, respectively, n52). A
cycle was considered as 4 weeks of treatment. Therapy was continued until
disease progression or intolerable toxicities. The primary end point was
response rate (RR). Secondary endpoints included toxicity, progression-free
survival (PFS) and overall survival (OS).
Results: The RR was 38.5% (95% confidence interval [CI], 25.3%-51.7%) for
GS and 31.5% (95% CI, 19.1%-43.9%) for G. The median PFS was 3.3 (95%
CI, 1.4-5.2) months for GS and 1.9 (95% CI, 1.0-2.8) months for G. The median
OS was 13.6 (95% CI, 7.1-20.1) months for GS and 12.0 (95% CI, 7.8-16.2)
months for G. In exploratory subgroup analysis, GS showed higher RR (40% vs.
0%, P0.043) and longer PFS (3.6 months vs. 1.7 months, P0.027) compared
with G in non-adenocarcinoma with EGFR wild type. Adverse events in both
arms were generally mild and consisted mainly of skin rashes.
Conclusion: Although superiority of GS compared with G was not demon-
strated in this unselected NSCLC population, GS showed higher RR and longer
PFS in non-adenocarcinoma with EGFR wild type compared with G. Simva-
statin may improve efficacy of gefitinib in those gefitinib-resistant NSCLC.
PD-006
Growth Rate of Metastatic Brain Tumors from Non-Small Cell
Lung Cancer
Heon Yoo1, Byung-Ho Nam2, Sang Hoon Shin1, Ho Shin Gwak1, Moon Soo
Kim3, Jae Il Zo3, Jin Soo Lee3, Seung Hoon Lee1 1Department of Neuro-
Oncology Clinic, National Cancer Center, Republic of Korea, 2Department
of Cancer Biostatistics Branch, National Cancer Center, Republic of Korea,
3Department of Center for Lung Cancer, National Cancer Center, Republic
of Korea
Introduction: The purpose of the study was to evaluate the growth rates of
metastatic brain tumors from non-small cell lung cancer.
Methods: The first population studied was patients with minimally
symptomatic brain metastases who were treated with front-line chemo-
therapy. Serial MRIs of 30 metastatic brain tumors in 19 patients were
reviewed. Tumor growth rate and volumetric doubling time were esti-
mated after chemo-resistance developed. The second was patients with
newly developed metastatic brain tumors after thoracotomy. Among 1372
patients who received lung cancer surgery, brain metastases developed in
72 patients (5.2%). We hypothesized that there were micro-metastases in
the brain at the time of lung surgery, even though there was no detectable
brain metastases on the MRI. We evaluate the growth rate of metastatic
brain tumors in this unique subset of patients. The third was mainly cystic
metastatic brain tumors. We evaluated the growth rate of the cyst in 9
cystic brain metastases.
Results: The median tumor growth rate was 12.1 mm3/day, volume doubling
time was 58.5 days after chemo-resistance developed during front-line chemo-
therapy. The median growth rate was 11.7mm3/day for newly developed
metastatic brain tumors after thoracotomy. There were no statistically significant
differences in tumor growth among lung cancer stages and growth rate was
similar regardless of the use of chemotherapy. The growth rate of cysts was
much higher than solid tumor (76.7mm3/day).
Conclusion: The growth rates of solid metastatic brain tumors were similar
regardless of chemotherapy and cancer stages. Cystic tumors showed higher
growth rate than solid tumors.
PD-007
Outcomes of Surgical N2-Positive Non-Small Cell Lung Cancer
Patients Based on Adjuvant Therapy Modality: Single Institute
Retrospective Analysis
Jihae Lee1, Yong Chan Ahn1, Hee Chul Park1, Do Hoon Lim1, Young Mog
Shim2, Kwhanmien Kim2, Jhingook Kim2, Yong Soo Choi2, Keunchil Park3,
Myung-Ju Ahn3, Jin Seok Ahn3 1Department of Radiation Oncology,
Samsung Medical Center, Sungkyunkwan University, Republic of Korea,
2Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan
University, Republic of Korea, 3Department of Internal Medicine, Samsung
Medical Center, Sungkyunkwan University, Republic of Korea
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Introduction: Surgical N2 disease, preoperatively unsuspected but found on
the surgical specimen, is not uncommon in non-small cell lung cancer
(NSCLC). We retrospectively analyzed the outcomes of surgical N2 disease
according to the adjuvant therapy modalities.
Methods: From 1995 to 2007, 198 patients who underwent surgical resec-
tion for NSCLC and had surgical N2 disease were included. 35 patients
received no adjuvant therapy (Group 1), 22patients chemotherapy (Group 2),
88patients radiation therapy (Group 3) and 53patients chemoradiotherapy
(Group 4).
Results: The patients’ characteristics were not comparable: high frequency
of age older than 60 years in Group 1 (p0.000) and high proportion of
preoperative PET staging in Group 2 (p0.000). After the median follow-up
of 24 months, the 5-year overall survival rate was 32% and the median
survival was 31 months in all patients. The 5-year overall survival were 4%,
47%, 30%, and 56% in Group 1, 2, 3, and 4, respectively (p0.001).
Multivariate analysis indicated that chemotherapy (p0.028), female
(p0.008), age younger than 60 years (p0.003), squamous cell carcinoma
or adenocarcinoma (p0.033), T1-2 stage (p0.003), and N2 disease in-
volving a single lymph node station (p0.024) were associated with favor-
able survival, and the addition of radiation therapy (p0.054) was with
borderline significance.
Conclusion: Based on the current retrospective analyses of heterogonous
patients’ population, no concrete conclusion could be drawn. Adjuvant
chemotherapy and radiation therapy has led to the improved survival, and
application of aggressive concurrent chemoradiotherapy seems worthwhile
whenever feasible in the patients with surgical N2 disease.
PD-008
Results of a Phase I/II Trial of Amrubicin (AMR) in Combina-
tion with Cisplatin (CDDP) as First-Line Treatment in Patients
with Advanced Non-Small Cell Lung Cancer (NSCLC)
Yoshihiro Hattori1, Nobuyuki Yamamoto2, Yukito Ichinose3, Shunichi Ne-
goro4, Toyoaki Hida5, Koji Takeda6, Noriyuki Masuda7, Kazuhiko Naka-
gawa8, Soichiro Yokota9, Masahiro Fukuoka8 1Department of Thoracic
Oncology, Hyogo Cancer Center, Japan, 2Department of Thoracic Oncol-
ogy, Shizuoka Cancer Center, Japan, 3Department of Thoracic Oncology,
National Kyushu Cancer Center, Japan, 4Department of Medical Oncology,
Hyogo Cancer Center, Japan, 5Department of Thoracic Oncology, Aichi
Cancer Center, Japan, 6Department of Medical Oncology, Osaka City
General Hospital, Japan, 7Department of Respiratory Medicine, Kitasato
University School of Medicine, Japan, 8Department of Medical Oncology,
Kinki University School of Medicine, Japan, 9Department of Respiratory
Medicine, Toneyama National Hospital, Japan
Introduction: Amrubicin (AMR), a totally synthetic 9-aminoanthracycline
and potent topoisomerase II inhibitor, is approved in Japan for the treatment
of lung cancer. We evaluated the safety and efficacy of a conventional dose
regimen of AMR in combination with CDDP in patients with advanced
NSCLC.
Methods: In phase I, eligible patients had advanced NSCLC, no history of
previous chemotherapy, an ECOG performance status (PS) 0-1 and adequate
organ function. They received AMR 35 mg/m2 i.v. on days 1-3 and CDDP
60 mg/m2 i.v. on day 1 (level 1) or AMR 35 mg/m2 i.v. on days 1-3 and
CDDP 80 mg/m2 i.v. on day 1 (level 2) every 3 weeks. In phase II, the
primary endpoint was objective tumor response rate (ORR by RECIST).
Secondary endpoints included time to progression (TTP) and overall survival
(OS).
Results: In phase I, the optimal, dose was level 2. In phase II, the ORR was
23.4% (11/47, CR 0%, PR 23.4%). Median TTP and 1-year survival rate
were 6.7 months and 73.5%, respectively. In the safety population (n47),
the most common grade 3 or 4 adverse events were neutropenia (93.6%) and
febrile neutropenia (29.8%). There were no deaths due to treatment toxicity.
Conclusion: AMR with CDDP has promising activity for TTP and 1-year
survival rate but causes high rate of myelosuppresion in advanced NSCLC
patients at the dose of AMR 35 mg/m2 x3 days and CDDP 80 mg/m2 on day
1 every 3 weeks.
EARLY DETECTION AND CHEMOPREVENTION
PD-009
Diagnostic Markers in Bronchial Fluid of Lung Cancer Patients;
Immunoassay Development and Validation
Guillermo Lopez Vivanco1, Sergio Carrera Revilla1, Rafael Zalacain2, Nuria
Marina2, Ainhoa Gomez Bonilla2, Jaime Algorta3, Itziar Rubio Etxebarria1,
Alberto Mun˜oz Llarena1, Estibaliz Iza1, Mireia Martinez1 1Department of
Medical Oncology, Cruces Hospital Baracaldo, Spain, 2Department of
Neumology, Cruces Hospital Baracaldo, Spain, 3Department of Proteomika,
Proteomika, Spain
Introduction: Previously we have identified using proteomic techniques
several proteins with significant different expression in patients diagnosed of
lung cancer. The aim of this study is to validate these potential markers using
high sensibility specific immunoassays.
Methods: We have included 204 bronchial fluid samples of lung cancer
patients (63 small cell lung cancer, 59 adenocarcinoma, 82 squamous) and 48
control cases with other pathologies. We have developed sandwich immu-
noassays based on Luminex xMAP technology, to identify and validate each
potential molecular marker. In each case, it is necessary to obtain a pair of
antibodies able to bind simultaneously to the marker. Once the assay has
been designed and optimized, the amount of each marker present in the
different samples is measured. The comparisons among both groups was
made using t-Student test and diagnostic capability of each marker was
evaluated using ROC curves.
Results: We have developed until now immunoassays for two differential
markers (M1 and M2) which showed a higher expression in diagnosed lung
cancer patients. Using immunoassays we have validated these results, and we
have showed that the concentration of each marker is significantly higher in
lung cancer patients (M1: 1668- 70vs. 770-146 p0.0001; M2: 2850-
125 vs. 920-163 p0.0001).
Conclusion: We have validated as diagnostic markers of lung cancer two of
the potential markers previously identified with proteomic techniques. It
seems reasonable a clinic validation in a higher population sample as a
previous step for the development of an applicable diagnostic test in medical
practice.
PD-010
Diagnostic Value of CEA and CYFRA 21-1 for the Differential
Diagnosis of Benign and Malignant Pleural Effusions
Jae Sung Choi, Ho Sung Lee, Ki Hyun Seo, Joo Ok Na, Yong Hoon Kim
Department of Internal Medicine, Soonchunhyang University Cheonan Hos-
pital, Republic of Korea
Introduction: The purpose of this study was to assess the clinical usefulness
of carcinoembryonic antigen (CEA) and CYFRA 21-1 tumor markers as
diagnostic tools that are complementary to cytology or pleural biopsy in the
diagnosis of malignant pleural effusions.
Methods: We prospectively enrolled patients with pleural effusion on chest
x-ray from May, 2006 to May, 2010. The levels of CEA and CYFRA 21-1
in pleural fluid and serum were assayed in 240 patients.
Results: The clinical diagnosis was malignant pleural effusions in 67
(27.9%) and benign pleural effusions in 173 patients (72.1%) which included
73 tuberculosis (TB) pleurisys (30.4%), 71 parapneumonic effusions
(29.6%), 8 empyemas (3.3%), and 21 transudative pleural effusions (8.8%)
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respectively. CEA and CYFRA 21-1 of malignant and benign pleural effusion
were significantly differences in both blood and effusion (p0.001). Among the
cell types of cancer, p value no significantly difference (p0.05). The cut-off
levels of CEA and CYFRA 21-1 in malignant pleural effusions, depending on
the basis of the best diagnostic acurracy (CEA 86.3%, CYFRA 21-1 63.9%),
were 5.26 ng/mL and 42.9 ng/mL, respectively. In malignant pleural effusions,
the sensitivity of CEA and CYFRA 21-1 were 73.1% and 50.8%, respectively,
with the specificity of 92.1% and 69.7%, respectively. In ROC analysis, serum
CYFRA 21-1 and CEA, and effusion CEA were useful markers.
Conclusion: The study suggests that pleural CEA could provide a useful
parameter for the differential diagnosis between benign and malignant
pleural effusion.
PD-011
Identification of Potential Diagnostic Markers in Bronchial
Fluid of Patients with Non Small Cell Lung Cancer (NSCLC)
Rafael Zalacain2, Guillermo Lopez Vivanco1, Sergio Carrera Revilla1, Jaime
Algorta3, Ines Marrodan Ciordia1, Eluska Iruarrizaga1, Eider Azkona1, Mikel
Arruti1, Nuria Marina2, Ainhoa Gomez Bonilla2 1Department of Medical
Oncology, Cruces Hospital Baracaldo, Spain, 2Department of Neumology,
Cruces Hospital Baracaldo, Spain, 3Department of Proteomika, Proteomika,
Spain
Introduction: Lung cancer ranks among the most common and most lethal
malignancies worldwide. An early detection might result in more favourable
outcomes for these individuals. New proteomic techniques can identify potential
diagnosis and prognostic markers. The aim of this study was to find protein
markers in bronchial fluid which could enable early diagnosis in NSCLC.
Methods: We have included 96 patients with NSCLC diagnosed using bron-
choscopy (64 squamous/29 adenocarcinoma/3 others) and 49 consecutive pa-
tients with non pathological bronchoscopy. Bronchial fluid was obtained from
each patient and potential protein markers were studied. Bronchial fluid was
centrifuged and supernatant proteins were analysed using bidimensional elec-
trophoresis with poliacrilamid gel stained with silver nitrate. Gel was scanned
and analysed with Progenesis PG6220 program, which measures intensity of
each spot. Resultant intensities in each group of patients (NSCLC/non patho-
logical bronchoscopy) were compared using T-Student method. We selected as
potential markers those spots with a p value of less than 0.05. We calculated
“fold change” of each spot as the ratio between mean intensity in NSCLC
bronchoscopes samples and non pathological bronchoscopes samples.
Results: We analysed 300 spots in each sample and we found 31 potential
markers whose fold-change ranges from 1.49 to 7.41; 15 of the markers were
expressed in a higher level in NSCLC samples and the other 16 were
expressed in a lower level.
Conclusion: We have identified 31 differential protein markers in bronchial
fluid among our patients. These results could lead in an early diagnostic test
which must be validated in future studies.
NON-SMALL-CELL LUNG CANCER - EARLY
DISEASE
PD-012
Expression of the Tumor-Specific Mage-A3 Gene in Asian Pa-
tients with Histologically Proven Stage I, II or III Non-Small
Cell Lung Cancer
Sumitra Thongprasert1, Jin-Hyoung Kang2, Jung-Shin Lee3, Kesavan Sit-
tampalam4, Ross Soo5, Aung Myo6, Diego D’agostino7, Frederic Lehmann7,
Pan-Chyr Yang8 1Department of Medical Oncology, Maharaj Nakorn
Chiangmai Hospital, Chiangmai University, Thailand, 2Department of Med-
ical Oncology, Seoul St. Mary’s Hospital, Republic of Korea, 3Department of
Oncology, University of Ulsan College of Medicine, Asan Medical Center,
Republic of Korea, 4Department of Pathology, Singapore General Hospital,
Singapore, 5Department of Haematology-Oncology, National University
Cancer Institute, National University Health System, Singapore, 6Depart-
ment of Oncology, Glaxosmithkline Biologicals, Singapore, 7Department of
Clinical Oncology, Glaxosmithkline Biologicals, Belgium, 8Department of
Internal Medicine, National Taiwan University Hospital, Taiwan, China
Introduction: The MAGE-A3 antigen is presented only in tumors; therefore
it is a suitable target for specific immunotherapy in NSCLC. The MAGE-A3
ASCI (Antigen-Specific Cancer Immunotherapeutic) has been developed to
induce an immune response against this tumor antigen and is currently under
investigation in MAGRIT Phase III trial. We report here from a retrospective
epidemiological evaluation, the MAGE-A3 gene expression in Asian patients
with pathologically proven Stage I, II or III NSCLC.
Methods: Formalin Fixed Paraffin-Embedded tumor tissue from surgical
samples is tested for MAGE-A3 expression by quantitative Reverse Tran-
scription Polymerase Chain Reaction. 326 valid samples from 6 sites (2 in
Korea, 2 in Singapore, 1 in Taiwan, 1 in Thailand) were analyzed.
Results: The MAGE-A3 expression is 26.4%. A univariate logistic regres-
sion of patient and tumor characteristics shows a statistically significant
difference in MAGE-A3 expression for gender (male: 31.2%; female:
15.2%), smoking status (ex-smokers: 37.8%; smokers: 26.0%; never-smok-
ers: 10.5%); histology (squamous cell carcinoma: 36.4%; adenocarcinoma:
20.0%) and size of tumor (4cm: 36.1%;4cm: 19.2%). In a multivariate
logistic regression, the variable gender was not significant probably because
males are more smokers (30%) than females (3%). An interaction was found
between size of the tumor and histology.
Conclusion: The MAGE-A3 expression in Asian NSCLC patients seems
lower in never-smoker female with adenocarcinoma and tumor of small size
(4 cm). Interestingly, this population of patients expressing less frequently
MAGE-A3 gene is the population for which a more frequent EGFR mutation
is observed according to the literature.
PD-013
Optimal Administration Duration of Uracil-Tegafur on Adju-
vant Chemotherapy for Completely Resected Stage I Lung
Adenocarcinoma: Retrospective Analysis from JLCRG Phase
III Study
Masahiro Tsuboi1, Chikuma Hamada2 1Department of Thoracic Surgery,
Kanagawa Cancer Center, Japan, 2Department of Faculty of Engineering,
Tokyo University of Science, Japan
Introduction: Adjuvant chemotherapy (CT) with uracil-tegafur (UFT) has
been shown to increase survival in stage I lung adenocarcinoma. In addition,
the cost-effectiveness of UFT for two years has been reported. However, the
optimal treatment duration of UFT is still unclear.
Methods: The subset of 881 patients who survived more than two years was
extracted from the JLCRG trial, which was a prospective randomized study
of CT with UFT for stage I lung adenocarcinoma, we analyzed UFT treated
patients (n431) and control patients with no treatment after surgery
(n450). The UFT treated patients were divided into 3 groups based on the
treatment duration (less than 1 year, 1 to 2 years, 2 years). Cox proportional
hazards models were used for overall survival to estimate the hazard ratios
(HRs) according to UFT treatment duration.
Results: The median follow-up time was 6.1 years. HRs for overall survival
were 0.73 (95% confidence interval [CI], 0.34 to 1.42) for less than 1 year
group(n108), 0.59 (95% CI, 0.27 to 1.15) for 1 to 2 years group(n143),
0.53 (95% CI, 0.26 to 0.98) for 2 years group(n180), respectively.
Conclusion: In retrospective exploratory analysis for JLCRG trial, the
longer duration of UFT administration more improved HR. Optimal admin-
istration duration of UFT seems to be two years on adjuvant chemotherapy
for completely resected stage I lung adenocarcinoma.
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SURGERY
PD-014
Approach to Metastasis-Suspected Nodule in Otherwise Opera-
ble Lung Cancer
Joon Suk Park, Hong Kwan Kim, Yong Soo Choi, Kwhanmien Kim, Young
Mog Shim, Jhingook Kim Department of Thoracic Surgery, Samsung Med-
ical Center, Republic of Korea
Introduction: Patients with pulmonary metastasis of non-small cell lung
cancer (NSCLCa) generally are not considered as surgical candidates. How-
ever, the diagnosis of pulmonary metastasis has been largely based on
radiologic results, often without pathologic confirmation. A lack of patho-
logical confirmation might lead to loss of survival chance in actually had
operable disease. We tried to uncover the reliability of radiologic diagnosis
of pulmonary metastasis of NSCLCa, and establish the appropriate manage-
ment guideline.
Methods: From January 2003 to December 2005, 47 patients who had
operable NSCLCa, only except suspected pulmonary metastasis in non-
primary lobe, underwent lung resections, either diagnostic or curative pur-
pose. Patient characteristics, operative data, pathologic results, and follow-up
information were analyzed retrospectively.
Results: In 30 patients, suspected metastasis was pathologically confirmed
by lung resection. In 17 patients in whom pathologic diagnosis was unavail-
able, curative resection for primary tumor was performed and suspected
lesion was carefully monitored. As a result, 12 patients were finally diag-
nosed to have had true metastasis. The accuracy of radiologic diagnosis of
pulmonary metastasis was 25.5%. Between true and false metastasis, there
was no significant difference in characteristics appeared in chest CT scan.
Five patients with true metastasis underwent curative resection and median
survival was 21.8 months.
Conclusion: The radiologic diagnosis of pulmonary metastasis was not
always reliable, and can deprive patients of the opportunity of curative
resection. Complete resection of both primary tumor and metastasis might
have benefit for these patients. Therefore, aggressive pathological assessment
must be considered for suspected pulmonary metastasis of NSCLCa.
PD-015
Localization of Pulmonary Nodules for Video-Assisted Thora-
coscopic Surgical Resection
Jung Min Seo1, Ho Yun Lee1, Kyung Soo Lee1, Hong Kwan Kim2, Young
Mog Shim2, Tae Sung Kim1, Jhingook Kim2, Yong Soo Choi2, Kwhanmien
Kim2 1Department of Radiology, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Republic of Korea, 2Department of Thoracic
Surgery, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Republic of Korea
Introduction: Development of helical CT and wide-spread use of chest CT
in health screens have allowed the increased detection rate of small solitary
pulmonary nodules including ground-glass opacity (GGO) nodules. Many
GGO nodules cannot be readily detected during surgical procedures such as
VATS. Hence, the techniques that can help confirm the location of these
tumors in collapsed lungs during surgery and assist thoracic surgeons in
determining the margin of the resected lung from GGO nodules should be
established. The purpose of this exhibit is to illustrate VATS procedures and
current techniques in the localization of pulmonary nodules, discuss the pros
and cons of the techniques, and finally to suggest the optimal technique for
nodule localization.
Results: CONTENT ORGANIZATION 1. Comprehensive review for
VATS resectionA. Indication B. Procedure 2. Consideration of nodule
intrinsic factors for successful localization A. Location and relationship
with surrounding structuresB. Distance from the pleural surfaceC. SizeD.
Density E. Pathology 3. Pros and cons of various techniques or models of
imaging-guided localization 4. Practical guideline of nodule localiza-
tion5. Introduction of our technique focused on the results of safety and
effectiveness.
Conclusion: The major teaching points of this exhibit are:1. To acknowledge
VATS resection procedures and to know what thoracic surgeons want in
localizing lung nodules. 2. To review the various current techniques used in
the localization of pulmonary nodules. 3. To consider which conditions and
materials should be met for the optimal localization of pulmonary nodules.
PD-016
Surgery versus Chemoradiation in Clinical N2 Non-Small Cell
Lung Cancer: Mid-Term Treatment Outcome
Kook Nam Han1, Chang-Hyun Kang2, Young Tae Kim2, Byung Soo Yoo2,
Joo-Hyun Kim2 1Department of Thoracic and Cardiovascular Surgery, Gil
Hospital, Gachon Medical School, Republic of Korea, 2Department of
Thoracic and Cardiovascular Surgery, Seoul National University Hospital,
Seoul National University College of Medicine, Republic of Korea
Introduction: The aim of this study is to evaluate the results after either
surgical or non-surgical treatment in clinical N2 non-small cell lung cancer
(NSCLC).
Methods: Between November 2004 and October 2009, 186 patients were
enrolled in our study and divided into the following 3 groups: patients who
underwent surgical resection (group A; n87); patients who underwent
concurrent chemoradiation (CCRT) in spite of resectable NSCLC (group B;
n68); and patients who underwent CCRT due to advanced or intolerability
to surgery (group C; n31).
Results: The operative mortality was 2.3% (n2). Seventy-three patients
(84%) received adjuvant chemotherapy and 30 patients (34.5%) received
adjuvant radiation. In groups B and C, complete remission and partial
response was achieved in 1 (1.4%) and 45 patients (66.1%) in group B,
and 3 (9.6%) and 11 patients (35.5%) in group C. Disease progression
during treatment occurred in 21 patients (30.9%) in group B and 17
patients (54.8%) in group C. The median follow-up period was 17 months
(0-59 months). Overall 3-year survivals were 86.0%, 77.2%, and 57.4%
in group A, B, and C. Group C showed significantly poorer survival than
other groups (p0.026). The progression-free survival in group A was
55%, which was significantly higher than 17.4% and 7.8% in group B and
C (p0.001).
Conclusion: Potential surgical candidates with operable stage and general
condition showed favorable prognosis in clinical N2 NSCLC compared to
inoperable patients. Surgical treatment demonstrated better disease control
than CCRT, therefore surgery should be considered as one of primary
treatment modality for resectable clinical N2 NSCLC.
ENDOSCOPY AND INTERVENTION
BRONCHOSCOPY
PD-017
Significance of Bronchial Washing Cytology in Endoscopically
Visible Lung Cancer
Ho Cheol Kim, Gee Dong Lee, Yu-Ji Cho, Yi-Yeong Jeong, Jong- Deog Lee,
Young-Sil Hwang Department of Internal Medicine, College of Medicine,
Gyeongsang National University, Republic of Korea
Introduction: Flexible bronchoscope has an essential role in the diagnostic
workup of a suspected lung cancer. We investigated the diagnostic yield of
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washing and forceps biopsy during bronchoscopy according to the endo-
scopic morphology and the site of sampling in patients with lung cancer.
Methods: The retrospective chart review was performed 739 of cases
suspected of a lung cancer were underwent a flexible bronchoscopy from
April 2003 to December 2008 at Gyeongsang National University Hospital.
Results: 611 patients with lung cancer were included. A forceps biopsy
by bronchoscopy was positive for lung cancer in 492 cases (80.5%) and
the diagnostic yield of the combination of forceps biopsy with washing
was 84.1% (514/611 cases) and increased by 3.8% with statistical
significance (p0.001) (table 3). Bronchoscopic procedures in tumor,
necrosis and infiltrative lesions gave higher diagnostic yields than the
other lesions but washing cytology in these lesions gave no additional
diagnostic yield to the combination with forceps biopsy (p0.05). In
normal and compressive lesions, the collection of washing specimens in
addition to forceps biopsy increased the diagnostic yield of forceps
biopsy with statistical significance (p0.05). When statistically stratified
to endobronchial versus peribronchial lesions by bronchial findings,
washing added diagnostic yields to forceps biopsy with significance
(p0.05).
Conclusion: The combination of forceps biopsy and washing cytology
through bronchoscopy had a better diagnostic yield, depending on the
endoscopic morphology and the site of sampling.
PD-018
The Role of Pleural Fluid MAGE RT-PCR in the Diagnosis of
Malignant Pleural Effusion
Eun Ju Jeon1, Hye Kyeong Park1, Kyeongman Jeon1, Won-Jung Koh1, Gee
Young Suh1, Man Pyo Chung1, Hojoong Kim1, O Jung Kwon1, Chang-Seok
Ki2, Sang-Won Um1 1Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Republic of Korea, 2Depart-
ment of Pathology, Samsung Medical Center, Sungkyunkwan University
School of Medicine, Republic of Korea
Introduction:Melanoma antigen (MAGE) gene is known to be expressed in
tumor cells, testis and placenta. The purpose of this prospective study was to
investigate the sensitivity, specificity and accuracy of pleural fluid MAGE
gene expression, tumor marker and cytology in the diagnosis of malignant
pleural effusion.
Methods: Between Jan 2009 and Dec 2009, the patients with unilateral
pleural effusion on chest radiography were included in the study. The
exclusion criteria were body temperature38.3°C and peripheral blood
leukocytosis (12,000/l). The MAGE genes were analyzed by RT-nested
PCR using MAGE A1-6 common primers.
Results: Of the 81 enrolled patients, fifty-three patients were diagnosed as
malignant pleural effusion and 25 patients were diagnosed as non-
malignant pleural effusion. However, diagnoses of three patients were not
confirmed in this study. The optimal cutoff value of pleural fluid CEA for
distinguishing between malignant and non-malignant pleural effusion
was identified as5 ng/mL (81.8 % for sensitivity, 100% for specificity,
and 91.4 % for accuracy). The diagnostic sensitivity, specificity, and
accuracy of cytology were 52.8%, 100%, and 67.9%, respectively. The
diagnostic sensitivity, specificity, and accuracy of MAGE RT-PCR were
54.7%, 96%, and 67.9%, respectively. The combined diagnostic sensi-
tivity, specificity, and accuracy of cytology and MAGE RT-PCR were
73.6%, 96% and 80.8%, respectively.
Conclusion: MAGE RT-PCR may be useful for the diagnosis of malignant
pleural effusion in patients with negative result for pleural fluid cytology.
However, pleural fluid CEA was most sensitive marker for the diagnosis of
malignant pleural effusion in this study.
RADIOTHERAPY
PD-019
Pretreatment FDG-PET Can Predict Survival Rates Following
Definitive Radiotherapy in Lymph Node Positive Non-Small Cell
Lung Cancer Patients
Hyun-Cheol Kang1, Hong-Gyun Wu1, Charn Il Park1, Keon Wook Kang2
1Department of Radiation Oncology, Seoul National University College of
Medicine, Republic of Korea, 2Department of Nuclear Medicine, Seoul
National University College of Medicine, Republic of Korea
Introduction: We investigated whether the maximum standardized uptake
value (mSUV) of [18F]fluorodeoxyglucose positron emission tomography
(FDG-PET) could be a prognostic factor for lymph node positive non-small
cell lung cancer (NSCLC) patients treated with definitive radiotherapy (RT).
Methods: A total of 68 NSCLC T1-4, N1-3, M0 patients underwent
FDG-PET before RT. Optimal cutoff values of mSUV ratio of lymph node
to primary tumor (mSUVR) were chosen based on distant metastasis-free
survival (DMFS) and overall survival (OS). Independent prognosticators
were identified by Cox regression analysis.
Results: With respect to DMFS and OS, the most significant cutoff value for
mSUVR was 0.9. The 2-year DMFS was 30% for patients with mSUVR0.9
and 50% for those with mSUVR0.9 (p0.04). Two year OS was 23% and
38% respectively (p0.01). In a multivariate analysis, including age, per-
formance status, stage, use of chemotherapy, and mSUVR, only stage IIIB
(p0.05) and mSUVR0.9 (p0.01) were significant predictors of OS. The
2-year survival for patients with both stage other than IIIB and mSUVR0.9
was significantly better than that for patients with either stage IIIB or
mSUVR0.9 (DMFS 72% versus 31%, p0.02; OS 77% versus 15%,
p0.01).
Conclusion: Our results suggested that the mSUVR was the strong prog-
nostic factor among the patients with lymph node positive NSCLC following
RT. The addition of mSUVR to stage identifies a subgroup of patients at
highest risk for death as a result of distant metastasis after RT.
PD-020
Treatment Outcome of 3-Dimensional Definitive Conventional
Radiotherapy Alone for Non-Metastatic Non-Small Cell Lung
Cancer
Yu Sun Lee, Eun Kyung Choi, Si Yeol Song, Sang Min Yoon, Sang-Wook
Lee, Seung Do Ahn, Jong Hoon Kim Department of Radiation Oncology,
Asan Medical Center, Republic of Korea
Introduction: To evaluate the treatment outcome of definitive conventional
radiotherapy alone for patients with non-metastatic non-small cell lung
cancer.
Methods: Sixty two NSCLC patients treated with 3-dimensional definitive
conventional radiotherapy alone from JAN 2002 to JUL 2007 were recruited
to this retrospective study. Among them, 25 patients excluded in the analysis
because of incomplete treatment, double primary, follow-up loss after treat-
ment. Median age was 72 years. Two-thirds patients had squamous cell
carcinoma and clinical stage was IB (11%), II (62%), III (27%). The causes
of radiotherapy alone were old age, poor lung function or co-morbid medical
problems. Radiotherapy dose was 66 Gy in 30 fractions, as fractionation size
was 2.2 Gy per day.
Results: Tumor response 1 month after radiotherapy was judged to major
response in 21(56.8%), stable disease in 15 (40.5%) and disease progression
in 1(2.7%) patients. During the follow-up period, 16 patients suffered from
disease recurrence and the first failure site was locoregional recur in 10,
distant metastasis in 4 and both in 2 patients. Median follow-up period was
14 months. Median survival time was 15 months and 2 year overall survival
rate was 38%. Among the 27 deaths, 26 died of lung cancer. Locoregional
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progression occurred in 13 patients and 2 year locoregional progression-free
survival was 52%.
Conclusion: Treatment outcome after conventional radiotherapy alone in
mostly locally-advanced NSCLC was promising, although it was inevitably
adopted because of medical problem. Major failure pattern after radiotherapy
alone was locoregional recurrence and it was necessary to try to escalate
radiotherapy dose with modern technique.
COMBINED MODALITY THERAPY
PD-021
Feasibility Study of Adjuvant Chemotherapy with S-1 for Non-
Small Cell Lung Cancer
Tomoshi Tsuchiya1, Takeshi Nagayasu1, Naoya Yamasaki1, Takuro
Miyazaki1, Tsutomu Tagawa2, Akihiro Nakamura3, Hiroyuki Minami3,
Hideki Taniguchi4, Shinji Akamine5, Hiroshi Hisano6, Yoshitaka Taniguchi7
1Department of Translational Medical Sciences, Nagasaki University Grad-
uate School of Biomedical Sciences, Japan, 2Department of Surgery, Na-
tional Hospital Organization Nagasaki Medical Center, Japan, 3Department
of Surgery, Sasebo Municipal Hospital, Japan, 4Department of Surgery, The
Japanese Red Cross Nagasaki Genbaku Hospital, Japan, 5Department of
Chest Surgery, Oita Prefectural Hospital, Japan, 6Department of Surgery,
Saiseikai Nagasaki Hospital, Japan, 7Department of Surgery, Fukuda Geka
Hospital, Japan
Introduction: Oral adjuvant chemotherapy without hospitalization might
reduce patients’ physiological and psychological burden when the effective-
ness is guaranteed. We conducted a multicenter feasibility study using S-1,
an oral derivative of 5-fluorouracil, as postoperative adjuvant chemotherapy
for curatively resected pathologically stage IB to IIIA non-small cell lung
cancer patients.
Methods: Adjuvant chemotherapy consisted of eight courses (4-week ad-
ministration and 2-week withdrawal) of S-1, at 80-120mg/body per day.
Fifty-one patients from seven institutions were enrolled in this pilot study,
from June 2005 to March 2007. The primary endpoint was the rate of
accomplishment of the scheduled adjuvant chemotherapy. Secondary end-
points were the incidence and grade of adverse reactions.
Results: Forty-nine patients (33 male, 16 female) were eligible including
pathologically stage IB (57.1%), IIA (20.4%), IIB (10.2%), and IIIA
(12.2%). Among the patients, S-1 administration was discounted in 25
patients due to adverse reactions. Although the adverse reactions such as
neutropenia, leukopenia, elevated total bilirubin, anorexia, general fatigue,
diarrhea, nausea, and stomatitis were seen in more than half of the patients,
no grade 4 adverse effects appeared. Total percent administration days were
78.6% and total percent administration amount was 72.7%, which was
calculable power for preventing recurrence. Against the adverse reactions,
dose reduction improved the completion rate up to 79.2% compared to 36.4%
without dose reduction. Therefore, we could achieve high completion rate of
73.5% (36 patients).
Conclusion: Postoperative one year administration of S-1 seems feasible as
adjuvant chemotherapy for lung cancer. The high completion rate was
archived when the administration dose was one-rank discounted.
PD-022
Postoperative Adjuvant Chemotherapy for ERCC1 Positive
Non-Small Cell Lung Cancer
Han Suk Ryu1, Xianhua Xu1, Sanghoon Jheon2, Jong-Seok Lee3, Jin Haeng
Chung1 1Department of Pathology, Seoul National University Bundang
Hospital, Republic of Korea, 2Department of Thoracic Surgery, Seoul Na-
tional University Bundang Hospital, Republic of Korea, 3Department of
Internal Medicine, Seoul National University Bundang Hospital, Republic of
Korea
Introduction: The role of excision repair cross-complementation Group1
(ERCC1) overexpression has been controversial in non-small cell lung
cancer (NSCLC) patients who received adjuvant chemotherapy with plati-
num agent. We investigated ERCC1 expression in NSCLC to clarify its
significance as a predictive marker for adjuvant chemotherapy.
Methods: Immunohistochemical analysis of a tissue microarray (TMA) with
183 resected NSCLC specimens was performed to study the expression of
ERCC1 in relation to chemotherapeutic effect. All patients were divided into
3 groups; 1) adjuvant chemotherapy (CTX) with platinum agent (29.5%,
54/183), 2) adjuvant CTX with Uracil-Tegafur (UFT) (32.2%, 59/183), and
3) no adjuvant CTX (38.8%, 70/183). These results were correlated with
other clinicopathologic features.
Results: Nuclear ERCC1 overexpression was detected in 67.2 % (123/183)
of NSCLC and significantly associated with shortened survival period of the
patients group who received platinum based CTX. The patients group that
received UFT showed the most prolonged survival period followed by that
did not receive adjuvant CTX (overall survival: p0.001, disease free
survival: p0.023). In multivariate analysis, ERCC1 overexpression was
significantly associated with short disease free survival periods of the
patients group who received platinum based chemotherapy. When confined
to stage I or II NSCLC (n146), UFT showed the most beneficial effect on
disease free and overall survival in ERCC1 positive NSCLC (p0.001 and
0.049).
Conclusion: These results suggest that surgically resected NSCLC patients
with ERCC1 positive tumors show a poor disease free survival period with
adjuvant CTX with platinum based regimen and may benefit from adjuvant
CTX with UFT.
NOVEL THERAPEUTICS AND MODALITIES
PD-023
Genetic Blockade of IGF-1R Via Recombinant Adenovirus in
Lung Cancer Can Be Enhanced by HDAC Inhibitor, Vorinostat
Dal Rae Kim, Mi-Young Park, Jong Sun Park, Sei Won Lee, Ho-Il Yoon, Jae
Ho Lee, Choon-Taek Lee Department of Internal Medicine, Seoul National
University Bundang Hospital, Seoul National University College of Medi-
cine, Republic of Korea
Introduction: Many approaches such as monoclonal antibody and TKI to
IGF-1R, major antiapoptotic molecule, have been introduced for cancer
treatment. Our team has introduced recombinant adenoviruses expressing
antisense, short hairpin RNA to IGF-1R. Also we reported that HDAC
inhibitor (SAHA, vorinostat) increased the transduction efficiency of adeno-
virus by increasing transduction via increased CAR and by enhancing
adenoviral transgene. In this study, we combined ad-shIGF-1R with vori-
nostat.
Methods: We measured the change of IGF-1R by combined treatment of
vorinostat and ad-shIGF-1R. Change of transduction efficiency of ad-
shIGF-1R was also measured by fluorescent microscopy. Changes of apo-
ptotic proportion and cell survival after combined treatment were measured
by sub-G1 assay and cell counts. The effect of NFkB activation was also
measured by NFkB p65 activation ELISA assay.
Results: Combined treatment of ad-shIGF-1R and vorinostat synergistically
suppressed the IGF-1R expression in lung cancer cell lines (A549, NCI
H460) and also increased transduction efficiency of ad-shIGF-1R. Combined
treatment of ad-shIGF-1R (200moi) and vorinostat (1 M) increased apo-
ptotic cell portion from 0.72% to 8.54%. Cotreatment of ad-shIGF-1R and
vorinostat also induced synergistic cell growth suppression compared with
single treatments in four lung cancer cell lines. Vorinostat induced the
suppression of NFkB activation which was activated by ad-shIGF-1R.
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Conclusion: Vorinostat could enhance the genetic blockade by ad-shIGF-1R
and combined treatment of vorinostat and ad-sh-IGF-1R showed the prom-
ising potential to be a new therapeutic modality in lung cancer.
SMALL CELL LUNG CANCER
PD-024
The Usefulness of Measuring Circulation Tumor Cells in Pa-
tients with Small-Cell Lung Cancer
Tateaki Naito1, Fumihiro Tanaka2, Kazue Yoneda2, Toshiaki Takahashi1,
Haruyasu Murakami1, Yukiko Nakamura1, Asuka Tsuya1, Akira Ono1,
Masahiro Endo1, Nobuyuki Yamamoto1 1Department of Thoracic Oncol-
ogy, Shizuoka Cancer Center, Japan, 2Department of Thoracic Surgery,
Hyogo College of Medicine, Japan
Introduction: There has been an increasing interest in the circulating tumor
cells (CTC) in various solid tumors for predicting clinical outcomes. How-
ever, there is little information about the usefulness of measuring CTCs in
small-cell lung cancer (SCLC) that is aggressive tumor with high metastatic
potential. The aim of this study is to evaluate the relationship between the
pretreatment CTC-count and the disease extent of SCLC.
Methods: A total of 35 patients with newly diagnosed SCLC who had
received chemotherapy with or without radiotherapy were prospectively
enrolled: 19 patients had limited disease (LD) and 16 patients had extensive
disease (ED). CTCs were isolated using the CellSearch System (Veridex
LLC), and the number of CTCs per 7.5ml of peripheral blood was deter-
mined following a manufacture’s protocol.
Results: Median age was 67 years (range, 56 - 92). Twenty-three patients
had received platinum-based chemotherapy alone and 12 patients had re-
ceived chemoradiotherapy. CTCs were detected in 28 patients (80.0%) and
the median of CTC-count was 4 (range, 0 to 5648) per 7.5ml. All of the
patients whose CTC-count was 0 per 7.5ml had LD-SCLC (n7). The
CTC-count of patients with ED-SCLC (median 15, range 3 to 5648) was
significantly higher than that of patients with LD-SCLC (median 1, range 0
to 50, p0.0001 in Wilcoxon test). In addition, the number of distant
metastatic sites was significantly correlated with CTC-count (Spearman’s
rho0.73, p0.0001).
Conclusion: The pretreatment CTC-count potentially reflects the disease
extent of SCLC especially the existence of distant metastasis.
POSTER ABSTRACTS
PROGNOSTIC AND PREDICTIVE MARKERS
P-001
Differentially Expressed Genes with Copy Number Gain Based
on Microarray and Copy Number Variation Test Correlated to
the Prognosis of NSCLC Patients
Yang Wang, Xu-Chao Zhang, Zhi-Hong Chen, Jian Su, Yi-Long Wu
Department of Guangdong Lung Cancer Institute, Guangdong Academy of
Medical Sciences & Guangdong General Hospital, China
Introduction: Non-small-cell lung cancer (NSCLC) patients with the same
TNM stage may suffer from large prognosis variations, indicating that
current staging system based on anatomic characteristics do not adequately
predict outcome. Our research focused on tumor biologic characteristics, in
order to identify differentially expressed genes relating to patient survival.
Methods: Total RNAs of both tumor and matched normal tissues (n120)
were isolated and purified as template for microarray tests (Affymetrix
Human Genome U133 Plus 2.0). DNAs of these samples were also subject
for Agilent 244K copy number variation tests. For a particular gene, the ratio
was calculated as number of samples with gene copy number gain 1 or more
and gene expression up-regulated by 2 folds in cancer vs adjacent normal
tissue over total number of samples. Differentially expressed genes in more
than 1/3 of the cohort were identified for prognostic values.
Results: 11 differentially expressed genes were selected based on ratio
threshold of 36%. Top differential genes were ECT2, SKP2 and TP63 with
ratios of 53.85%. Following 3 genes were IGFBP3, EHF and HOXA10.
Basing on these 11 genes, we further identified a five-gene classifier (DST,
TP63, HOXA10, DAP3 and SKP2) for disease free survival (hazard ra-
tio2.8; 95 CI, 1.09 to 7.18; P0.032) and a five-gene classifier (DST,
DAP3, SKP2, TP63 and ECT2) for overall survival (hazard ratio2.805; 95
CI, 0.987 to 7.971; P0.053).
Conclusion: Differentially expressed genes between cancer and adjacent
normal tissues may represent good candidates for the identification of
prognostic classifiers for NSCLC.
P-002
EGFR Gene Mutation Consistency of the Primary Tumor and
Brain Metastases of Non-Small Cell Lung Cancer
Yu-Juan Huang, Yi-Long Wu Department of Guangdong Lung Cancer
Institute & Cancer Center, Guangdong General Hospital, Guangdong Acad-
emy of Medical Sciences, China
Introduction: Little is knowed about epidermal growth factor receptor
(EGFR) gene mutation consistency of primary tumors and brain metastases
of non-small cell lung cancer (NSCLC).
Methods: The gene analysis was performed by bi-directional DNA sequenc-
ing method. We obtained tumor tissues of primary tumors of lung, adjacent
tissues and brain metastases for 3 cases, also obtained tumor tissues of
primary and cerebral lesions for another 4 cases. All of these samples were
sequenced, analysed with EGFR 18, 19, 20 and 21 exons, and also K-RAS
mutation status.
Results: In these 7 cases, 4 cases had synchronized brain metastases and 3
cases presented brain metastases after lobectomy. Only 1 patient mutation
status was inconsistency, and the concordance rate was 85.7%. For the 4
cases who had synchronous brain metastases (case 1,5,6,7), the EGFR and
K-RAS mutation status of different tissues were consistency. For the other 3
asynchronous brain metastases cases, the gene mutation status of one case
(case 2) is inconsistent: the primary tumor’s EGFR and K-RAS were wild
type, however the brain metastases had exon21 point mutation, K-RAS
wild-type, but the supraclavicular lymph nodes synchronized with brain
metastases were EGFR and K-RAS wild type. After brain surgery the
Gefitinib therapy of case 2 achieved an iconography complete response (CR),
and the time to progression (TTP) was as long as 2 years.
Conclusion: EGFR and K-ras gene mutations of primary tumour and brain
metastases of NSCLC have a quite high consistency, especially for the cases
who had synchronous brain metastases.
P-003
Incidence of EML4-ALK in Unselected Non-Small Cell Lung
Cancer Population and Its Association with Other Tumor
Biomarkers
Edgardo S. Santos1, Jorge E. Gomez1, Kathleen D. Danenberg2, Luis E.
Raez1 1Department of Medicine, University of Miami/Sylvester Comprehen-
sive Cancer Center, United States of America, 2Department of Genetics,
Response Genetics, Inc., United States of America
Introduction: ALK gene is frequently involved in translocations that lead to
gene fusions in a variety of human malignancies, including lung cancer. The
presence of this genetic alteration is associated with poor response to
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chemotherapy and TKI, and hence, the importance of identifying this fusion
gene. In addition, characterization of EML4-ALK association patterns with
other biomarkers could be of benefit in better understanding the biology of
lung cancer.
Methods: As part of a DNA and genetic testing protocol, we have analyzed
45 samples for EML4-ALK fusion gene and other biomarkers including
EGFR, K-ras, ERCC1, TS, and RRM1. By using ResponseDx test, RNA
expression of EML4-ALK, EGFR, ERCC1, TS, and RRM1 by RT-PCR from
patient’s tumor tissue was analyzed. PCR analysis of DNA was used to
determine K-ras and EGFR mutation status.
Results: 45 lung cancer tumors were sent for analysis; 4 cases did not have
enough tissue for EML4-ALK testing. From all 41 samples in which
biomarkers were tested, we did not identify a positive case of EML4-ALK
fusion gene. Patient’s characteristics were: median age: 66 (47-80 yr), 24
males, 32 adenocarcinomas, 16 never smokers, and ethnicity distribution: 21
Hispanic, 17 White, and 3 African American.
Conclusion: Although 78% and 40% of our cohort was adenocarcinoma and
never smoker, respectively, we did not identify any EML4-ALK fusion gene.
More than 50% of our cohort is from Hispanic origin, a population not well
studied for this genetic alteration. Association with other tumor biomarkers
will be presented at the meeting.
P-004
Loss of PTEN Expression is an Independent Poor Prognostic
Factor in Non-Small Cell Lung Cancer
Seol Bong Yoo1, Gheeyoung Choe1, Xianhua Xu2, Hyunju Lee2, Sanghoon
Jheon3, Choon-Taek Lee4, Jin-Haeng Chung1 1Department of Pathology,
Seoul National University College of Medicine, Seoul, Republic of Korea,
2Department of Pathology, Seoul National University Bundang Hospital,
Seongnam, Republic of Korea, 3Department of Thoracic and Cardiovascular
Surgery, Seoul National University Bundang Hospital, Seoul National Uni-
versity College of Medicine, Republic of Korea, 4Department of Internal
Medicine, Seoul National University Bundang Hospital, Seoul National
University College of Medicine, Republic of Korea
Introduction: The PTEN gene acts as a tumor suppressor gene and there are
various mechanisms involved to suppress its function, including mutation,
homozygous deletion, and promoter methylation. Recently, the role of PTEN
loss is focused on drug resistance mechanism, such as gefitinib. We inves-
tigated PTEN protein expression in non-small cell lung cancer (NSCLC) and
correlated with clinicopathologic features to evaluate prognostic signifi-
cance.
Methods: Surgically resected 288 NSCLC samples including 168 adenocar-
cinomas (ADCs), 99 squamous cell carcinomas (SCCs) and 21 other
NSCLCs were analyzed for the expression of PTEN by immunohistochem-
istry (IHC). The IHC results were graded with semi-quantitative scoring
method, into four categories: 0, negative; 1, 1-25% positive; 2, 26-50 %
positive; 3,50% positive in tumor cells. When the staining was less than 50
% (grade 0 and 1), it was considered as lost or reduced staining and more
than 50% staining (grade 2 and 3) referred to as normal.
Results: Loss or reduced expression of PTEN was detected in 42.4%
(122/288) of NSCLC, specifically 28.6% (48/168) of ADC, 66.7% (66/99) of
SCC and 38.1% (8/21) of other NSCLC. Loss or reduced expression of
PTEN was significantly associated with SCC histology, smokers, male, large
size of tumor and high stage. In multivariate analysis, loss or reduced
expression of PTEN showed significant short progression-free survival
(p0.037).
Conclusion: These results suggest that loss or reduced expression of PTEN
is related with aggressive tumor behavior and PTEN protein loss is indepen-
dent poor prognostic factor in NSCLC patients.
P-005
Novel Biomarker of Lung Cancer from MicroRNA Profiles
Analysis
Tatsuo Ohira, Koichi Yoshida, Shuji Ichinose, Hisashi Saji, Masatoshi
Kakihana, Hideetoshi Honda, Jitsuo Usuda, Masaharu Nomura, Naohiro
Kajiwara, Osamu Uchida, Norihiko Ikeda Department of Surgery, Tokyo
Medical University, Japan
Introduction: The incidence of lung cancer has been increasing in the world.
Lung cancer has been the most frequent malignancy. It should be important to
identify novel biomarkers for early detection and appropriate therapy in order to
improve outcome. We are interesting in the micro RNA. Micro RNAs are a
distinct class of small encoding RNAs that post-transcriptionally repress expres-
sion of target genes. MicroRNA expression profiles were investigated for the
involvement in carcinogenesis. Micro RNA was examined with formalin-fixed,
paraffin-embedded tissue. These samples should give us much good information.
Fresh frozen tissue specimens collected at surgery and formalin-fixed, paraffin-
embedded tissue showed similar Micro RNA expression profiles.
Methods: We examined micro RNA expression profiles using formalin-
fixed, paraffin-embedded tissue from lung cancer patients who received
operation in our hospital. Then possible biomarkers were picked out.
Results: We could take high quality samples from Formalin-fixed, Paraffin-
embedded tissue. We got similar micro RNA profiles between formalin-
fixed, paraffin-embedded tissue and fresh frozen tissue specimen. Specific
microRNA profiles for lung cancer were detected from both of these
samples. Has-let 7f and has-miR-16, 21, 26a are detected in both samples.
High expression of Has -miR-205 was detected.
Conclusion: We got good RNA samples from formalin-fixed, paraffin-
embedded tissue for investigation of microRNA profiles. It should give us
possibility of detection for early stage lung cancer cases and selection of
appropriate therapies. Some novel biomarkers were picked out for treatment
and detection of lung cancer.
P-006
Prognostic Value of Sialylated Glycoprotein KL-6 in Resected
Non-Small Cell Lung Cancer
Osamu Uchida, Masahiro Taira, Hisashi Saji, Masatoshi Kakihana, Jitsuo
Usuda, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda Department of
Surgery, Tokyo Medical University, Japan
Introduction: KL-6 has been studied as a usefull marker for interstinal lung
disease. However it was first discovered as a lung cancer related antigen. The
aim of this retrospective study was to assess the prognostic value of serum
KL-6 levels in resected non-small cell lung cancer.
Methods: Between April 2004 and December 2009, 445 patients with
non-small cell lung cancer were treated with surgery after having their serum
KL-6 levels measured at Tokyo Medical University Hospital.
Results: The serum KL-6 levels ranged from 108 to 1880 (median, 384), and
14% of 61 patients showed a level higher than the cut-off level of 500U/ml. The
5-year survival of the patients with an elevated serum KL-6 level (500U/ml)
was only 59.6% compare to 72.4% in patients with a lower serum KL-6 level
(500 U/ml).
Conclusion: Our data suggest that non-small cell lung cancer patients with high
serum KL-6 levels before operation tend to have a poor clinical outcome.
P-007
Quantification of Serum Free RNA as a Predictive Biomarker in
Patients with Lung Cancer
Choonhee Son1, Soo-Jung Um1, Mee Sook Roh2 1Department of Pulmonol-
ogy, Dong-A University, Republic of Korea, 2Department of Pathology,
Dong-A University, Republic of Korea
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Introduction: Recent studies suggested that circulating cell free RNA
(cRNA) might correlate with tumor burden. Furthermore, experimental study
using cancer cell line showed that the changes of cRNA were predictive for
the response to the chemotherapy. The objective of this study was to find out
whether cRNA could be used as a biomarker for clinical response to
chemotherapy in patients with lung cancer.
Methods: Thirty-two patients with lung cancer were divided into two groups
according to the response of chemotherapy. Blood samples were collected
before and after 2 cycles of chemotherapy. Glyceride 3-phosphate dehydro-
genase gene was checked by a real-time quantitative RT-PCR assay for the
level of cRNA.
Results: Pre chemotherapy cRNA concentration expressed as Ct GAPDH
level was not different between two groups. (41.391.65 vs. 41.251.65,
p0.83). Post chemotherapy Ct GAPDH was significantly lower as com-
pared with pre chemotherapy Ct GAPDH in response group (39.821.74 vs.
41.391.65, p0.01). However, pre and post chemotherapy Ct GAPDH was
not significantly different in non response group (40.761.40 vs.
41.251.65, p0.43). Post chemotherapy Ct GAPDH level was more likely
to decrease in response group (decrease 81.8%, increase 18.2%) as compared
with non-response group (decrease 40%, increase 60%) (p0.04). Decrease
in Ct GAPDH after chemotherapy was only factor to predict clinical response
to chemotherapy (OR, 19.29, 95% CI, 1.81-205.60 p0.014).
Conclusion: This finding suggests the change of cRNA level before and after
chemotherapy may be predictive for response to the chemotherapy in patients
with lung cancer.
P-008
Study the Correlation between EGFR Mutation and Gene Copy
Number Status, and the Relationship between EGFR Gene
Status and Clinicopathological Variables of No-Small Cell Lung
Carcinomas in Chinese Patients
Lan Jun Zhang, Zhe Li Department of Thoracic Surgery, Cancer Centre of
Sun Yat-Sen University, China
Introduction: To investigate EGFR mutation and gene copy number status
in no-small cell lung carcinomas in Chinese patients. Study the correlation
between EGFR mutation and gene copy number status, and the relationship
between EGFR gene status and clinicopathological variables.
Methods: Using formalin fixed and paraffin embedded tissue samples,
EGFR mutations were investigated in 118 cases of no-small cell lung
carcinomas by microdissection and Real-Time PCR. The status of EGFR
gene copy number was investigated by FISH. Then, the correlation between
EGFR mutation and gene copy number status, and the relationship between
EGFR gene status and clinicopathological variables of no-small cell lung
carcinomas were analyzed.
Results: The overall mutation rate of EGFR was 41.5%. The mutation rate
in adenocarcinoma and squamous carcinoma were 50.0%, 5.0%, respec-
tively. In addition, no EGFR mutation were found in one sarcomatoid
carcinoma case and one adenosquamous carcinoma case. The overall FISH
positive rate of EGFR was 70.3%.FISH positive rates in adenocarcinoma and
squamous carcinoma were 78.1%, 35.0%, respectively. The FISH positive
was found in one sarcomatoid carcinoma case, one adenosquamous carci-
noma case was negative. Therefore, EGFR mutation and high copy number
mainly occurred in the adenocarcinoma, advanced stadge, female gender,
no-smoking patients. The remarkable correlation was found between them.
Conclusion: There are higher EGFR mutation rate and FISH positive rate in
non-small cell lung carcinoma in Chinese patients (especially in the adeno-
carcinoma, female gender, advanced stadge, no-smoking patients). Com-
bined analysis of EGFR mutation and gene copy number by FISH may
provide a superior approach in selecting patients who may benefit anti—
EGFR target therapy.
P-009
The Efficacy of Gefitinib for Non-Adeno Non-Small-Cell Lung
Cancer Patients Harboring EGFR Mutations: A Pooled Analysis
Takehito Shukuya1, Toshiaki Takahashi1, Akira Ono1, Yukiko Nakamura1,
Asuka Tsuya1, Hirotsugu Kenmotsu1, Tateaki Naito1, Kyoichi Kaira1, Ha-
ruyasu Murakami1, Masahiro Endo2, Nobuyuki Yamamoto1 1Department of
Thoracic Oncology, Shizuoka Cancer Center, Japan, 2Department of Diag-
nostic Radiology, Shizuoka Cancer Center, Japan
Introduction: Because only a few percent of patients who enrolled the
clinical trials to evaluate the efficacy of gefitinib for non-small cell lung
cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) muta-
tion were non-adeno NSCLC, the efficacy of gefitinib for these patients is
unclear. We conducted a pooled analysis to clarify the efficacy of gefitinib
for non-adeno NSCLC patients harboring EGFR mutations.
Methods: We performed a systematic search of the PUBMED databases to
identify all clinical reports that contained advanced non-adeno NSCLC
patients harboring EGFR mutations and treated with gefitinib. The selected
patients were advanced non-adeno NSCLC patients harboring EGFR muta-
tions who were treated with gefitinib and had the data of histology, status of
EGFR mutations and response to gefitinib.
Results: We selected 33 patients from 15 reports. Of the 33 patients, 27
patients and 3 patients were squamous cell carcinoma and adenosquamous
cell carcinoma, respectively. Each one patient was large cell carcinoma,
pleomorphic carcinoma and spindle cell carcinoma. 21 patients (64%) had
sensitive EGFR mutations. Response rate (RR), disease control rate (DCR)
and median progression free survival (mPFS) was 27%, 67-70% and 3.0
months, respectively. These factors were statistically significantly inferior in
non-adeno NSCLC patients harboring EGFR mutations to adenocarcinoma
patients harboring EGFR mutations selected from the same published reports
(RR: 27% vs 66%, p0.000028, DCR: 67-70% vs 92-93%, p0.000014,
mPFS: 3.0 months vs 9.4 months, p0.0001).
Conclusion: Gefitinib is less effective in non-adeno NSCLC harboring
EGFR mutation than adenocarcinoma harboring EGFR mutation.
P-010
The Expression and Clinical Significance of -tubulin in 91
Cases Non-Small Cell Lung Cancer
Sujun Gao1, Zhi Li2, Qingsong Liu2, Wei Liu2 1Department of Oncology,
First Hospital of Jilin University, China, 2Department of Thoracic Surgery,
First Hospital of Jilin University, China
Introduction: -tubulin is one of the most common members of the tubulin
family that make up microtubules. The previous studies had shown that
microtubules dynamics played a critical role in tumor cell division, cytoskel-
etal formation, cell motility and apoptosis. Several similar studies of -tu-
bulin showed that it was highly expressed in non-small cell lung cancer
(NSCLC) and related to patient’s gender, tumor pathological types, the
response to anti-microtubules agent and even prognosis. But the studies of
-tubulin expression and its clinical significance in NSCLC are hardly to be
found in the published literatures.
Methods: The expression of -tubulin was assessed under immunohisto-
chemistry method by using tissue microarray technique. The correlations
between NSCLC clinicopathologic findings and the expression of -tubulin
were analyzed by 	2 test or Fisher exact test; the survival analysis was
generated by the Kaplan-Merier method using log-rank test.
Results: -tubulin was expressed in all NSCLC patients and over-expressed
in 38.46% (35/91) patients. The over-expression were statistically significant
in younger age (younger than 55 yrs), squamous carcinoma and early PTNM
stage (Stage I and II) compared to older age (older than 55 yrs, 56.7% vs
29.5%, p0.012), adenocarcinoma(47.2% vs 26.3%, P0.044) and Stage III
(44.8% vs 20.8%, p0.039)respectively. In younger age and squamous
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carcinoma, the patients with over-expression had better prognoses than
lower-expression (76 vs 28 months; 80 vs 37 months, P0.05).
Conclusion: The expression of -tubulin is common in NSCLC, and the
over-expression of -tubulin is related to patient’s age, squamous carcinoma,
early stage and prognosis.
P-011
A Fully Automated and Rapid System for the Detection of
EGFR Mutation in Lung Adenocarcinoma
Tatsuhiko Kashii1, Kensuke Suzuki2, Toshiro Miwa1 1Department of Med-
ical Oncology, Toyama University Hospital, Japan, 2Department of Respi-
ratory Medicine, Toyama University Hospital, Japan
Introduction: Activating mutations of the EGFR gene in lung adenocarci-
noma have been associated with response to tyrosine kinase inhibitors,
erlotinib and gefitinib. It is important to detect EGFR mutation rapidly for
deciding treatment plan of the patients. We have developed a system utilizing
EGFR mutation specific quenching probe (QP-system) to detect EGFR
mutation.
Methods: We compared QP-system with PCR-Invader assay and direct
sequencing using 5 lung adenocarcinoma patient’s specimens (4 paraffin-
embedded, 1 pleural effusion).
Results: Deletion of exon 19 was detected in 4 specimens with both
methods. Mutation of L858R was detected in 1 specimen from pleural
effusion with only PCR-Invader assay. However mutation of T790M, re-
ported for resistance to tyrosine kinase inhibitors, was detected in 1 specimen
with only QP-system.
Conclusion: These results suggest that QP-system is more sensitive and
useful than PCR-invader assay for detecting EGFR mutation including
T790M.
P-012
Pyrosequencing Method to Detect EGFR Mutations in Lung
Cancer
Hee Joung Kim1, Sun Jong Kim1, Gang Ha Yoo1, Won Dong Kim1, Seo
Young Oh2, Wan Seop Kim2, Kye Young Lee1 1Department of Internal
Medicine, Konkuk University School of Medicine, Republic of Korea, 2De-
partment of Pathology, Konkuk University School of Medicine, Republic of
Korea
Introduction: Direct sequencing is known to be the standard method to
detect EGFR mutations in lung cancer, but its relatively low sensitivity limits
its clinical usefulness. Pyrosequncing is a bioluminometric, real-time DNA
sequencing technique and has advantages over direct sequencing much
higher sensitivity, faster automated system and cost-effectiveness.
Methods: Two hundred and two pathologically proven lung cancer patients
of Konkuk University Hospital were analyzed for EGFR mutations using
pyrosequencing method.
Results: Overall EGFR mutation positive rate is 26.7% (54/202). It is
significantly higher in female (52.1% vs. 13.0%), never-smoker (47.8% vs.
15.8%), and adenocarcinoma (35.2% vs. 5.2%). However, significant num-
bers of EGFR mutation positive patients were identified in some male,
ever-smoker, or non-adenocarcinoma patients. The combinations of favor-
able clinicopathologic factors, such as female, never-smoker and adenocar-
cinoma, does not significantly increase the positive EGFR mutation rate
(female52.1%; female and never-smoker52.6%; female, never-smoker
and adenocarcinoma51.9%) This suggests that EGFR mutation analysis is
mandatory to predict the response to EGFR-TKI rather than favorable
clinicopathologic factors. Exon 19 del is the most common (63.6%) and exon
21 L858R showed 32.7%. One case of exon 20 T790M mutation was
detected before the exposure to EGFR-TKI. EGFR mutation status is signif-
icantly related with the response to EGFR-TKI; ORR in EGFR mutation ()
group is 82.4% while 5.9% in EGFR mutation (-) group.
Conclusion: These data strongly indicate the importance of EGFR mutation
analysis in the clinical practice of lung cancer and that pyrosequencing
method is a sensitive and valuable methodology for analyzing EGFR muta-
tions.
NON-SMALL-CELL LUNG CANCER –
ADVANCED DISEASE
P-013
A Phase II Trial of Neoadjuvant Erlotinib (TARCEVA®) Fol-
lowed by Surgery for Selected Patients with Stage IIIA, N2-
Positive Non-Small Cell Lung Cancer
Taekyu Lim, Kyung Kee Baek, Jun Ho Yi, Jong-Mu Sin, Jeeyun Lee, Yeon
Hee Park, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park Department of
Hematology-Oncology, Samsun Medical Center, Republic of Korea
Introduction: Patients with locally advanced non-small cell lung cancer
(NSCLC) can expect better clinical outcome with preoperative neoadjuvant
treatment. Erlotinib (Tarceva®), an oral epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, has been approved its efficacy and safety
in patients with NSCLC especially in women, adenocarcinoma, never-
smoker and Asian population. This study reports efficacy, toxicity and
predictive factor for response of preoperative treatment with erlotinib in
patients with stage IIIA, N2 positive NSCLC.
Methods: From May 2007 to Jan 2010, 29 patients with histologically
confirmed stage IIIA, N2 positive NSCLC were enrolled. All patients were
non-smokers and had adenocarcinoma. 25 were female.(86.2%) Patients took
150mg of erlotinib per day for 8 weeks before surgery.
Results: Radiological overall response rate was 51.7%. No patients experi-
enced grade 34 toxicities. The most common adverse event was grade 1
and 2 skin rash (13 for each, 44.8%). 25 out of 29 (86.2%) patients
underwent surgical resection. Pathological downstaging rate to N0N1 was
8.0% (2/25) and downstaging rate in T stage was 16.0% (4/25) No major
perioperative morbidity or mortality were observed. 1 patient had early
relapse and could not receive adjuvant therapy. We carried out univariate
analysis for predictive factor for pathologic response, but all the variables
including age, sex, EGFR mutation status, performance status, adverse
events failed to show predictive power.
Conclusion: Although we carried out neoadjuvant treatment with erlotinib in
population with known favorable factors, overall response rate fell behind
our expectation. However, in regard of safety profile, perioperative morbidity
or mortality the results are excellent.
P-014
A Prospective Randomized Multi-Center Trial of Three Che-
motherapy Regimens in Korean Patients with Advanced Non-
Small Cell Lung Cancer - Analysis of Korean Association for
Study of Lung Cancer (KASLC)-0301 Trial
Maan-Hong Jung1, Young-Chul Kim2, Sun-Young Kim3, Jeong-Seon Ryu4,
Tae-Won Jang1, Kyu-Sik Kim2 1Department of Pulmonology, Kosin Uni-
versity Gospel Hospital, Republic of Korea, 2Department of Pulmonology,
Chonnam National University, Hwasun Hospital, Republic of Korea, 3De-
partment of Pulmonology, Chungnam National University Hospital, Repub-
lic of Korea, 4Department of Pulmonology, Inha University Hospital, Re-
public of Korea
Introduction: The response of chemotherapy in non-small-cell lung cancer
(NSCLC) is different by the ethnic groups. This is a randomized prospective
trial to determine the response of chemotherapy in Korean patients with stage
IIIb/IV NSCLC.
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Methods: A total of 333 patients were randomly assigned to one of regimens
of 3-weekly cycle: cisplatin of 60 mg/ m2 on day 1 with docetaxel of
75mg/m2(DP) or paclitaxel of 130 mg/ m2(TP) on day 1, or gemcitabine of
1200mg/ m2 on day 1 and 8(GP). After 23 cycles of chemotherapy,
non-responding patients were crossly assigned to the second-line mono-
therapy of either docetaxel or gemcitabine. During the follow-up, 130
patients were treated with tyrosine kinase inhibitor (TKI).
Results: There was no difference in sex, stage, and performance status
between the 3 groups. The overall response rate was 37.3%, a median
survival time of 11.3 months (95% CI: 9.313.3 months) and median
progression free survival time of 5.4 months (95% CI: 4.66.1 months). In
130 patients treated with TKI, the median survival time was significantly
longer than those not treated (19.8 months vs. 7.4 months: p0.0001). The
first-line treatment with GP was associated with a significantly lower inci-
dence of grade 3, 4 neutropenia than DP or TP (8.2% vs. 22.8% or 15.6 %,
respectively: p0.022), but grade 3, 4 thromobocytopenia was higher (7.3%
vs. 1.8% or 0%, respectively: p0.0001).
Conclusion: There were no survival advantages among the three regimens in
patients with advanced NSCLC. But the complication rates were different,
and adding the third-line TKI improved the survival time.
P-015
Additional Biomarker Analyses from the Phase III OPTIMAL
Study of First-Line Erlotinib versus Gemcitabine/Carboplatin
(GC) in Chinese Patients (pts) with Advanced Activating EGFR
Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Jifeng Feng1, Yi-Long Wu2, Caicun Zhou3, Shun Lu4, Li Zhang5, Xiuyi Zhi6,
Ying Cheng7, Lei Chen8, Yi Luo9, Chunhong Hu10 1Department of Medical
Oncology, Jiangsu Province Cancer Hospital, China, 2Department of Med-
ical Oncology, Guangdong Lung Cancer Institute, Guangdong General
Hospital, China, 3Department of Medical Oncology, Shanghai Pulmonary
Hospital, Tongji University, China, 4Department of Medical Oncology,
Shanghai Chest Hospital, Affiliated to Shanghai Jiao Tong University,
China, 5Department of Medical Oncology, Sun Yat-Sen University Cancer
Center, China, 6Department of Medical Oncology, Xuanwu Hospital of
Capital Medical University, China, 7Department of Medical Oncology, Jilin
Province Cancer Hospital, China, 8Department of Medical Oncology, Can-
cer Hospital Shantou University Medical College, China, 9Department of
Medical Oncology, Hunan Province Cancer Hospital, China, 10Department
of Medical Oncology, Second Xiangya Hospital Central South University,
Changsha, China
Introduction: Rosell et al (2010) demonstrated the promising efficacy of
erlotinib in pts with advanced NSCLC whose tumours harbour activating
EGFR mutations in exon 19 or 21 (mut). OPTIMAL was initiated to
compare erlotinib vs GC for first-line mutadvanced NSCLC. Additional
biomarker analyses were performed to assess correlation with clinical out-
comes.
Methods: Chemotherapy-naı¨ve Chinese pts with mutadvanced NSCLC
were randomised to receive either erlotinib (150mg/d) until progression or
unacceptable toxicity, or gemcitabine (1000mg/m2 d1d8) plus carboplatin
(AUC5, d1) for up to 4 cycles. The primary endpoint was progression-free
survival (PFS), and secondary endpoints included extensive biomarker anal-
yses. Of the 83 pts in the erlotinib arm, 70 had sufficient diagnostic tumour
samples available to carry out further biomarker analyses at baseline. KRAS,
EGFR T790M, PI3K and PTEN mutation status, as well as C-MET ampli-
fication, were determined by a central laboratory.
Results: KRAS mutations were not found in any of the pts. A T790M
mutation was detected in 1 pt (1.4%). The degree of C-MET amplification
was assessed in 67 evaluable pts, and an amplification rate of 5.9% was
observed. Analyses are still being conducted, including correlations of
secondary mutations or C-MET amplification with clinical outcome, and
complete results will be reported.
Conclusion: KRAS mutations were not found in these 70 patients with
activating EGFR mutation-positive NSCLC. The influence of secondary
biomarkers on efficacy outcomes with erlotinib in activating EGFR muta-
tion-positive disease will be assessed in the full biomarker analyses from this
study.
P-016
Association between A61G Polymorphism of EGF Gene and
Risk of Non-Small Cell Lung Cancer
Alena Mikhalenko, Evelina Krupnova, Natalia Chakova, Natalia Cheb-
otareva Department of Laboratory of Modelling Genetic Processes, Institute
of Genetics Institute of Genetics and Cytology of The National Academy of
Sciences of Belarus, Belarus
Introduction: Epidermal growth factor (EGF) is a ligand of epidermal
growth factor receptor (EGFR) which is involved in the processes of
proliferation, differentiation and apoptosis of cells as wells in angiogenesis
initiation. Functionally significant EGF polymorphism is described in un-
translated region in61 position (A61G polymorphism). Cells with the
genotype AA are known to produce a significantly lesser level of EGF than
those with genotypes GG or GA. The research results in the association of
A61G polymorphism of EGF are discrepant with development of oncologic
diseases.
Methods: A61G polymorphism of EGF was analyzed using PCR-RFLP in
110 non-small cell lung cancer patients and 298 individuals without any
oncological pathology.
Results: No significant difference was revealed between the occurrence
frequency of the genotypes of A61G polymorphism in adenocarcinoma (AC)
patients and in the control group. A statistically significant protective effects
of genotype AA was found in patients with squamous cell lung carcinoma
(SCC) (OR0,31; 95%CI: 0,13 - 0,74). A comparison between groups of
patients SCC and AK showed that the genotype AA was met 2 times less,
and the GG genotype in 1,5 times more frequently in lung squamous cell
carcinoma patients than in adenocarcinoma patients.
Conclusion: The obtained data probably indicate that the formation of a
specific histologic type of tumor, in particular SCC or AC, is due to the
A61G polymorphism of EGF.
P-017
Association of Clinical Activity of BMS-690514 with VeriStrat®
Classification and EGFR Status in NSCLC
Chris Harbison, Ashok Dongre, Jiwen Chen, Qing Xiao, Oksana Mokliat-
chouk, John Kurland, Mark Salvati, David Berman Department of Oncology,
Bristol-Myers Squibb R & D, United States of America
Introduction: BMS-690514 is a potent, reversible oral inhibitor of EGFR,
ErbB2, HER4, and VEGFR1-3. This analysis of BMS-690514 activity is
from a Phase I/II study of erlotinib-naı¨ve and -resistant patients with
advanced/metastatic NSCLC, using EGFR status and protein-profiling based
VeriStrat® (Biodesix®) classification (VSC) as candidate predictive biomar-
kers of disease control rate (DCR) or PFS.
Methods: DCR (CR, PR, SD  4 months), safety, and biomarkers (EGFR
mutations and copy number, VSC) were assessed. Blinded ‘VSC-Good’ or
‘VSC-Poor’ classification was determined from integrated intensities derived
fromMALDI-TOF mass spectrometric plasma protein profiling. Logistic and
Cox proportional hazard regression as a function of biomarker (EGFR or
VSC), cohort (erlotinib-resistant or –naı¨ve) and biomarker-by-cohort inter-
actions were used to assess associations and define hazard ratios (HR).
Results: DCR was 43% (13/30) in erlotinib-naive and 23% (7/31) in
erlotinib-resistant patients, N61. DCR was significantly higher in patients
with mutant EGFR (7/10) than with wild-type (6/21) (P0.017) and with
high EGFR copy number (10/18) than normal copy number (4/17)
(P0.089). PFS was longer in patients with mutant EGFR than wild-type
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(P0.059, HR0.29 erlotinib-naı¨ve, 0.47 erlotinib-resistant) and only in
erlotinib-naive patients with high EGFR copy number (P0.029, HR0.24
erlotinib-naı¨ve, 1.48 erlotinib-resistant). All EGFR mutation-positive pa-
tients were classified “VSC-Good”. PFS was longer in “VSC-Good” patients
(P0.011, HR0.23 erlotinib-naive and 0.64 erlotinib-resistant).
Conclusion: BMS-690514 showed activity in erlotinib-naı¨ve and -resistant
NSCLC patients. EGFR mutation, high EGFR copy number, and ‘VSC-
Good’ status may identify patients expected to have enhanced benefit with
BMS-690514. A phase II study of BMS-690514 versus erlotinib in NSCLC
is underway.
P-018
Baseline Levels and Decline in Serum Soluble Intercellular
Adhesion Molecule-1 during Chemotherapy Predict Objective
Response and Survival in Patients with Advanced Non-Small
Cell Lung Cancer
Qian Qian Department of First Department of Respiratory Medicine, Nan-
jing Chest Hospital, China
Introduction: This study aimed to assess the predictive and prognostic roles
of serum soluble intercellular adhesion molecule-1 (sICAM-1) and vascular
endothelial growth factor (VEGF) during chemotherapy in patients with
advanced non-small cell lung cancer (NSCLC).
Methods: Changes in serum levels of sICAM-1 and VEGF during first-line
conventional chemotherapy were studied prospectively using an enzyme-
linked immunosorbent assay (ELISA) at baseline and after every two courses
of therapy in 124 patients with advanced NSCLC. Data were correlated with
radiologic objective response (OR) and survival.
Results: The prognostic values of serum sICAM-1and VEGF were explored
in 115 advanced NSCLC patients and 61 patients were evaluated for
radiologic and serologic responses after two chemotherapy courses. Of the
115 patients, 79 patients had baseline serum ICAM-1 levels above 232.84
ng/mL, which is the cut-off value for distinguishing malignant tumors from
benign. Statistically significant correlations were observed between baseline
sICAM-1 levels and OR and between a sICAM-1 response and OR (Odds
ratios [ORs] 8.05 and 5.40, respectively). However, there was no correlation
between baseline VEGF levels and OR (P0.543). The median Progression-
free survival (PFS) from response assessment was 4 months. In a multivar-
iate analysis, performance status (PS) (hazard ratio [HR], 1.47; 95% confi-
dence interval (95%CI), 1.03-2.10), disease stage (HR, 1.43; 95%CI, 1.07-
1.90), baseline sICAM-1 (HR, 1.12; 95%CI, 1.01-1.21), and sICAM-1
response (HR, 0.58; 95%CI, 0.39-0.88), were confirmed as independent
prognostic factors for survival.
Conclusion: Baseline sICAM-1 and sICAM-1 responses appeared to be
reliable surrogate markers of chemotherapy efficacy and were prognostic
factors in patients with advanced NSCLC.
P-019
CEA as An Early Predictor to Response to First Line Chemo-
therapy in Advanced Non Small Cell Lung Cancer
Kashif Iqbal Department of Oncology, Nuclear Medicine, Oncology and
Radiotherapy Institute, Islamabad, Pakistan
Introduction: In an era of promising new therapies for advanced NSCLC,
early predictors of response to therapy are needed.
Methods: 29 previously untreated patients of advanced NSCLC, with
measurable disease were evaluated. All patients were treated with systemic
chemotherapy. Serum samples were obtained before the start of 1st and 2nd
cycles of chemotherapy.
Results: 10 patients had partial response, 9 had stable disease, 9 had
progressive disease. None had complete response. 72 % patients had an
elevated baseline value of CEA. 62 % patients had a decrease in CEA
after 1 cycle of chemotherapy. The average reduction in the 2nd reading
was irrespective of whether baseline value was normal or not. (P0.002;
95% CI, from 0.8369 to 3.49464; paired sample t test). 80% patients with
partial response had a reduction in their 2nd reading of CEA (P0.019).
66% patients whose disease remains stable also had a decrease in their
subsequent reading (P0.0106). Although 5 out of 9 (55%) patients, who
had an increase in their 2nd reading had progressive disease, it was not
statistically significant (P0.537). 14 out of 19 (73%) who had partial
response or stable disease, had a reduction in their 2nd value of CEA (P
0.004). We also observed that except for 1 patient, all patients who had
a decrease of 42% or more had either responded to chemotherapy or had
stable disease (P 0.001).
Conclusion: Monitoring of serum marker CEA, early during chemotherapy
may be a useful prognostic tool for evaluation of early tumor response.
P-020
Chemotherapy in Patients Older Than or Equal to 75 Years
with Advanced Non Small Cell Lung Cancer (NSCLC)
Seung Kim, Sang Shin, Kyong Park, Sang Oh, Jae Seo, Jun Kim, Yeul Kim
Department of Hematology-Oncology, Korea University College of Medi-
cine, Republic of Korea
Introduction: As the number of elderly patients with non small cell
carcinoma (NSCLC) makes progress, elderly NSCLC patients receiving
chemotherapy also go on increasing more and more. However, there is
limited data for clinical outcome in patients older than or equal to 75 years
with advanced NSCLC.
Methods: Between May 2002 and October 2009, 48 patients older than or
equal to 75 years with advanced NSCLC who had been treated with
chemotherapy were analyzed retrospectively.
Results: The median age at the time of first line chemotherapy was 76 years
(range, 75-87) and the median Charlson comorbidity index was 2 (1-4). Forty
three patients (90%) were treated by platinum based doublet as first line
chemotherapy regimens, and only five patients (10%) received single agent
chemotherapy. Median progression free survival (PFS) for first line chemo-
therapy was 5.7 months (95% C.I. 4.93-6.47) with an overall response rate of
33.3%. After the failure for first line chemotherapy, only 14 of 48 (29.2%)
patients received second line chemotherapy. The median overall survival
(OS) was 8.2 months (95% C.I. 4.44-11.96). In multivariate analysis, female
gender and receiving post first line chemotherapy were independent prog-
nostic factors for increased OS for all 48 patients. There were nine treatment
related deaths (18.8%).
Conclusion: Patients older than or equal to 75 years with advanced NSCLC
might get the clinical benefit from platinum based doublet or single agent
chemotherapy. However, oncologists must consider the aspect of safty as
well as the clinical benefit when managing these patients’ group.
P-021
Clinical Characteristics of Acquired Resistance to Gefitinib in
Non-Small Cell Lung Cancer
Kye Young Lee1, Hee Joung Kim1, Young-Chul Kim2, Kyu-Sik Kim2, In-Jae
Oh2, Hee Jung Ban3, Sung Yong Lee3, Tae Won Jang4, Kyeong-Cheol Shin5,
Gwan Ho Lee5, Jae Chol Lee6, Jeong-Seon Ryu7, Seung Hoon Jang8, Jeong
Eun Lee9, Sun Young Kim9 1Department of Internal Medicine, Konkuk
University School of Medicine, Seoul, Republic of Korea, 2Department of
Internal Medicine, Chonnam National University Medical School, Hwasun
Hospital, Republic of Korea, 3Department of Internal Medicine, Guro
Hospital, Korea University Medical School, Republic of Korea, 4Department
of Internal Medicine, Kosin University Medical College, Republic of Korea,
5Department of Internal Medicine, Yeungnam University College of Medi-
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cine, Republic of Korea, 6Department of Internal Medicine, Korea Cancer
Center Hospital, Republic of Korea, 7Department of Internal Medicine, Inha
University School of Medicine, Republic of Korea, 8Department of Internal
Medicine, Hallym University School of Medicine, Republic of Korea, 9De-
partment of Internal Medicine, Choongnam National University Hospital
and Cancer Research Institute, Republic of Korea
Introduction: The NSCLC patients who experienced good clinical re-
sponses even sometimes dramatic responses to EGFR-TKIs gefitinib or
erlotinib will inevitably develop acquired resistance. However, the clin-
ical definition of acquired resistance is not clear. We investigated the
clinical characteristics of acquired resistance to gefitinib in NSCLC
retrospectively.
Methods: We analyzed four hundred and forty NSCLC patients who had
taken gefitinib more than 6 months duration. All clinical data were obtained
from 11 centers of Korean Molecular Lung Cancer Group (KMLCG). The
timing, clinical manifestations, and the association of EGFR genotype were
analyzed in the aspect of acquired resistance development.
Results: The mean duration of gefitinib prescription was 12.37.1 months.
Significant predominance in Female (63.2%) and non-smoker (68.9%) was
noted. Among the patients who examined EGFR genotype, the mutation rate
was 54.0% (68/126), relatively lower than expectation. The relative ratio of
local vs. systemic progression is 62.8%:38.2% and symptomatic progression
rate is 63.8%. The survival time after the development of acquired resistance
is 9.39.5 months.
Conclusion: These retrospectively analyzed clinical data for the develop-
ment of acquired resistance to gefitinib will help set up the clinical definition
of acquired resistance to EGFR-TKI.
P-022
Clinical Outcomes of Leptomeningeal Metastasis in Patients
with Non-small Cell Lung Cancer in the Modern Era
Jin Hyun Park, Yu Jung Kim, Jeong-Ok Lee, Keun-Wook Lee, Jee Hyun
Kim, Soo-Mee Bang, Jong-Seok Lee Department of Internal Medicine, Seoul
National University Bundang Hospital, Seongnam, Republic of Korea
Introduction: We intended to analyze the patterns of treatment and clinical
outcomes of leptomeningeal metastasis (LM) in patients with non-small cell
lung cancer (NSCLC).
Methods: We retrospectively reviewed the data of NSCLC patients who
were diagnosed with LM from 2003 to 2009 in Seoul National University
Bundang Hospital.
Results: Of the 50 patients with cytologically proven LM, 25 were male
(50%), 14 (28%) had ECOG performance status (PS)3, and the median age
was 62.5 years (range, 34-81). The patients were diagnosed with LM after
median 9.5 month (range, 0-85) from the initial diagnosis of metastatic
NSCLC. LM presented in 11 patients at the time of initial diagnosis. The
median overall survival (OS) after LM presented was 4.0 months (95% CI
1.5-6.4). Forty-eight patients (96%) received intrathecal chemotherapy and
cytological response rate was 40%. The median survival was 5.4 months in
cytologic responders and 1.4 months in nonresponders (p0.109). The
median OS in patients with ECOG PS 1-2 was longer than in those with
ECOG PS 3-4 (5.8 vs. 0.7 months, p0.001). Twenty-two patients (44%)
underwent cytotoxic chemotherapy or EGFR tyrosine kinase inhibitor (TKI)
after being diagnosed with LM. These patients showed prolonged survival
(10.9 vs. 1.4 months, p0.001), and in 13 patients (36%) who received
EGFR TKI, the median OS was 19.2 months. In patients with ECOG PS 1-2,
patients who received further systemic chemotherapy showed improved
survival (11.5 vs. 2.1 months, p0.001).
Conclusion: In NSCLC with LM, systemic chemotherapy in addition to
intrathecal chemotherapy might confer survival benefit, especially in patients
with good ECOG PS.
P-023
Comparative Study of the Accuracy of Positron Emission To-
mography Scan and Repeat Mediastinoscopy in the Restaging of
Non-Small Cell Lung Cancer after Induction Therapy
Sergi Call1, Carme Obiols1, Ramon Rami-Porta1, Jose Manuel Gonzalez2,
Montserrat Ysamat2, Montserrat Buxeda2, Guadalupe Gonzalez-Pont3, Roma
Bastus-Piulats4, Mireia Serra-Mitjans1, Jose Belda-Sanchis1 1Department of
Thoracic Surgery, Hospital Universitari Mutua Terrassa, Spain, 2Depart-
ment of Nuclear Medicine, Centro Tecnologia Diagnostica (Ctd), Spain,
3Department of Pathology, Hospital Universitari Mutua Terrassa, Spain,
4Department of Oncology & Hematology, Hospital Universitari Mutua
Terrassa, Spain
Introduction: In 2004, routine positron emission tomography (PET) was
introduced in our restaging protocol to evaluate the metabolic response in the
mediastinum and to rule out extrathoracic disease. The objective of this study
is to compare the accuracy of PET and repeat mediastinoscopy (reMS) in the
restaging after induction chemotherapy or chemoradiotherapy for non-small
cell lung cancer (NSCLC).
Methods: From January 2004 to February 2009, 30 patients (28 men;
median age: 54.3 years) underwent induction chemotherapy or chemora-
diotherapy for pathologically proven stage III-N2 NSCLC. In all of them,
the mediastinum was reassessed by PET and reMS. Patients with persis-
tant N2-NSCLC at reMS underwent definitive chemotherapy or chemo-
radiotherapy. Patients in whom reMS was negative underwent thoracot-
omy for lung resection and systematic nodal dissection. Systematic nodal
dissection was the gold standard to compare results of reMS and PET.
Pathological findings were reviewed and staging values were calculated
using the standard formulas.
Results: PET showed no evidence of mediastinal nodal disease in 24 cases
(7 false-negative), and residual mediastinal disease in 6 cases (4 false-
positive). Remediastinoscopy was technically feasible in all patients. There
were 3 false-negative results.The sensitivity, specificity, positive predictive
value, negative predictive value, and accuracy of PET were 0.22, 0.80, 0.33,
0.71 and 0.63 respectively. These staging values for reMS were 0.67, 1, 1,
0.88, 0.9, respectively.
Conclusion: The accuracy of PET in the restaging after induction therapy for
NSCLC is low. Techniques providing cyto-histological information are still
necessary to assess objective tumour response in mediastinal lymph nodes.
P-024
Consolidation Chemotherapy after Concurrent Chemoradiation
for Non-Resectable Non-Small Cell Lung Cancer
Sung-Ja Ahn1, Young-Chul Kim2, Kyu-Sik Kim2, In-Jae Oh2, Sun-Seog
Kweon3, Mi-Sun Yoon1, Kook-Joo Na4, Sang-Yun Song4 1Department of
Radiation Oncology, Chonnam National University Hwasoon Hospital, Re-
public of Korea, 2Department of Pulmonary Medicine, Chonnam National
University Hwasoon Hospital, Republic of Korea, 3Department of Jeonnam
Regional Cancer Center, Chonnam National University Hwasoon Hospital,
Republic of Korea, 4Department of Thoracic and Cardiovascular Surgery,
Chonnam National University Hwasoon Hospital, Republic of Korea
Introduction: To test the survival benefit of the consolidation chemotherapy
after concurrent chemoradiotherapy in patients with non-resectable non-
small cell lung cancer.
Methods: 318 patients who were completed CCRT between 2004 and 2008
were included. Median age, 67 and 287 was male. Squamous cell 217 and
adenocarcinoma 76. Stage was IA/IB/IIB/IIIA/IIIB/IV(2/3/17/70/225/1). Ra-
diotherapywas given 2-2.4Gy fraction, weekly 5 fractions and dose was over
60 Gy. Concurrent chemotherapy was weekly given to 6 times. The standard
regimen was paclitaxel 45mg/m2/week and cisplatin 20mg/m2/week. Four
weeks after the completion of CCRT, the three weekly consolidation che-
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motherapy: Paclitaxel 150mg/m2 cisplatin 60mg/m2 was given in selected
patients who were tolerable to CCRT.
Results: Consolidation chemotherapy was combined in 156 patients and
CCRT alone was in 144 patients. Induction chemotherapy was given in 18
patients. The median survival was 24.8 months in induction chemother-
apy group, 28 months in consolidation group and 37.2 months in CCRT
alone group (p0.419). In the univariate and multivariate analyses on the
overall survival, the statistically significant prognostic factors were the
primary tumor size (5cm vs. 5cm), ECOG (0/1/2-3) and Hg level at
the time of radiotherapy (12 vs. 12g/dl). Treatment failure was shown
in 174 patients (54.7%). Locoregional failure alone was in 78 patients and
distant failure alone was in 62 patients and combined in 34. The crude
locoregional failure rate was 35.2% and the crude distant failure rate was
30.2%.
Conclusion: In this retrospective analysis, consolidation chemotherapy after
concurrent chemoradiotherapy does not provide the survival benefit in
patients with non-resectable NSCLC.
P-025
Effect of Cigarette Smoking and the Qualitative Difference on
Frequency of KRAS Mutations in Korean Patients with Lung
Adenocarcinoma
Jung Ryun Ahn, Joo-Hang Kim, Byoung Chul Cho Department of Medical
Oncology, Yonsei Cancer Center, Republic of Korea
Introduction: KRAS mutations were thought to be present only in heavy
smokers. However, recent report demonstrated that KRAS mutations occur
in approximately 15% of never smokers with adenocarcinoma. We investi-
gated the frequency of KRAS mutations in Korean patients and the associ-
ation between smoking and KRAS mutations with lung adenocarcinoma.
Methods: We identified the frequency and the type of KRAS codon 12 and
13 mutations in Korean lung adenocarcinoma. Smoking histories were
obtained from the patients by standard protocol.
Results: KRAS mutational analyses were done on 205 lung adenocarcino-
mas, 16 (7.8%) of which were observed with KRAS mutations. KRAS
mutations were found in 5.7% (7 of 22) of tumors from never smokers.
KRAS mutations of former smokers and current smokers were 14.6% (6 of
41) and 7.1% (3 of 42), respectively. There were no significant differences in
frequency of KRAS mutations by smoking history. The frequency of KRAS
mutations was not associated with age, gender, ECOG performance status,
stage, also. The age at first cigarette, total pack-years, total smoke-years,
smoke-free years were not correlated with KRAS mutations. The qualitative
difference is observed that transition mutations are more likely to be found
in never smokers. While, transversion mutations are more in former and
current smokers.
Conclusion: Our data showed that the frequency of KRAS mutations with
lung adenocarcinoma is rare in Korean patients compare to western coun-
tries. Smoking history may not influence the frequency of KRAS mutations,
but qualitative difference.
P-026
Effect of Epidermal Growth Factor Receptor Tyrosine Kinase
Inhibitors on Brain Metastases in Patients with EGFR-Mutant
Non-Small Cell Lung Cancer
Qing Zhou, Xuchao Zhang, Chongrui Xu, Jinji Yang, Xuening Yang,
Shejuan An, Zhihong Chen, Jian Su, Binchao Wang, Yisheng Huang, Zhen
Wang, Yujuan Huang, Yi-Long Wu Department of Pulmonary Oncology,
Guangdong Lung Cancer Institute, Guangdong General Hospital & Guang-
dong Academy of Medical Sciences, Guangzhou , China
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are remarkably effective for EGFR-mutant non-small cell
lung cancer (NSCLC). We retrospectively evaluated the efficacy of EGFR
TKIs in patients with brain metastases (BM) from EGFR-mutant NSCLC
without radiotherapy to brain.
Methods: Patients with BM from NSCLC and harbouring EGFR activating
mutations were eligible. They received gefitinib or erlotinib to control both
extracranial and intracranial disease. If extracranial disease remained stable
or remissive, but intracranial disease progressed first, or asymptomatic BM
turned into symptomatic BM, or symptoms from BM did not be released
within two weeks, or symptoms deteriorated after initial release, patients
would receive radiotherapy to brain and continue taking TKIs until extracra-
nial disease progressed.
Results: In 30 eligible patients, objective response rate (ORR) and ORRintra
was 80% and 66.7%, respectively. Median progression free survival (PFS)
was 10.9 months (95%CI, 7.3 to 14.5). Median PFSintra was 12.0 months
(95% CI, 8.8 to 15.2) and median PFSextra was 15.9 months (95% CI, 14.3
to 17.5). Median PFS of patients with exon 19 deletion was significantly
longer than other mutations (12.6 vs 7.6 months, P0.045). Median overall
survival (OS) was 18 months (95% CI, 17.3 to 18.7). There was no
significant difference of median OS between patients who received radio-
therapy or not after intracranial disease progression (19.8 vs 18.0 months,
P0.076).
Conclusion: EGFR TKIs are effective for BM from EGFR-mutant NSCLC.
Radiotherapy to brain might not be necessary in this setting. Efficacy of TKIs
for intracranial and extracranial disease should be evaluated separately.
P-027
EGFR Mutations as A Prognostic Factor in Korean Patients
with Advanced Lung Adenocarcinoma Who Had Not Been
Treated with Received EFGR-TKI
Seung Kim, Yeul Kim, Yoon Choi, Kyong Park, Sang Oh, Jae Seo, Sang
Shin, Jun Kim Department of Hematology-Oncology, Korea University
College of Medicine, Republic of Korea
Introduction: Epidermal growth factor receptor (EGFR) mutations as prog-
nostic marker in patients with non-small cell lung cancers (NSCLCs) remain
controversial. In particular, there are only a limited amount of data on the
subject in Asian patients with advanced lung adenocarcinomas.
Methods: We analyzed 50 patients with advanced lung adenocarcinoma,
who received only best supportive care (BSC) with and without cytotoxic
chemotherapy, between March 2006 and December 2008. All patients had
never treated with EGFR- tyrosine kinase inhibitors (TKIs). Tumor
tissues of all 50 patients were analyzed for the status of EGFR gene
mutations.
Results: EGFR gene mutations were detected in 11 patients (22%).: Seven
of them had in frame deletion within exon 19, resulting in the loss of codon
746 through 750 (delE746-A750), 2 patients had L858R in exon 21, and 2
patients had point mutation at codon 709 in exon 18, resulting in the
substitution of glycine either with glutamic acid or alanine. The status of
EGFR mutations was not significantly associated with gender, smoking
status, ages, metastatic sites and the number of metastasis sites. Seventeen
patients received only best supportive care without cytotoxic chemotherapy
and 33 patients received the standard platinum based doublet chemotherapy.
The median overall survival (OS) was 8.90 months (95% CI, 4.01-13.79)
There was no significant differences in OS (p0.282) according to the status
of EGFR mutations.
Conclusion: EGFR mutation was not a prognostic marker in Korean patients
with advanced lung adenocarcinoma who had not been treated with the
EGFR-TKIs.
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P-028
Erlotinib for Squamous Cell Carcinoma of the Lung: A Pro-
spective Phase II Study
Eun Kyoung Kim1, Chang-Min Choi1, Dae Ho Lee1, Jene Choi2, Se Jin
Jang2, Cheolwon Suh1, Jung Shin Lee1, Sang-We Kim1 1Department of
Oncology, Asan Medical Center, Republic of Korea, 2Department of Pathol-
ogy, Asan Medical Center, Republic of Korea
Introduction: It is well known that the response to erlotinib is higher in
women, nonsmoker, Asian, patients with adenocarcinoma. But erlotinib also
showed survival benefit in patients with squamous cell carcinoma of lung in
BR 21 study. We conducted a phase II study to evaluate whether erlotinib is
active and tolerable in patients with squamous cell lung cancer.
Methods: Between February 2008 and February 2009, 42 patients were
enrolled at our institution. Patients with stage III or IV squamous cell lung
cancer and with performance status from 0 to 2 were eligible and they had
received one or two prior chemotherapy regimen. Erlotinib was administered
continuously at a dose of 150mg per day orally in 28-day cycles. EGFR
amplification and mutation were analyzed from available tissue. Primary
endpoint was disease control rate. Secondary endpoints were response rate,
disease-free survival and overall survival.
Results: The median age was 61 years (range, 39-83). Thirty-eight patients
were men and 37 patients were smokers. The response rate was 11.9% with
5 PR and disease control rate was 45.2%. Three patients were not evaluable.
Most patients received erlotinib as second-line treatment or third-line treat-
ment. The median progression-free survival was 3.3 months and overall
survival was 8.6months. Most common toxicities were skin rash and anemia.
They were all manageable. Among 30 available tissue specimens, 2 speci-
mens showed EGFR gene mutations and two other specimens showed EGFR
gene amplifications.
Conclusion: Erlotinib showed activity and comparable survival and was
tolerable in squamous cell lung cancer patients.
P-029
Erlotinib- Induced Cheilosis and Glossitis May Be Related with
Riboflavin Deficiency: A Case Report
Seong Min Yoon, Seok-Hyun Kim, Kyung Tae Park Department of Internal
Medicine, Samsung Changwon Hospital, Sungkyunkwan University School
of Medicine, Republic of Korea
Introduction: Erlotinib is an oral tyrosine kinase inhibitor, recently ap-
proved for treating patients with advanced non-small cell lung cancer or
pancreatic cancer. The using is now increasing, but there are adverse
cutaneous reactions caused by erlotinib. However, we don‘t know the exact
cause of adverse cutaneous effects yet. Deficiency of riboflavin (vitamin B2)
can occur due to interaction with drugs and most dermatologic manifesta-
tions are cheilosis and sore red tongue.
Conclusion: A 73-year-old female patient received her third-line che-
motherpy with erlotinib (150 mg) for non-small cell lung cancer with
multiple bone metastaisis which was diagnosed as adenocarcinoma by left
pleural biopsy. Previously she had been treated with 2 cycles of paclitaxel
and carboplatin and 4 cycles of gemcitabine and vinorelbine. On the 20th day
after erlotinib, she visited with complaints of painful red tongue and dry,
itchy skin. Because of no other significant changes, we recommended
observation without discontinuation of erlotinib. When she vitisited again 4
weeks later, she looked so uncomfortable. She had suffered from angular
cheilosis, glossitis, paronychia and fissuring of all distal fingers. Based on
clinical symptoms, riboflavin deficiency was suspected and measured blood
vitamin B2 level was low (1.5 ug/dL, reference value 1.7-4.6). Hence, she
has undergone vitamin B complex supplementation and erlotinib 100mg has
been given again 2 weeks later because her symptoms improved greatly.
Until now, her condition and response have been good. This report suggests
possibility of relationship between Erlotinib-induced cutaneous toxicities
and riboflavin deficiency.
P-030
Genetic Polymorphisms in Folate Metabolic Pathway Genes
Correlate with Clinical Outcomes in Pemetrexed-Treated Ad-
vanced NSCLC Patients.
Jung A Kim1, Jong-Mu Sun2, Soo-Youn Lee3, Seonwoo Kim4, Jin Seok
Ahn2, Keunchil Park2, Myung-Ju Ahn2 1Department of Hematology-Oncol-
ogy, Seoul Paik Hospital, Inje University School of Medicine, Republic of
Korea, 2Department of Hematology-Oncology, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Republic of Korea, 3Depart-
ment of Laboratory Medicine and Genetics, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Republic of Korea, 4Depart-
ment of Clinical Pharmacology, Clinical Trial Center, Samsung Medical
Center, Sungkyunkwan University School of Medicine, Republic of Korea
Introduction: Pemetrexed is an anti-folate anti-neoplastic agent which
inhibits multi-targeted enzymes, TYMS, DHFR, GARFT, and
AICARFT(ATIC). The clinical relevance of polymorphisms of pathway
genes for pemetrexed metabolism has not been fully elucidated yet. The main
goal of this study was to evaluate the association between polymorphisms in
the genes involved in the metabolic pathways of pemetrexed and clinical
outcome in NSCLC patients treated with pemetrexed.
Methods: Total 173 patients with advanced NSCLC who had been treated
with pemetrexed at Samsung Medical Center between Jan 2007 and Sep
2009 were analyzed. Clinical data, including patient characteristics, response
rate, PFS, and OS were collected retrospectively. Genomic DNA obtained
from peripheral blood was analyzed for 64 single nucleotide polymorphism
(SNP)s and haplotype from 13 genes (ABCB1, ABCC1, ABCC2, ATIC,
DHFR, FPGS, GARFT, GGH, MTHFR, PPAT, SHMT1, SLC19A1,
TYMS).
Results: Two SNPs in GGH (rs 16930092, rs3780130) and 2 SNPs in
SHMT1 (rs12939757, rs4924750) had significant effect on higher rate of
disease control rate (DCR) by pemetrexed. One haplotype in GGH (AGCTC-
CCGTACT) and one haplotype in SHMT1 (GACGCGGC) were signifi-
cantly associated with DCR. Subgroup analysis of patients with adenocar-
cinoma also showed the consistent results. Survival analysis including PFS
and OS are undergoing.
Conclusion: This study suggests that several genetic variations associated
with folate metabolic pathway and the downstream events have significant
correlation with clinical outcomes in patients treated with pemetrexed.
Further results including the survival will be presented to validate these
polymorphisms as a useful biomarker in pemetrexed treated NSCLC
patients.
P-031
Pelvic Lymph Node of Lung Cancer; A Case Report
Young Hyeok Choi1, Jin Young An1 1Department of Internal Medicine,
Chungbuk National University Hospital, Republic of Korea, 2Department of
Internal Medicine, Chungbuk National University Hospital, Republic of
Korea
Introduction: Lung cancer is the first leading cause of death from cancer in
korea. The most frequent metastatic sites are regional lymph node, the other
site of lung, brain, bone, adrenal gland. Metastasis in the pelvic lymph node
without any significant extrapulmonary metastasis has not been previously
reported.
Case Report: A 65year-old man was referred for the evaluation of a cavitory
mass in Left lower lung field. Sonographic biopsy revealed a moderately
differentiated squmaous cell carcinoma. A subsequent PET CT scan of whole
body revealed a 15- mm sized nodular uptake in anterior portion of left external
iliac artery as well as lung mass uptake. Laparoscopic excision biopsy revealed
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metastatic squamous cell carcinoma. The Sigmoidoscopy was performed for
differential diagnosis between metastasis from anus origin carcinoma. The
sigmoidoscopy resulted in negative findings. So we concluded Nonsmall cell
lung cancer with pelvic lymph node metastasis. And then We performed Left
lower lobectomy with lymph node dissection. The pathologic findings revealed
a 6.5 X 6.0 X 8.0cm sized mass with one lymph node metastasis at 10L. At one
month after surgery, we started chemotherapy.
P-032
Predictive Value of EGFR Mutation in Locally Advanced Ade-
nocarcinoma of the Lung Treated with Concurrent Chemora-
diotherapy
Hiroaki Akamatasu1, Kyoichi Kaira1, Haruyasu Murakami1, Akira Ono1,
Asuka Tsuya1, Yukiko Nakamura1, Tomotsugu Kennmotsu1, Tateaki Naito1,
Toshiaki Takahashi1, Hideyuki Harada2, Masahiro Endo3, Nobuyuki
Yamamoto1 1Department of Thoracic Oncology, Shizuoka Cancer Center,
Japan, 2Department of Radiation Oncology, Shizuoka Cancer Center, Japan,
3Department of Diagnostic Radiology, Shizuoka Cancer Center, Japan
Introduction: Concurrent chemoradiotherapy (CCR) is the standard care for
locally advanced non-small cell lung cancer (LA-NSCLC). Epidermal
growth factor receptor (EGFR) mutation is well known predictive marker in
metastatic NSCLC, but the frequency in LA-NSCLC (especially adenocar-
cinoma) is unknown. Therefore, it should be evaluated whether EGFR
mutation could be a prognostic marker for predicting outcome after CCR in
patients with LA-NSCLC.
Methods: Between September 2002 and December 2009, 92 adenocarcino-
mas of 170 LA-NSCLC patients who received CCR were retrospectively
reviewed. Forty-three tissues of these 92 adenocarcinoma were available.
The 43 patients were included in this study, and EGFR mutation status was
investigated.
Results: EGFR mutation was observed in 27.9% of 43 patients. The median
progression free survival was 304 days in EGFR wild type (n31) and 254
days in EGFR mutant group (n12), demonstrating no significant difference
(p0.62). Median survival time (MST) in EGFR wild type group was
882days and that in EGFR mutation group was not reached, demonstrating
no significant difference (p0.22).
Conclusion: Frequency of EGFR mutation in locally advanced adenocarci-
noma of the lung was about 30%. EGFR mutation was not a predictive
marker in this population treated with CCR.
P-033
Prognostic Model to Predict Outcomes in Non-Small Cell Lung
Cancer Patients with Erlotinib as Salvage Treatment
Seung Kim, Myung-Ju Ahn, Jeeyun Lee, Jong-Mu Sun, Jin Ahn, Keunchil
Park, Yeon Park Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Republic of Korea
Introduction: To devise a prognostic model based on clinical parameters for
non-small cell lung cancer (NSCLC) patients treated with erlotinib as a
salvage therapy.
Methods: Between July, 2006 and September, 2008, 257 metastatic/relapsed
NSCLC patients who had been treated with erlotinib as a salvage therapy
were analyzed retrospectively.
Results: For 257 patients, median overall survival (OS) and progression
free survival (PFS) from erlotinib treatment were 12.4 and 2.8 months.
Multivariate analysis showed that ECOG performance status of 2 or
more, elevated serum LDH level and absence of skin rash were indepen-
dent adverse prognostic factors for OS and the presence of intra-abdom-
inal metastasis, prior chemotherapy  2, and absence of skin rash for
PFS. Patients were categorized into four prognosis groups estimated on
the basis of each adverse prognostic factor; good, intermediate, poor, and
very poor prognostic group. The median OS for the good, intermediate,
poor, and very poor prognostic group were 22.0, 9.3, 5.4, and 2.7 months
(p0.001) and the median PFS were 6.5, 3.0, 1.2, and 0.9 months
(p0.001).
Conclusion: This prognostic model based on clinical parameters would be
useful to identify patients who might be most likely to benefit from erlotinib
therapy in clinical practice.
P-034
Prospective Phase II Trial of a Combination of Gemcitabine and
UFT as First-Line Treatment in Elderly Patients with Advanced
Non-Small Cell Lung Cancer
Jin Ho Baek1, Jong-Joon Ahn1, Yangjin Jegal1, Kwang Won Seo1, Chang
Ryul Park2, Yong Jik Lee2, Hee Jeong Cha3, Woon Jung Kwon4, Young Ju
Noh5, Young Joo Min1 1Department of Internal Medicine, Ulsan University
Hospital, Republic of Korea, 2Department of Thoracic and Cardiovascular
Surgery, Ulsan University Hospital, Republic of Korea, 3Department of
Pathology, Ulsan University Hospital, Republic of Korea, 4Department of
Radiology, Ulsan University Hospital, Republic of Korea, 5Department of
Radiation Oncology, Ulsan University Hospital, Republic of Korea
Introduction: The standard regimen in elderly patients with non-small-cell
lung cancer (NSCLC) is still uncertain. Several phase II trials specifically
designed for elderly patients with advanced NSCLC have confirmed the role
of gemcitabine in this setting. Oral UFT was associated with a survival
advantage in the adjuvant setting. Therefore, we performed a phase II study
using the combination of gemcitabine and UFT as first-line therapy in elderly
patients with advanced NSCLC.
Methods: Chemotherapy-naı¨ve patients (age  70 years) with stage IIIB or
IV NSCLC with a performance status of 1–2 were enrolled. Patients received
gemcitabine (1250mg/m2 on days 1 and 8) and UFT (400mg/day on days
1-14) every 3 weeks for up to four cycles. Patients who had not progressed
after four cycles continued UFT monotherapy until progression. Primary
endpoint was ORR and secondary endpoints were OS, TTP and safety
profiles.
Results: A total of 39 patients were enrolled. The median age was 74 years
old (range: 70–84 years). Twenty-four patients (61.5%) completed four
cycles. Response was evaluated in 31 patients. PR was achieved in ten
(25.6%) patients and SD in 18 (46.2%) patients. Disease control rate was
71.8%. The median OS was 6.1 months (95% CI 5.3–6.9), the 1-YSR was
30.1% and the median TTP was 4.3 months (95% CI 4.3–6.4). Toxicities
were mild and mostly hematological adverse events. Grade 3/4 neutropenia
occurred in 10.3% of patients and one patients experienced febrile neutro-
penia.
Conclusion: The combination of gemcitabine and UFT was effective and
well-tolerated first-line regimen in elderly patients with advanced NSCLC.
P-035
Radiotherapy for Locoregional Recurrent Non-Small Cell Lung
Cancer
Mi Young Kim1, Jong-Seok Lee2, Jae-Sung Kim3 1Department of Radiation
Oncology, Seoul National University Hospital, Republic of Korea, 2Depart-
ment of Internal Medicine, Seoul National University Bundang Hospital,
Republic of Korea, 3Department of Radiation Oncology, Seoul National
University Bundang Hospital, Republic of Korea
Introduction: To evaluate treatment outcomes of curative radiotherapy (RT)
and post-treatment lung complication in locoregional recurrent NSCLC
patients.
Methods: From 2004 to 2008, 21 patients received curative RT for locore-
gionally recurrent NSCLC without systemic metastasis. The interval between
initial surgery and diagnosis of recurrence was median 15 months. Distribu-
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tion of recurrence sites were as follows; 10 in mediastinal LN, 4 in ipsilateral
hiar area, 4 in ipsilateral lung, 2 in bronchial stump and 1 in ipsilateral
supraclavicular area. RT was administered with median 66 Gy by 3-D
conformal technique. Thirteen patients received chemotherapy concurrently
during RT. PFT was also analyzed to detect the lung function change after
RT.
Results: The median survival and 2-YSR were 17 months, 34%, respec-
tively. In multivariate analysis, good PS, longer DF interval and radiation
dose more than 66 Gy increased in survival significantly (p0.043, 0.019,
and 0.012, respectively). Concurrent chemotherapy did not affect survival
(p0.411). DLCO of lung after RT decreased significantly compared with
pre-RT status (p0.033), but not FEV1 (p0.312). Radiation pneumonitis of
any grade was seen in 11 patients. Three patients died of acute respiratory
distress syndrome (bacterial pneumonia, exacerbation of underlying intersti-
tial pulmonary fibrosis and radiation pneumonitis, each).
Conclusion: This study showed that curative RT for locoregionally recurrent
NSCLC resulted in median survival of 17 months and 2-YSR 34%. Patients
suitable for curative RT could be treated aggressively, but lung function
should be carefully evaluated to avoid serious lung damage after treatment.
P-036
Randomized Phase II Study of Pemetrexed versus Gefitinib for
Patients with Previously Treated Non-Small Cell Lung Cancer
Junshik Hong, Sun Young Kyung, Sang Pyo Lee, Jeong Woong Park, Sung
Hwan Jung, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae
Hoon Lee Department of Internal Medicine, Gachon University Gil Hospital,
Gachon University of Medicine and Science, Graduate School of Medicine,
Republic of Korea
Introduction: The efficacy and safety between pemetrexed and gefitinib in
patients with pretreated advanced NSCLC were evaluated and compared.
Methods: Patients with histologically or cytologically confirmed advanced
(stage IIIB or IV) or recurrent NSCLC were eligible if they were; age  18
years, with measurable lesion, previously treated, an Eastern Cooperative
Oncology Group (ECOG) Performance Status (PS) 0 to 2, and with adequate
organ function. Patients received either 500 mg/m2 of pemetrexed intrave-
nously every 3 weeks with vitamin supplementation or gefitinib 250 mg/day
per os until disease progression, intolerable toxicity or withdrawal of consent.
Results: 64 patients were enrolled (pemetrexed, n32; gefitinib, n34).
Disease control rate in the intent-to-treat population with pemetrexed and
gefitinib were 40.6% and 35.3%, respectively (P0.88) and the overall
response rate were 6.3% and 11.8%, respectively (P0.74). With a median
follow up duration of 14.4 months, median progression-free survival of
pemetrexed and gefitinib were 2.0 and 2.3 months, respectively (P0.74)
and median overall survival were 8.1 and 7.9 months, respectively (P0.60).
Frequently reported toxicities were fatigue (46.9%) and anorexia (40.6%) for
pemetrexed, and skin rash (44.1%) and anorexia (38.2%) for gefitinib.
diarrhea was more frequent in patients with gefitinib. Both of the agents
reported no grade 4 adverse event. No difference of clinical outcomes
according to clinical characteristics (gender, tumor histology, smoking,
ECOG PS and treatment sequence) was observed in the subgroup analysis.
Conclusion: Both of pemetrexed and gefitinib showed comparable efficacy
each other with excellent tolerability.
P-037
Retreatmentof Gefitinib in the Patients with Non-Small Cell
Lung Cancer (NSCLC) Previously Responded to Gefitinib; A
Single Arm, Open Label, Phase II Study
In-Jae Oh1, Hee-Jung Ban1, Su-Young Chi2, Hyun-Ju Cho3, Manaljav
Tesden-Ish3, Young-Soo Kwon2, Kyu-Sik Kim1, Sung-Chul Lim2, Young-
Chul Kim1 1Department of Lung and Esophageal Cancer Clinic, Chonnam
National University Hwasun Hospital, Republic of Korea, 2Department of
Internal Medicine, Chonnam National University Medical School, Republic
of Korea, 3Department of The Brain Korea 21 Project, Center for Biomed-
ical Human Resources, Chonnam National University, Republic of Korea
Introduction: The lack of an established therapeutic option for the non-
small cell lung cancer (NSCLC) patients who have progressive disease after
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
failure leave physicians with great challenges on how best to manage this
growing group of patients. We hypothesize that reintroduction of the ge-
fitinib will lead to significant clinical and radiological improvements or
disease stabilization in certain percentage of patients with progressive disease.
Methods: This is a single arm, open label, prospective, phase II trial of
gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC
patients who previously responded to gefitinib. Initial responses to gefitinib
of 22 recruited patients were partial remission (PR) in 7 cases (31.8%) and
stable disease (SD) in 15 cases (68.2%). Before retreatment with gefitinib,
progressive disease (PD) should be observed with at least one cytotoxic
treatment following initial gefitinib failure. Patients received gefitinib 250mg
orally once daily.
Results: After retreatment with gefitinib, 18 cases were eligible for response
evaluation. PR was observed in 4 cases (22.2%) and SD in 9 cases (50.0%),
while 5 cases (27.8%) showed PD (72.2 % disease control rate, DCR).
Among 6 patients who showed PR with initial gefitinib treatment, 2 patients
showed PR and 3 patients showed SD (DCR 83.3%). Among 12 patients who
showed SD with initial gefitinib treatment, 2 patients showed PR and 6
patients showed SD (DCR 66.7%).
Conclusion: Significant proportion of NSCLC patients who progressed after
prior gefitinib treatment showed another PR or disease control with gefitinib
retreatment.
P-038
Safety and Efficacy Trial of Cisplatin (P) and Vinorelbine (V)
Followed by Gefitinib (G) and Concurrent Thoracic Radiother-
apy (TRT) for Unresectable Locally Advanced Non-Small Cell
Lung Cancer (LA-NSCLC). JCOG0402
Yuichiro Ohe1, Satoshi Ishikura2, Akira Yokoyama3, Shinji Atagi4, Taro
Shibata5, Tomohide Tamura6, Nagahiro Saijo7, Masahiro Fukuoka8 1De-
partment of Thoracic Oncology, National Cancer Center Hospital East,
Japan, 2Department of Radiation Oncology, Kanagawa Cancer Center
Hospital, Japan, 3Department of Internal Medicine, Niigata Cancer Center
Hospital, Japan, 4Department of Internal Medicine, Nho Kinki-Chuo Chest
Medical Center, Japan, 5Department of Data Center, Jcog, Japan, 6Depart-
ment of Thoracic Oncology, National Cancer Center Hospital, Japan,
7Department of Medical Oncology, Kinki University School of Medicine,
Japan, 8Department of Medical Oncology, Izumi Municipal Hospital, Japan
Introduction: JCOG0402 was conducted to evaluate safety and efficacy of
P with V followed by G and TRT for unresectable LA-NSCLC.
Methods: The pts received induction chemotherapy with P (80mg/m2,
d1&22) and V (25mg/m2, d1, 8, 22, 29) followed by G (250mg, beginning
on d43) and TRT (60Gy/30fr, d57-98). G was continued for 1 year if neither
unacceptable toxicity nor tumor progression were observed.
Results: From Oct 2004 to Sep 2008, 38 pts (14 men, 24 women) with
LA-NSCLC were enrolled from 12 hospitals in Japan. Most of the pts were
Japanese and were never or light smokers. Two pts developed grade 2 or
worse pneumonitis and G was suspended in 14 pts because of transient
toxicity. Of the 38 pts, 23 pts (61%) completed treatment without experi-
encing grade 2 or worse pneumonitis; this percentage was slightly less than
our previously defined criterion for treatment feasibility. During the concur-
rent phase of G and TRT, grade 3/4 transaminase elevations were observed
in 31%/6% of the pts, respectively. Efficacy was evaluated among 37 pts.
The overall response rate was 73% (95%CI: 5686%, 1CR, 26PR) and the
MST was 28.1 months. The 1-, 2-, 3-year survival rates were 94%, 61%,
36%, respectively.
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Conclusion: P with V followed by G and TRT was effective among highly
select pts with unresectable LA-NSCLC. Although the results did not meet
our criterion for feasibility, the toxicity level was acceptable. P with V
followed by G and TRT might warrant further evaluation among select pts,
such as EGFR mutation positive LA-NSCLC.
P-039
Survival Determinants in Gefitinib-Sensitive Non-Small Cell
Lung Cancer (NSCLC) Patients Receiving Two Sequences of
Gefitinib and Chemotherapy
Young Joo Lee1, Tak Yun2, Ji-Youn Han2, Heung Tae Kim2, Jin Soo Lee2
1Department of Center for Clinical Trial, National Cancer Center, Republic
of Korea, 2Department of Lung Cancer Branch, National Cancer Center,
Republic of Korea
Introduction: Clinical trials have demonstrated better progression-free sur-
vival of gefitinib than chemotherapy as first-line therapy in molecularly-
sensitive NSCLC patients. However, limited data exist about overall survival
(OS) which should be evaluated regarding the effect of subsequent therapy.
Methods: We retrospectively identified 520 advanced NSCLC patients who
received gefitinib and chemotherapy in either sequence at National Cancer
Center Hospital between 2002 and 2008. The analysis was limited to good
performance status (PS) (ECOG PS 2) patients showing tumor response or
durable ( 6 months) disease stabilization after gefitinib.
Results: Of 130 patients, 44 received gefitinib followed by chemotherapy
(first-line G), and 86 chemotherapy followed by gefitinib (second-line G).
Most patients were female never-smokers with adenocarcinoma. The
median age was 61 and 59 years (P0.137) and the proportion of ECOG
PS 2 was 15.9 and 9.3% (P0.265) in first-line G and in second-line G,
respectively. Platinum-based chemotherapy was used in 53.6% of first-
line G whereas in 77.9% of second-line G (P0.083). Median follow-up
time was 20.7 months. Median OS from start of first-line therapy was not
different between two groups (31.3 vs. 28.5 months in first-line G vs.
second-line G; P0.714). In multivariate analysis, ECOG PS (ECOG PS
0-1 vs. 2; hazard ratio0.50; P0.022) and tumor burden (no. of
metastatic sites2 vs.  2; hazard ratio0.41; P0.001) remained
significant predictors for OS, in contrast to gefitinib timing and exposure
to platinum.
Conclusion: In terms of OS, both sequences of gefitinib and chemotherapy
were equivalent for gefitinib-sensitive patients.
P-040
The Combination Chemotheray of Gemcitabine, Carboplatin
and Bevacizumab in Patients with Advanced Non-Small Cell
Lung Cancer
Moon-Hyung Lee, Jin-Ah Whang, Young Mee Ahn, Yong Ho Noh, Seung-
Hyun Nam, Bong-Seog Kim Department of Internal Medicine, Seoul Veter-
ans Hospital, Republic of Korea
Introduction: The addition of bevacizumab in combination of paclitaxel and
carboplatin showed significant benefits in progression-free survival and
overall survival in patients with advanced non-small cell carcinoma. We are
conducting a phase II clinical study of combination chemotherapy with
gemcitabine, carboplatin and bevacizumab in same patients population.
Methods: The regimen consists of gemcitabine of 1,000mg/m2 on D1 and
D8, carboplatin of AUC 5 and bevacizumab of 15mg/kg on D1. Treatment
repeats every 3 weeks.
Results: Fifteen patients enrolled in this study till now. Fourteen patients
were male. The median age of patients was 66 (5578) years. Eight patients
were stage IV or recurrent disease, five were IIIB and two were IIIA. Eight
patients were squamous cell carcinoma, five were adenocarcinoma and two
were unclassified non-small cell carcinoma.Thirteen patients had ECOG
perfomance status of 1and two had 2. Total 34 cycles of therapy were
administered and median cycles of therapy were 2 (15). Five of nine
evaluable patients showed partial response, two had stable disease. The
overall response rate was 55.5%. In total 34 cycles grade 3 and 4 neutropenia
were 12% and 3%, respectively. Grade 4 thrombocytopenia were 9% and
grade 3 anemia were 6%. One patient died due to septic shock with
neutropenia. Non-hematologic toxicities were mild and manageable, but two
patients complained grade 3 general weakness and one grade 4 pneumonia.
Conclusion: The addition of bevacizumab in combination of gemcitabine
and carboplatin is active in terms of response rate. We need more enrollment
and longer follow-up.
P-041
The Efficacy of Pleurodesis on Non-Small-Cell Lung Cancer
with Large Malignant Pleural Effusion
Madoka Kimura1, Tateaki Naito1, Hirokazu Kenmotsu1, Yukiko Nakamura1,
Asuka Tsuya1, Kyoichi Kaira1, Haruyasu Murakami1, Toshiaki Takahashi1,
Masahiro Endo2, Nobuyuki Yamamoto1 1Department of Thoracic Oncol-
ogy, Shizuoka Cancer Center Hospital, Japan, 2Department of Diagnostic
Radiology, Shizuoka Cancer Center Hospital, Japan
Introduction: The presence of malignant pleural effusion (MPE) indicates
poor prognosis with some clinical features, such as cough and dyspnea, in
patients with non-small-cell lung cancer (NSCLC). Pleurodesis is an useful
treatment for the management of MPE.
Methods: Patients with NSCLC having large MPE (filled over 1/3 of the
cavity on one side of the thorax determined by chest X-ray) were eligible,
while patients without any chemotherapy were excluded. A retrospective
analysis was conducted to evaluate the efficacy of pleurodesis.
Results: Between 2005 and 2008, 50 patients were identified. Baseline
characteristics of patients with pleurodesis (n19) and patients without
pleurodesis (n31) were as followes; median ages 65/67 yrs; % females: 42
and 29%; % non-smokers: 26 and 35; % ECOG PS0-1: 74 and 74; %
adenocarcinoma: 100 and 90; % stage IV: 74 and 55. The proportions of the
first line chemotherapy conducted by platinum doublet/single agent/gefitinib
were 79/16/5% and 71/13/16%, the response rates were 16 and 32%, the
disease control rates were 74 and 90%, median survival times were 12 and
16 months (p0.47), respectively. From the first thoracentesis until the first
chemotherapy, median durations were 19 and 8 days (p0.05). There is no
significant difference in improvement of PS, dyspnea, and the rates of
re-thoracentesis between the two groups.
Conclusion: MPE might be manageable with chemotherapy alone if given
soon after the first thracentesis, thus pleurodesis might be avoidable.
P-042
The Results of CyberKnife Stereotactic Radiosurgery for Pa-
tients with Brain Metastasis from Non-small Cell Lung Cancer
Jinwook Hwang, Hae Won Lee, Hee Jong Baek, Jong Ho Park Department
of Thoracic Surgery, Korea Cancer Center Hospital, Republic of Korea
Introduction: About 20% of non-small cell lung cancer (NSCLC) patients
develop brain metastases. We investigated the results of CyberKnife stereo-
tactic radiosurgery (CKSRS) for solitary brain metastasis of NSCLC com-
pared with conventional brain radiotherapy (BRT).
Methods: From 1999 through 2009, 78 solitary brain metastases from
NSCLC were treated with BRT and/or CKSRS in Korea Cancer Center
Hospital. Retrospective reviews of medical records and imaging studies were
done for evaluation of the effect of CKSRS. We analyzed clinical outcomes,
including overall survival in CKSRS group (n53) compared with BRT
treatment group (n25).
Results: Solitary brain metastases after NSCLC treatment developed in 43
patients (metachronous patients). Thirty five patients had brain metastases at
diagnosis (synchronous patients). Five year survival rate of all patients was
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15.3% (MST: 20.01.77 months). CKSRS group showed a better survival
than BRT group (MST: 26.05.2 vs. 11.02.5 Months, p0.01). Metachro-
nous group showed better survival than synchronous group (MST:
33.018.9 vs. 13.04.5 Months, p0.01). In CKSRS group, there was a
significant survival difference between metachronous (n21) and synchro-
nous patients (n31) (p0.01). But, there were no differences in BRT
group. In histologic factor, non-squamous cell carcinoma patients showed
better survival. However, we could not find any difference in local recurrence
between these two groups. In multivariate analysis, squamous cell carci-
noma, synchronous metastasis, and no primary tumor resection were detected
as poor prognostic factors (p0.05).
Conclusion: In this study, we found that CKSRS for solitary brain metastasis
from NSCLC showed better benefit in survival, even though no difference in
local recurrence.
P-043
The Serological Features of High-Grade Non-Small Cell Neu-
roendocrine Carcinoma
Akira Ono1, Ichiro Ito2, Tateaki Naito1, Kyoichi Kaira1, Haruyasu Mu-
rakami1, Toshiaki Takahashi1, Masahiro Endo3, Toru Kameya2, Takashi
Nakajima2, Nobuyuki Yamamoto1 1Department of Thoracic Oncology,
Shizuoka Cancer Center, Japan, 2Department of Diagnostic Pathology,
Shizuoka Cancer Center, Japan, 3Department of Diagnostic Radiology,
Shizuoka Cancer Center, Japan
Introduction: Pro-gastrin-releasing peptide (ProGRP) and neuron-specific
enolase (NSE) are specific neuroendocrine serological markers of small cell
lung cancer (SCLC), the carcinoembryonic antigen (CEA) is not as specific
marker for SCLC. Some of non-small cell lung cancer (NSCLC) raises serum
neuroendocrine markers level. The aim of this study is to assess the feature
of serological markers between with SCLC and high-grade non-small cell
neuroendocrine carcinoma (HNSCNEC) proposed by us, which likely in-
cludes most pulmonary large cell neuroendocrine carcinoma (LCNEC)
except for combined types.
Methods: Newly diagnosed patients with SCLC and HNSCNEC at our
institution between September 2002 and June 2010, we retrospectively
reviewed 161 patients with SCLC and 35 patients with unresectable HNSC-
NEC, which was defined using biopsy specimens.
Results: The serum proGRP levels were elevated (46 pg/ml) in 130 SCLC
patients(81.2 %, median levels: 407 pg/ml) and in 14 HNSCNEC patients
(40.0 %, median levels: 27.4 pg/ml) (p0.0001), NSE levels were elevat-
ed(10 ng/ml) in 145 SCLC patients (90 %, median levels: 32 ng/ml) and in
29 HNSCNEC patients (82.8 %, median levels: 25.0 ng/ml) (p0.09), CEA
levels were elevated (5 ng/ml) in 85 SCLC patients (54 %, median levels:
5.7 ng/ml) and in 24 HNSCNEC patients (68.5 %, median levels: 12.3 ng/ml)
(p0.01), respectively.
Conclusion: In this series, significantly low serum ProGRP levels and high
serum CEA levels compared with SCLC patients represent clinical features
of serological marker with HNSCNEC, while NSE is high positive rate in
both SCLC and HNSCNEC patients.
P-044
Third-Line Therapy for Advanced Non-Small-Cell Lung Cancer
Patients: Feasible Drugs for Feasible Patients
Yongfeng Yu1, Zhengbo Song1, Chunxiao Wu2, Shun Lu1 1Department of
Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong
University, China, 2Department of Oncology Prevention, Shanghai Munici-
pal Center for Disease Control and Prevention, China
Introduction: Nowadays, there is definitive benefit of first and second-line
treatment for advanced stage non-small cell lung cancer(NSCLC). But the
role of third-line treatment in advanced NSCLC is still controversial although
epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) approved
by most countries in third-line setting. We retrospectively evaluated the
outcome of advanced NSCLC patients treated as third-line therapy in our
institution, especially focused on efficacy and safety in monotherapy and
doublets chemotherapy.
Methods: We identified consecutive 126 eligible patients with advanced
NSCLC who had received third-line therapy after the failure of the previous
therapies including chemotherapy and/or EGFR-TKIs.
Results: The median survival time of all patients was 24.03 months, 1-year
survival rate was 84.9%, 2-year survival rate 48.4%. 24 patients received
single agent chemotherapy, 33 patients received EGFR-TKIs, 69 patients
received doublets chemotherapy in third-line treatment. The progression-free
survival (PFS) in third-line was 2.37months in all patients and 2.80months,
2.30months, 2.97months, in doublets chemotherapy, single chemotherapy or
EGFR TKIs respectively (P0.033). Cancer-related symptom improvements
were confirmed in 78.9% (60/78). In all the patients, 63 patients (50%)
presented with III/IV grade toxicities. EGFR TKIs group had 18.2%(6/33)
grade III/IV toxicity, the monochemotherapy group was 41.6%(10/24),
doublet group was 68.1% (47/69) (P0.00).
Conclusion: Patients with advanced NSCLC slightly benefit from third-line
treatment. The patients get a moderate disease-free progression time and
conspicuous improvement in cancer-related symptom. Monotherapy is rec-
ommended in third-line treatment.
P-045
Thoracoscopic Intrapleural Perfusion Hyperthermic Chemo-
therapy for Malignant Pleural Dissemination or Effusion in
Non-Small Cell Lung Cancer
Moon Chul Kang, Jung-Moon Lee, Hee Chul Yang, Yochun Jung, Sanghoon
Jheon, Sook Whan Sung Department of Thoracic and Cardiovascular
Surgery, Seoul National University Bundang Hospital, Republic of Korea
Introduction: The purpose of this study was to determine the feasibility of
intrapleural perfusion hyperthermic chemotherapy (IPHC) for the treatment
of malignant pleural seeding or effusions.
Methods: We evaluated the outcomes of 28 patients undergoing IPHC for
pleural dissemination in initial diagnosis or late pleural recurrence of
non-small cell lung cancer under thoracoscopic guidance between June
2003 and January 2010. We performed IPHC with Cisplatin 150-200
mg/m2 BSA. There were 12 male and 16 female patients, and the ages
ranged from 33 to 79 years (median, 63 years). All the patients were
undergone pulmonary resection for the primary lesion. Among all the
patients, 9 patients had pleural dissemination detected intraoperatively
(Group A), 11 patients had pleural dissemination or malignant pleural
effusion diagnosed by preoperative workup (Group B), and 4 patients had
late pleural recurrences (Group C).
Results: Overall, 2-year survival rate and 3-year survival rate were 61.7%
and 42.3%, respectively (median survival period; 34.3 months). And, 2-year
survival rate in the various groups was as follows; 60.0% in Group A, 48.0%
in Group B (median survival, 24.3 months), and 80.0% in Group C after
IPHC. 10 patients were survived more than 2 years after IPHC and 5 patients
among these 10 patients survived without pleural recurrence. There was no
procedure related mortality. The serious complications that we had experi-
enced were 2 cases of renal failure.
Conclusion: These results suggest that IPHC is relatively safe and have
synergic effect on the treatment of pleural dissemination with combination of
resection of primary lesion and other adjuvant treatment.
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P-046
Using FDG-PET in Xenograft Models to Identify Dosing Regi-
men in a Phase I Trial of Intercalated BMS-690514 in Combi-
nation with Paclitaxel/Carboplatin (PC) in Patients with Ad-
vanced or Metastatic Solid Tumors
Laura Q Chow1, Mark Salvati2, Patrick Chow2, Ashok Gupta2, Justin
Kopik2, John Kurland2, Grace Dy3, Alex Adjei3 1Department of Oncology,
Ottawa Hospital Cancer Centre, Canada, 2Department of Oncology, Bristol-
Myers Squibb Company, United States of America, 3Department of Medi-
cine, Roswell Park Cancer Institute, United States of America
Introduction: BMS-690514 is a potent, reversible oral inhibitor of EGFR,
ErbB2, HER4, and VEGFR1-3. FDG-PET in tumor xenografts was utilized
to determine the optimal combination regimen of BMS-690514 with PC.
This intercalated schedule was used in a Phase 1 study in patients with
advanced/metastatic solid tumors.
Methods: In xenografts, mice received various BMS-690514 doses, fol-
lowed by intercalated, fixed-dose BMS-690514 with PC. FDG-PET was
performed assessing tumor glucose metabolism and growth inhibition to
define maximal response. This preclinically-defined intercalated
BMS-690514 with PC regimen was utilized in the Phase 1. Endpoints
included safety, MTD and tumor response.
Results: Single-agent BMS-690514 reduced xenograft tumor FDG uptake.
Intercalated PC followed by BMS-690514 demonstrated maximal tumor
inhibition (-11%) and reduction in glucose metabolism (-44%) and tolera-
bility. Phase I BMS-690514 cohorts were: 7-100mg, 6-150mg, and 4-200mg.
DLT was Grade 3 diarrhea (patients): 1@100mg; 1@150mg; 2@200mg. The
BMS-690514 MTD was 150mg/d, and the intercalated BMS-690514 with
PC cohort was expanded to 24. Grade 3/4 MTD AEs (8/24 patients) were
diarrhea (21%) and leukopenia (10%). 30/34 patients (MTD and 200mg)
were efficacy evaluable: 9 partial responses (PR), 6 stable disease (SD), 3
progressive disease (PD), 12 not yet evaluable. Among 8 NSCLC patients,
responses were 5 PR, 1 SD and 2 PD.
Conclusion: These results support using FDG-PET in preclinical models to
evaluate and choose sequential regimens combining TKI targeted agents with
chemotherapy. Intercalated BMS-690514 with PC was well tolerated and
demonstrated promising clinical activity, in particular in NSCLC. Future
studies will explore using FDG-PET to assess intercalated BMS-690514 with
PC activity.
P-047
When Should We Use Gefitinib or Erlotinib? A Retrospective
Analysis for Non-Small-Cell Lung Cancer Patients with Epider-
mal Growth Factor Receptor Mutations in Japan
Kenichi Nishie1, Tomoya Kawaguchi1, Kazuhiro Asami1, Yu Kurahara1,
Sachiko Hamaguchi1, Masaki Kanadu1, Akihiro Tamiya1, Hideki Ya-
manaka1, Kyoichi Okishio1, Shinji Atagi1, Masanori Kitaichi1, Akihide
Matsumura1, Seiji Hayashi1, Minoru Takada2, Yosihito Maruyama3 1De-
partment of Pulmonary, National Hospital Organization Kinki-Chuo Chest
Medical Center, Japan, 2Department of Medical Oncology, Sakai Hospital
Kinki University Faculty of Medicine, Japan, 3Department of Business and
Commerce, Keio University, Japan
Introduction: It is controversial when we should use gefitinib or erlotinib in
non-small-cell lung cancer patients with epidermal growth factor receptor
(EGFR) mutations.
Methods: Clinical information for non-small-cell lung cancer (NSCLC)
patients with EGFR mutations was obtained from 2002 to 2010 using a
database from the National Hospital Organization Kinki-chuo Chest Medical
Center, Japan.Timing of use of gefitinib or erlotinib was classified as 1st line
(1st ), 2nd line (2nd )and more than 3rd line (3rd ). Multivariate analysis for
survival was performed including gender, age, ECOG performance status
(PS: 0-3), histology (adenocarcinoma vs. others), stage (IIIB vs. IV), brain
metastasis and mutations (exon 19 vs. exon 21).
Results: There were 43 males and 92 females with activating EGFR
mutations, and median age was 67 years (34-88 years). A total of 69 patients
had mutations of exon 19 and 66 exon 21. Forty eight patients were treated
as 1st , 49 as 2nd , 15 as 3rd .Median survival time was 910 days for 1st ,
1006 days for 2nd , 1878 days for 3rd , and there was no significant
difference between them (p0.3104). Cox analysis showed that good PS
(PS2/PS0: HR5.248, p0.0128, PS3/PS0: HR5.973, p0.0152) and
exon 19 (/exon21: HR0.397, p0.0047) was associated with improved
survival but timing of the drug use was not.
Conclusion: Our retrospective analysis showed that there was no significant
association between timing of gefitinib or erlotinib use and prognosis in
patients with activating EGFR mutations.
CANCER CONTROL AND EPIDEMIOLOGY
P-048
Clinical and Radiological Features of Primary Lung Cancer
with Thin-Walled Cavity
Chi Young Jung1, Byung Hak Rho2, Young June Jeon1 1Department of
Internal Medicine, Keimyumg University School of Medicine, Republic of
Korea, 2Department of Radiology, Keimyung University School of Medicine,
Republic of Korea
Introduction: Pulmonary thin-walled cavity is not usually considered to be
neoplastic lesion. There are a few case reports in the literature of the lung
cancer with thin-walled cavity. In this study, we report our findings about
clinical and radiological features of thin-walled cavitary lung cancer.
Methods: A retrospective analysis was made of 6 patients who were
diagnosed as having primary lung cancer with thin-walled cavity at the
Keimyung University Dongsan Hospital between August 2001 and Novem-
ber 2009.
Results: There were 5 men and 1 woman, with a median age of 62.5 years.
Clinical symptoms at presentation were asymptomatic state with abnormal
cavitary lesions on routine chest X-ray in 4 cases and blood tinged sputum
in 2 cases. Histologically, there were 3 cases of squamous cell carcinoma and
3 cases of adenocarcinoma. CT scan of chest showed that all cavities had a
minimum wall thickness of 1-2mm and all of the squamous cell carcinoma
had an irregular internal wall of cavity than adenocarcinoma. Bronchoscopic
exam was performed in 5 patients and failed to yield a diagnosis. All patients
underwent CT-guided percutaneous needle biopsy and then pneumothorax
occurred in 5 cases. Biopsy for diagnosis was delayed in 3 cases because of
possibility of benign lesion.
Conclusion: Primary lung cancer with thin-walled cavity is rare disease and
it is difficult to diagnose. However, the presence of a thin-walled cavity of
the lung does not exclude the possibility of carcinoma as a diagnosis.
P-049
Clinicophopathologic Features in ALK-Rearranged Lung Ade-
nocarcinoma in the Korea
Eun Kyoung Kim1, Chang-Min Choi1, Dae Ho Lee1, Jene Choi2, Se Jin
Jang2, Cheolwon Suh1, Jung Shin Lee1, Sang-We Kim1 1Department of
Oncology, Asan Medical Center, Republic of Korea, 2Department of Pathol-
ogy, Asan Medical Center, Republic of Korea
Introduction: ALK rearrangement is predominant in adenocarcinoma of
lung, female, and non-smoking population. We investigated ALK rearrange-
ment in patients with adenocarcinoma of the lung who have no EGFR
mutations and evaluated their clinicopathologic features in Korea.
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Methods: ALK rearrangement was investigated in 116 patients with adeno-
carcinoma of lung who were never or light smokers without EGFR mutation.
EML4-ALK protein expression was studied by fluroscence in situ hybrid-
ization (FISH) and was define as positive if  10% of counted at least 60
tumor cells showed split signals.
Results: Of 116 tumors screened, 23 (19.8%) were ALK rearrangement.
Patients with ALK gene rearrangement was more common in men (73.9%,
17/23) (P0.05) and in younger (46 vs. 54) (p0.004) and appeared more
likely to be in non-smoker (P0.56). When we investigated ALK rearrange-
ment in 23 smoking patients, there were 3(13%) patients with ALK rear-
rangement.
Conclusion: Lung adenocarcinoma characterized ALK rearrangement was
more common in Korean population. ALK rearrangement is more common
in young male patients and can be appeared in smoker. Therefore, analysis
for ALK rearrangement should be considered in young male patients of lung
adenocarcinoma without EGFR mutation irrespective of smoking history.
P-050
CYP1A1 MspI and Exon7 Gene Polymorphisms and Lung
Cancer Risk: An Updated Meta-Analysis of 50 Case-Control
Studies
Ping Zhan1, Jing Wang2, Qian Qian1, Shu-Zhen Wei3, Li-Xin Qiu4, Li-Ke
Yu1, Yong Song3 1Department of Respiratory Medicine, Nanjing Chest
Hospital, China, 2Department of Hematology, The Affiliated Drumtower
Hospital of Nanjing University School of Medicine, China, 3Department of
Respiratory Medicine, Jinling Hospital, Nanjing University School of Med-
icine, China, 4Department of Medical Oncology, Cancer Hospital, Shanghai
Medical College, Fudan University, China
Introduction: Many studies have examined the association between the
CYP1A1 MspI and exon 7 gene polymorphisms and lung cancer risk in
various populations, but their results have been inconsistent.
Methods: To assess this relationship more precisely, a meta-analysis was
performed.
Results: Ultimately, 50 studies, comprising 14,587 subjects from 38 case-
control studies of the MspI genotype and 15,618 patients from 32 case-
control studies of the exon 7 genotype, were included. A significantly
elevated lung cancer risk was associated with 2 MspI genotype variants (for
type C vs Type A: OR1.21, 95% CI1.12-1.42, P0.023 for heterogene-
ity; for types B and C vs Type A: OR1.12, 95% CI1.04-1.21, P0.000
for heterogeneity). In the stratified analysis by ethnicity, significantly in-
creased risks were observed among Asians but not in Caucasians. Two
variants of the exon 7 polymorphism were associated with a significantly
higher risk for lung cancer (for Val/Val vs Ile/Ile: OR1.24, 95% CI1.09-
1.42, P0.104 for heterogeneity; for (Ile/ValVal/Val) vs Ile/Ile: OR1.11,
95% CI1.02-1.21, P0.000 for heterogeneity). In the stratified analysis by
ethnicity, Asians and Caucasians experienced significantly greater risks.
Conclusion: This meta-analysis suggests that the MspI and exon 7 poly-
morphisms of CYP1A1 correlate with lung cancer risk and that the latter is
a risk factor for the development of lung cancer in Asians and Caucasians.
The MspI polymorphism, however, increases such risks in Asians, not in
Caucasians.
P-051
Is Surgical Resection a Safe and Effective Treatment for Non-
Small Cell Lung Cancer Patients over 75-Years-Old?
Fumihiro Ogawa1, Wang Guoqin2, Keiko Hoshi2, Yoshio Matsui1, Hideki
Amano1, Naomi Kurohzu1, Hidenori Hara1, Kenji Nezu1, Akira Iyoda1,
Yukitoshi Satoh1 1Department of Thoracic Surgery, Kitasato University
School of Medicine, Japan, 2Department of Clinical Research Center,
Kitasato University School of Medicine, Japan
Introduction: Lung cancer is a typical disease of elderly patients. Recent
studies reported the safety of pulmonary resection in carefully selected
elderly patients. We evaluated the safety, effect, and indication of surgical
resection for non-small cell lung cancer (NSCLC) in elderly patients.
Methods: The clinical records of 119 consecutive patients over-75–
years–old (Group A) and 608 control patients (Group B) less than
75–years–old with NSCLC, who underwent radical curative resection
from January 1998 to September 2009 in the Kitasato University Hospi-
tal, were retrospectively reviewed. We assessed overall survival (OS),
disease-specific survival (DSS), and the relationships among age, com-
plications and survival.
Results: Patients’ median age in Group A and B was 78 (75-85) and 63
(16-74), retrospectively. Preoperative complications, particularly cardiovas-
cular complications and cancers, were more frequently recognized in Group
A (92%) than in Group B (75%). Postoperative complications, particularly
cardiovascular complications and delirium, were more frequently observed
in Group A (49%) than in Group B (40%) ( p0.05). Thirty-day mortality in
Groups A and B was 0% and 1% (n4), retrospectively. The 5-year OS was
significantly worse in Group A (53%) than in Group B (71%) ( p0.05).
DSS was 66% in Group A and 73% in Group B but not statistically
significant ( p0.13).
Conclusion: Survival after radical surgery for NSCLC patients is dependent
on factors such as complications but not age. Elderly patients over 75–years–
old, who are sufficiently fit, should not be considered ineligible for surgical
treatment based on age alone.
P-052
Effect of Genetic Polymorphisms in Patients with Bupropion
Treatment for Smoking Cessation
Ji Young Kang1, Sang Haak Lee1, Sun-Young Lee2, Ho-Shik Kim2, Hyeon
Hui Kang1, Ju Sang Kim1, Chan Kwon Park1, Jin Woo Kim1, Yong Hyun
Kim1, Hwa Sik Moon1 1Department of Internal Medicine, College of
Medicine, The Catholic University of Korea, Republic of Korea, 2Depart-
ment of Biochemistry, College of Medicine, The Catholic University of
Korea, Republic of Korea
Introduction: Recent research demonstrates a strong association between
smoking-related behavior and genetic variation. In addition, it is suggested
that the effect of smoking cessation therapies may be related with genetic
influences. We investigated the clinical features and genetic effects of
dopamine receptors and serotonin transporter on the smoking cessation in the
patients with bupropion therapy.
Methods: Smokers (n51) who wanted to quit smoking were included.
They were genotyped for the polymorphisms in dopamine D2 receptor
(DRD2) (TaqI and 141C), dopamine D4 receptor (DRD4), and serotonin
transporter (5HTT). They took bupropion for three weeks and were followed
up for one year.
Results: Eighteen patients (35.3%) stopped smoking at the six months. In
two groups of cessation success or not, there were no significant differences
in average smoking rate, starting age of smoking, gender, nicotine depen-
dence, respiratory symptoms, and forced expiratory volume in one second.
As for the genes in the dopamine pathway, the polymorphisms of DRD2
TaqI (A1 allele) and DRD2 141C (Ins C allele) did not have any differences
in genotype between the two groups (p0.245 and 0.409, respectively). The
genetic variation in the DRD4, variable number of tandem repeat (VNTR)
also showed similar distribution in the frequency to the success and failure
groups. Regarding the polymorphisms of 5HTT, there was no difference in
long allele between the two groups (p0.852).
Conclusion: This study suggests that the genetic variations of DRD2 Taq1,
DRD2 141C, DRD4 VNTR, and 5HTT might have few influences on the
treatment response of bupropion in success of smoking cessation.
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P-053
Biological Significance of Tumor Infiltrating Myeloid
CD11cand Monocyte-Derived CD16Dendritic Cells in Pa-
tients with Non-Small Cell Lung Cancer
Mee Sook Roh1, Jong-Young Kwak4, Choonhee Son2, Soo-Jung Um2,
Soo-Keol Lee2, Pil Jo Choi3, Boram Seo4 1Department of Pathology,
Dong-A University College of Medicine, Republic of Korea, 2Department of
Internal Medicine, Dong-A University College of Medicine, Republic of
Korea, 3Department of Thoracic and Cardiovascular Surgery, Dong-A
University College of Medicine, Republic of Korea, 4Department of Medical
Research Center for Cancer Molecular Therapy, Dong-A University College
of Medicine, Republic of Korea
Introduction: The efficacy of immune response to control cancer remains
controversial. It is particularly debated whether the tumor infiltrating den-
dritic cells (TIDC) lead to tumor-specific tolerance rather than immunization.
Furthermore, the role of TIDC turned out to be more complex with the
discovery of different DC populations. The object of this study was to
understand the role of TIDC according to DC subsets in non-small cell lung
cancers (NSCLC).
Methods: We performed immunohistochemical detection of CD11c (my-
eloid DC marker) and CD16 (myelomonocytic marker) on full cross-sections
from 272 NSCLCs (151 adenocarcinomas, 112 squamous cell carcinomas,
and 9 large cell carcinomas). Peritumoral infiltrating cells with brown
membranous expression were considered as positive for each antibody.
Results: The NSCLC tissues revealed four DC subsets in peritumoral
stromas; CD11c/CD16(145 cases), CD11c/CD16- (55 cases), CD11c-/
CD16(20 cases), and CD11c-/CD16- (52 cases). The tumors with
CD11c/CD16DC subset had less lymph node mestastsis than in tumors
with other DC subsets (P0.037). The DC subset was not significantly
correlated with other clinicopathologic factors. The Kaplan-Meier survival
curves demonstrated that the patients with a tumor having CD11c/
CD16DC subset had a significantly longer survival time than those patients
with a tumor having other DC subsets (P0.043).
Conclusion: These results suggest that DC subsets according to CD11c and
CD16 expression pattern might paly an important role in tumor cell immune
escape and NSCLC progression. Further studies will be required to establish
the specific role of the TIDC subsets in tumor immunity and to draw
conclusions for the design of immunotherapeutic strategies.
P-054
Clinicopathologic Implication of mTOR/pAKT Expression in
Non-Small Cell Lung Cancer
Mee-Hye Oh1, Jae Sung Choi2, Yong Hoon Kim2, Seok Yeol Lee3, Sook
Whan Sung5, Choon-Taek Lee5, Sanghoon Jheon6, Jin Haeng Chung4
1Department of Pathology, Soonchunhyang University Cheoan Hospital,
Republic of Korea, 2Department of Internal Medicine, Soonchunhyang
University Cheoan Hospital, Republic of Korea, 3Department of Thoracic
and Cardiovascular Surgery, Soonchunhyang University Cheoan Hospital,
Republic of Korea, 4Department of Pathology, Seoul National University
Bundang Hospital, Republic of Korea, 5Department of Internal Medicine,
Seoul National University Bundang Hospital, Seoul National University
College of Medicine, Republic of Korea
Introduction: The mammalian target of rapamycin (mTOR) pathway is
up-regulated in many human cancers, and agents targeting the mTOR
pathway are in various stages of clinical development and application. The
aim of this study is to determine whether or not overexpression of mTOR and
activated Akt [i.e., phosphorylated Akt (pAkt)] is correlated with survival
and clinicopathologic parameters in non-small cell lung cancer (NSCLC).
Methods: Immunohistochemical analysis of tissue microarray (TMA) with
574 surgically resected NSCLC specimens was performed to evaluate rela-
tion between expression of mTOR/pAkt and clinicopathologic features or
survival.
Results: The expression of mTOR and pAKT was significantly associated
with adenocarcinoma (ADC), female, non-smokers and lower stage. Survival
analysis regarding expression of mTOR and pAkt, revealed the patients with
coexpression of mTOR and pAKT had the most prolonged overall survival
period (p0.037) than patients with double negative for mTOR and pAKT.
However, in multivariate Cox regression analysis, performance status
(p0.002), age (p0.006) and stage (p0.001) were independent prognostic
factors of cancer specific survival.
Conclusion: Components of the mTOR pathway are significantly associated
with pathological features such as ADC histology, female, non-smokers and
lower stage. However, not all NSCLC seem to be equally amenable to mTOR
targeted therapy. Additional studies of human NSCLCs are warranted to
drive the development of targeted tumor specific antineoplastic therapies.
P-055
Correlative Analysis between Expression of AKT1/p-AKT and
EGFR Status in NSCLC
Sujun Gao1, Qingsong Liu2, Zhi Li2, Yehui Tan1, Wei Liu1 1Department of
Oncology, First Hospital of Jilin University, China, 2Department of Thoracic
Surgery, First Hospital of Jilin University, China
Introduction: Lung cancer is the most common life-threatening malignancy,
in which non-small cell lung cancer (NSCLC) composes of 80%. With the
mutation and activation of epithelial growth factor receptor (EGFR), Akt1/
p-Akt is involved into the downstream of EGFR signal pathway in NSCLC.
This research is aimed to investigate the expression status and clinical
significance of Akt1/p-Akt and the possible correlations with EGFR/p-EGFR
expression and mutations in 126 Chinese NSCLC patients.
Methods: The expressions of Akt1 (ser473)/p-Akt and EGFR/p-EGFR
(p-1045 & p-1068) were detected in paraffin slides by immunohistochemical
staining. EGFR mutations (exon18, 19, 21) were performed by DNA se-
quence analysis. The correlative analysis among Akt1 (ser473)/p-Akt,
EGFR/p-EGFR (p-1045 & p-1068), EGFR mutations and clinicopathological
findings were analyzed by 	2 test.
Results: Akt1/p-Akt was expressed in 77.98% (97/126) and 79.37% (100/
126) NSCLC patients respectively. Univariate analysis showed the expres-
sion of Akt1 was correlated to EGFR mutation (	24.79, P0.029), ade-
nocarcinoma (	23.95, P0.046), EGFR expression (	24.71, P0.03)
and p-EGFR(1045) expression (	24.27, P0.039); the expression of p-Akt
was correlated to adenocarcinoma (	26.04, P0.014), p-EGFR(1045)
expression (	25.15, P0.023), p-EGFR (1068) expression (	211.82,
P0.001) and EGFR expression (	211.40, P0.001). Neither Akt1 nor
p-Akt was correlated to age, gender, smoking history and TNM staging
(P0.05). Multivariate analysis showed p-Akt was highly correlated to
EGFR and p-EGFR (1068) expression (P0.013, P0.01 respectively). The
expression of Akt1 is positively correlated to p-Akt also. (P0.035).
Conclusion: Akt1/p-Akt were highly expressed and closely correlated to
EGFR/p-EGFR expression and EGFR mutations in NSCLC; Akt1/p-Akt
plays important roles in EGFR related signal pathway.
P-056
Cytological Feature of EML4- ALK-Positive Lung Adenocar-
cinoma
Harumi Nakamura1, Koji Tsuta1, Akihiko Yoshida2, Yasuo Shibuki1, Hitoshi
Tsuda1 1Department of Pathology Division, National Cancer Center Hos-
pital, Japan, 2Department of Pathology, University of Tokyo, Japan
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Introduction: Approximately 5% of lung adenocarcinomas have EML4-
ALK gene fusion, and they may be responsive to target therapy. Cytological
features of this subset have not been detailed.
Methods: Imprint smears were obtained from 10 surgically resected ALK-
translocated lung adenocarcinomas whose genetic status was confirmed by
multiplex reverse-transcription polymerase chain reaction (RT-PCR), fluo-
rescence in situ hybridization (FISH), and immunohistochemistry. We stud-
ied 8 cytological parameters: the presence of abundant mucin in background,
cluster with cribriform and/or papillary pattern, single tumor cells, signet-
ring cells, nuclear pleomorphism, prominent nucleolus, intranuclear inclu-
sion, and significant inflammation.
Results: Of 10 tumors, 2 (20%) showed abundant mucin in the background,
4 (40%) showed definite cluster patterns, 7 (70%) showed single tumor cells,
4 (40%) showed signet-ring cells (SRCs), 3 (30%) showed nuclear pleomor-
phism, 4 (40%) showed prominent nucleolus, and 6 (60%) showed signifi-
cant inflammation. A nuclear inclusion was not observed.
Conclusion: No specific cytological pattern emerged for EML4-ALK posi-
tive lung adenocarcinoma from the present analysis. However, abundant
mucin in the background and signet-ring cell morphology may be overrep-
resented in this subtype.
P-057
Evuation of Claudin-1, 3, 4, 5, 7 and 10 as Prognostic Markers
in Adenocarcinoma of Lung
Ilseon Hwang, Kun-Young Kwon Department of Pathology, Keimyung
University School of Medicine, Republic of Korea
Introduction: Claudins are adherant junction proteins and claudin expres-
sion is variable in many organs. Claudins are prognostic factors of many
human carcinomas, however loss of claudin is not always correlated with
poor prognosis of carcinoma. We assessed the expression of claudin-1, 3, 4,
5, 7 and 10 to establish as prognostic markers in adenocarcinoma of lung.
Methods: We corrected 62 cases of pulmonary adenocarcinoma and exam-
ined clinical information. We made tissue microarrays with paraffin blocks
of pulmonary adenocarcinoma and performed immunohistochemical stain-
ings for claudin-1, 3, 4, 5, 7 and 10. Statistical analyses such as Kaplan-
Meier survival test or Cox regression test were performed.
Results: High expression of claudin-1, 4, 5 was significantly correlated with
disease recurrence (p0.035, 0.026 and 0.024), but Claudin 3, 7 and 10 was
not correlated with disease recurrence in Kaplan-Meier survival test. High
expression of claudin-1 was also significantly correlated with overall survival
(p0.008). In multivariated analysis (Cox regression test), nodal status (pN
stage) and claudin-4 expression were independent prognostic factors of
disease free survival, but only claudin-1 expression was independent prog-
nostic factor of overall survival.
Conclusion: High expressions of claudin-1, 4, or 5 are poor prognostic
factors of pulmonary adenocarcinoma.
P-058
Frequency of EGFR Mutation in Korean Lung Cancer Patients
According to Histologic Subtypes
Pingli Sun1, Hyesil Seol1, Xianhua Xu1, Sanghoon Jheon2, Jong-Seok Lee3,
Choon-Taek Lee3, Jin Haeng Chung1 1Department of Pathology, Seoul
National University College of Medicine Bundang Hospital, Republic of
Korea, 2Department of Thoracic Surgery, Seoul National University Bun-
dang Hospital, Republic of Korea, 3Department of Internal Medicine, Seoul
National University Bundang Hospital, Seoul National University College of
Medicine, Republic of Korea
Introduction: EGFR mutation has been known to be specific to subtypes of
adenocarcinoma (ADC) with bronchioloalveolar (BAC) feature. As there is
evidence that different patterns of disease in the mixed lesions are biologi-
cally and clinically different, we evaluated EGFR mutations of lung ADC
with special emphasis on mixed histologic subtypes.
Methods: Three hundred forty-four Korean patients with lung ADCs were
investigated for EGFR mutations (exon 18-21). The histologic subtypes were
classified based on the two major components of the tumor. The results were
correlated with clinicopathologic features.
Results: EGFR mutations were detected in 175 of 344 ADCs (50.9%) and
more frequent in female than male (64.2% vs. 33.8%, P0.000), in non-
smokers than smokers (63.0% vs. 29.6%, P0.000). Regarding histologic
subtypes, the mixed acinar and BAC (AB) pattern showed the most frequent
EGFR mutation (69.1%) followed by mixed papillary and acinar (PA)
(65.7%), mixed solid and acinar (SA)(37.9%), micropapillary and acinar
(MpA) (33.3%), and acinar and mucinous BAC (AmB) (14.3%), In addition,
EGFR mutations were more frequently observed in tumors with BAC or
papillary components than those without these components.
Conclusion: EGFR mutation frequency is quite different from histologic
subtypes and the mixed AB and PA subtype can predict higher EGFR
mutation in lung ADC. In addition, high frequency of EGFR mutation in
males and smokers was remarkable in the Korean lung cancer patients.
P-059
Prognostic Implications of Hypoxia-Inducible Factor-1 in Epi-
dermal Growth Factor Receptor Negative Non-small Cell Lung
Cancer
Seugn Yeon Ha1, Sanghui Park1, Eun Kyung Cho2 1Department of Pathol-
ogy, Gachon University Gil Hospital, Republic of Korea, 2Department of
Internal Medicine, Gachon University Gil Hospital, Republic of Korea
Introduction: Hypoxia-inducible factor (HIF)-1 is a regulatory subunit of
HIF-1 that is stabilized and activated under hypoxic conditions. In non-small
cell lung cancer (NSCLC), over-expression of HIF-1 has been associated
with poor overall survival. However, there is conflicting data on the role of
HIF-1 as a prognostic factor. Some studies have demonstrated close
association between the HIF-1 signal pathways and epidermal growth
factor receptors (EGFRs).
Methods: We evaluated the prognostic significance of HIF-1 expression in
178 NSCLC patients using tissue microarray in the context of EGFR gene
copy number and protein expression status. EGFR gene copy number was
evaluated using fluorescent in situhybridization (FISH), and EGFR protein
expression was determined using immunohistochemistry(IHC).
Results: The difference in overall survival (OS) between HIF-1-positive
and HIF-1-negative groups was statistically significant in patients with low
EGFR gene copy number and negative EGFR expression (log-rank test,
P0.03). In univariate and multivariate analyses, HIF-1 was a significant
worse prognostic factor for OS in patients with low EGFR gene copy number
and negative EGFR expression (hazard ratio2.992; CI, 1.113 to 8.045;
P0.03 in univariate analysis and hazard ratio8.127; CI,1.874 to 35.251;
P0.01 in multivariate analysis).
Conclusion: The results demonstrated that the prognostic significance of
HIF-1 should be validated in the context of EGFR status in NSCLC
patients, and the gene and protein status of EGFR and HIF-1 will be
important to help select patients most likely to derive the greatest clinical
benefit from EGFR or HIF-1 targeted therapies.
P-060
Towards an Evidence Based Proposal for the Best Minimal
Immunohistochemical Panel to Infer Lung Adenocarcinoma
Metastatic to Supraclavicular Lymph Node
Nirmala A Jambhekar1, Rajiv Kumar1, Alberto M Marchevsky2, Rajesh
Dikshit1, Pramesh C S1 1Department of Pathology, Tata Memorial Hospital,
India, 2Department of Pathology, Cedars Sinai Hospital, United States of
America
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Introduction: Supraclavicular Lymph Node (SCLN) metastasis is a frequent
occurrence in various malignancies. Immunohistochemistry (IHC) is invalu-
able to infer the origin of a metastatic deposit. Commercially available
monoclonal antibodies have differing degrees of sensitivity and specificity.
In a low resource setting the importance of selecting the best minimal IHC
panel which will give an accurate diagnosis cannot be overemphasised. This
study aims to find out the best minimal cost-effective IHC panel which will
accurately recognize Lung cancer as the primary site in metastatic SCLN s.
Methods: 135 metastatic SCLN biopsies were divided into two groups :
Category I comprising 110 cases where the primary was established to be in
the lung and Category II comprising 25 cases wherein the primary was in
sites other than lung .An IHC panel comprising cytokeratin 7(CK7), cyto-
keratin 20(CK20) ,Epithelial membrane antigen, Carcinoembryonic antigen,
Thyroid Transcription factor 1 (TTF1), Surfactant protein B(SPB) and
Vimentin was employed on all 135 cases. The results were analysed statis-
tically using SPSS14.0 and STATA software.
Results: The best minimal panel comprising four markers was CK7, CK20,
TTF1 and SPB; the binomial probability for diagnosing lung cancer was
0.90.
Conclusion: SCLN biopsy is a simple and rapid method to confirm meta-
static disease. This study concluded that a panel comprising two screening
markers (CK7 and CK 20) and two lineage specific markers (TTF1 and SPB)
proved very dependable and cost-effective in establishing the primary site as
Lung in SCLN. An “Evidence based medicine” concept and statistical
methods have been used to make this inference.
NON-SMALL-CELL LUNG CANCER - EARLY
DISEASE
P-061
High Expression of LSD1 and AKT2 Indicated Poor Prognosis
in Patients with Stage I/II Non-Small Cell Lung Cancer
Tangfeng Lv, Xiaohui Miao, Yanling Lv, Yong Song Department of Respi-
ratory Medicine, Jinling Hospital, China
Introduction: The aim of this study is to evaluate the prognostic significance
of LSD1 and AKT2 expression and correlation in patients with stage I/II
non-small-cell lung cancer.
Methods: LSD1 and AKT2 expression were decteced by western blot and
semi-quantitatively immunohistochemistry (IHC) assay in tumor specimens.
A retrospective review of the medical records of 80 patients with stage I/II
lung cancer undergoing surgical resection was performed. The clinical data
of each patient was collected for analysis including age, smoking habits,
gender, tumor diameter, histologic type, visceral pleural invasion, pathologic
stage, and type of operation.
Results: We found that LSD1 and AKT2 expressions were increased and
correlation in lung cancer tissue. Our results showed that the over-expres-
sions of LSD1 and AKT2 in lung cancer were associated with the overall
survival in patients, morover, the levels of AKT2 were linked with the
magnitude of the primary lung tumor.
Conclusion: High expression of LSD1 and AKT2 indicated the poor prog-
nosis in stage I/II non-small-cell lung cancer (NSCLC) patients and the
expression of LSD1 and AKT2 was correlation. Over-expression of AKT2
was associated with the magnitude of the primary tumor, should play an
important role in cell proliferation and tumor growth. Patients with high
expression of LSD1 and AKT2 after surgery had worst survival and may be
good candidates for adjuvant chemotherapy. The correlation of LSD1 and
AKT2 indicated LSD1 may regulate the AKT2 expression.
P-062
Risk Factors for Recurrence in Completely Resected Stage IA
Non-Small Cell Lung Cancer Ptients with Tumors Less Than 2
cm in Maximum Dimension
Yujin Kudo, Syuji Ichinose, Hiroaki Kataba, Hisashi Saji, Masatoshi Kaki-
hana, Jitsuo Usuda, Naohiro Kajiwara, Osamu Uchida, Tatsuo Ohira, Nori-
hiko Ikeda Department of Thoracic Surgery, Tokyo Medical University
Hospital, Japan
Introduction: Although patients with stage IA non-small cell lung cancer
(NSCLC), especially those with tumors less than 2 cm in maximum dimen-
sion, have the best prognosis of all patients with lung cancer, some die of
recurrence. The purpose of this study was to evaluate stage I NSCLC patients
with tumors less than 2 cm in maximum dimension who underwent surgical
resection, and to investigate the risk factors for recurrence.
Methods:We retrospectively examined the incidence and clinical features of
stage IA non-small lung cancer in 378 patients (184 men and 194 women,
average age 63 years) treated between 1999 and 2008. Lobectomy was
performed in 296 (78.3%) , and lesser resection such as segmentectomy and
partial resection was performed in 82 (21.7%). The histological type was
adenocarcinoma in 333 patients (87.9%), squamous cell carcinoma in 37
(9.8%) and large cell carcinoma in 8 (2.1%). Vessel invasion was present in
47 patients (12.4%) and lymphatic invasion in 66 (17.4%).
Results: Among 378 patients, 24 (6.3%) developed recurrence after surgical
resection. Twelve patients developed distant metastasis only, 11 developed
local recurrence only, and 1 developed both local recurrence and distant
metastasis. The 5-year overall survival and disease-free survival rates were
94.9% and 92.6%, respectively. On multivariate analysis, vessel invasion,
and lesser resection were independently significant recurrence risk factors.
Conclusion: The incidence of recurrence after surgery was about 6%. Vessel
invasion and lesser resection were risk factors for recurrence in our study, so
it is necessary for patients with these to be examined carefully for recurrence.
P-063
Use of Tumor Markers in Cytological Fluid for Diagnosis of
Non-Small-Cell Lung Cancer: A Prospective Comparison of
Serum Tumor Markers
Yoo Jin Hong1, Jin Hur1, Hye-Jeong Lee1, Ji Eun Nam1, Se Kyu Kim2, Joo
Hang Kim2, Joon Chang2, Kyung Young Chung3, Byoung Wook Choi1, Kyu
Ok Choe1 1Department of Radiology, Yonsei University College of Medi-
cine, Republic of Korea, 2Department of Internal Medicine, Yonsei Univer-
sity College of Medicine, Republic of Korea, 3Department of Thoracic and
Cardiovascular Surgery, Yonsei University College of Medicine, Republic of
Korea
Introduction: Cytological fluid obtained from a needle aspiration biopsy
(NAB) is obtained directly from tumor tissue and therefore many biomarker
candidates will be present in high concentrations.
Methods: To prospectively assess the diagnostic values of tumor markers in
cytological fluid for the diagnosis of non-small cell lung cancer (NSCLC),
we included 113 patients with suspected malignant pulmonary lesions who
underwent percutaneous needle aspiration biopsy (NAB) procedures. Levels
of CYFRA 21-1, CEA, and SCC-Ag were measured by immunoassay in
serum and in cytological fluid obtained during the aspiration biopsy. The
cut-off value for tumor markers was selected on the basis of best accuracy
through receiver operating characteristic (ROC) curves.
Results: 87 patients (77%) had NSCLC and 26 (23%) patients had benign
lesions. Using cut-off values of 2.72 ng/mL, 4.52 ng/mL, and 0.9 ng/mL for
serum CYFRA 21-1, CEA, and SCC-Ag, respectively, the sensitivity, spec-
ificity, and accuracy for diagnosing NSCLC were as follows: CYFRA 21-1,
41.4%, 84.6% and 49.6%; CEA, 37.9%, 96.2%, and 48.7%; SCC-Ag, 34.5%,
92.3%, and 48.7%, respectively. Using cut-off values of 13.2 ng/mL, 1.38
ng/mL, and 1.9 ng/mL for cytological fluid, the sensitivity, specificity and
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accuracy were as follows: CYFRA 21-1, 81.6%, 96.2%, and 84.1%; CEA,
68.9%, 92.3%, and 73.3%; SCC-Ag, 43.7%, 84.6%, and 53.1%, respectively.
The sensitivity and accuracy of cytological CYFRA 21-1 and CEA were
significantly higher than serum CYFRA 21-1 and CEA (p0.001).
Conclusion: The determination of CYFRA 21-1 and CEA in the cytological
fluid may aid in the clinical diagnosis of NSCLC.
P-064
Video-Assisted Thoracic Surgery Lobectomy for Stage I Non-
Small Cell Lung Cancer
Moon Chul Kang, Sanghoon Jheon, Jung-Moon Lee, Hee Chul Yang,
Yochun Jung, Sook-Whan Sung Department of Thoracic and Cardiovascu-
lar Surgery, Seoul National University Bundang Hospital, Republic of Korea
Introduction: We evaluated the outcome of Video-Assisted Thoracoscopic
Surgery (VATS) lobectomy for early non-small cell lung cancer (NSCLC)
and compared with those of open lobectomy.
Methods: The clinicopathological and surgical data obtained from the
medical records were analyzed in this retrospective study. The outcomes of
175 patients who underwent open lobectomy (OL group) for clinical stage I
NSCLC were evaluated to compare their results with 254 patients who
underwent VATS lobectomy (VL group).
Results: The number of females, patients with adenocarcinoma and stage IA
disease were greater in VL group (p0.05). Open conversion was needed in
20 cases (7.9%). The chest tube indwelling time and the length of postop-
erative hospital stay were significantly shorter in the VL group (p0.001).
The morbidity late was 22.4% in VL group and 34.3% in OL
group(p0.007). There was 1 in-hospital death due to acute myocardial
infarct. For the pathologic stage I patients, there was no significant difference
in the 5-year survival rates (5YSR) between the two groups (VL group,
95.6% ; OL group 83.2% ; p0.08). And, the disease free 5YSR were 87.7%
for VL group and 80.2% for OL group (p0.047).
Conclusion: VATS lobectomy is a safe procedure with low operative
mortality and morbidity. VATS lobectomy is feasible for early stage NSCLC
and it provides comparable outcomes to those for open lobectomy.
SURGERY
P-065
Assessment and Follow-Up of Intercostal Nerve Damage after
Video-Assisted Thoracic Surgery
Takuro Miyazaki, Naoya Yamasaki, Tomoshi Tsuchiya, Takeshi Nagayasu
Department of Surgical Oncology, Nagasaki University Hospital, Japan
Introduction: Chronic pain is a common complication after thoracic sur-
gery. The most important factor appears to be intercostal nerve damage. The
purpose of this study was to objectively evaluate intercostal nerve damage
associated with post-thoracotomy pain using current perception threshold
(CPT) testing after three surgical procedures.
Methods: 32 patients were categorized into three groups: video-assisted
thoracic surgery (VATS) with (n15) or without (n7) metal retractors, and
conventional thoracotomy (n10). Intercostal nerve function was assessed
by a series of 2000-Hz (A - fiber), 250-Hz (A
), and 5-Hz (C) stimuli using
CPT testing (Neurometer CPT/C®). CPT values were measured before and 1,
2, 4, 12, and 24 weeks after surgery. The intensities of ongoing pain were
also assessed using a numeric rating scale (0 – 10).
Results: VATS without metal retractors showed no changes in any CPT
frequency values and no residual pain more than 12 weeks after surgery.
VATS with metal retractors and conventional thoracotomy showed signifi-
cant higher CPT values at 2000 and 250 Hz 1 week after surgery, with pain
in approximately 70% of patients. CPT values and the intensities of ongoing
pain were not correlated among the groups.
Conclusion: The results suggest that A and A
 fibers play significant roles
in the development of intercostal nerve damage. The CPT values clearly
demonstrated that VATS without metal retractors is a less invasive procedure
that results in less post-thoracotomy pain.
P-066
Clinical Outcome of Stage IIIA-N2() NSCLC Patients with
Neoadjuvant Chemotherapy
Hae Won Lee, Jin Wook Hwang, Hee Jong Baek, Jong Ho Park Department
of Thoracic Surgery, Korea Institute of Radiological and Medical Science,
Republic of Korea
Introduction: According to several clinical guidelines, neoadjuvant chemo-
therapy is recommended for stage IIIA, N2 NSCLC. But a few studies have
been reported for positive results about neoadjuvant chemotherapy for stage
IIIA, N2 NSCLC in Asian patients.
Methods: We conducted a retrospective study that compare 95 neoadjuvant
chemotherapy patients with 381 pathologic stage IIIA, N2 patients (except
neoadjuvant treatment).
Results: 62 (65.2%) of 95 neoadjuvant chemotherapy patients underwnet a
surgery. Refusal of operation and disease progression are the main causes of
patients not reach to surgery after neoadjuvant chemotherapy. The 5 year
survival rate and median survival were 37.3%, 29.6 months in neoadjuvant
chemotherapy group and 32.7%, 28.3 months in the pathologic IIIA, N2
group (p0.90). And, 47%, 52.5 months in neoadjuvant chemotherapy with
surgery (n62) and 9.9%, 11.9 months in neoadjuvant chemotherapy with-
out surgery (n33).
Conclusion: Surgery group with neoadjuvant chemotherapy had survival
gain compared to the control group (p.00). But the role of neoadjuvant
chemotherapy for stage IIIA, N2 NSCLC was not confirmed due to large
number of unenrolled patients to surgery. We would like to recommend a
large randomized prospective multicenter study for neoadjuvant chemother-
apy in stage IIIA, N2 NSCLC in Asian patients.
P-067
Comparative Study between Preoperative versus Intraoperative
99mTc-MSA Injection for Sentinel Lymph Node Identification
in Early Stage Lung Cancer
Hyun Koo Kim1, Sungeun Kim2, Jae Min Jeong3, Young Ho Choi1 1De-
partment of Thoracic and Cardiovascular Surgery, College of Medicine,
Korea University Guro Hospital, Republic of Korea, 2Department of Nuclear
Medicine, Nuclear Medicine, Republic of Korea, 3Department of Nuclear
Medicine, College of Medicine, Seoul National University Hospital, Republic
of Korea
Introduction: We aimed to evaluate the results of sentinel node mapping
according to injection time (preoperative versus intraoperative) of 99mTc-
MSA in early stage lung cancer.
Methods: Eighty-two patients (55 men, 27 women; mean age 62.99.3
years) that were candidates for lobectomy with mediastinal lymph node
dissection for clinical stage I non-small cell lung cancer were enrolled.
99mTc- MSA was administered under the chest CT guidance 2 hours before
surgery (group 1) or soon after thoracotomy (group 2), respectively. The
radioactivity in the lymph nodes was counted after dissection (ex vivo) with
a handheld gamma probe.
Results: The patient’s age and sex ratio of both group showed similar
(p0.05). Tumor size, pathology, and total number of dissected lymph node
(22.812.4 vs, 20.910.20) were not different (p0.05). The sentinel nodes
were detected in 46 of the 48 patients (95.8%) in group 1 and 33 of the 34
patients (97.1%) in group 2 (p0.05). The number of sentinel nodes per
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patient was 2.11.14 in group 1 and 2.61.25 in group 2 (p0.05).
False-negative sentinel nodes were detected in one (1/46, 2.2%) of the 11
patients with pathologic N1 or N2 disease in group 1 and one (1/33, 3.0%)
of the 6 patients with pathologic N1 or N2 disease in group 2 (p0.05). The
additional cost per patient for sentinel lymph node procedure was 330 dollars
(US) in group 1 and 1 dollar in group 2.
Conclusion: The intraoperative Sentinel node identification using 99mTc-
MSA may be preferred because of less cost and less psychological burden to
the patients.
P-068
Early Experience Using the Da Vinchi® Surgical System for the
Treatment of Mediastinal Tumor
Naohiro Kajiwara1, Masahiro Taira1, Koichi Yoshida1, Masaru Hagiwara1,
Masatoshi Kakihana1, Jitsuo Usuda1, Osamu Uchida1, Tatsuo Ohira1, Nori-
hiko Kawate2, Norihiko Ikeda1 1Department of Surgery, Tokyo Medical
University, Japan, 2Department of Health Science and Social Welfare,
Waseda University School of Human Sciences, Japan
Introduction: Robotic surgery has yet been done very few cases in selected
thoracic surgical field in our country. Recently, we have used the da Vinci ®
Surgical System for a various type of mediastinal tumors. Only few reports
of the using for da Vinci ® Surgical System in thoracic surgery, we report the
experience of a robotic surgery for mediastinal tumor in clinical practice.
Methods: The da Vinci ® Surgical System consists of a surgeon console
connected to a patient-side cart, a manipulator unit with three instrument
arms and a central arm to guide the endoscope as we reported previously. We
evaluated the feasibility and safety of the robot surgical system for the
surgical treatment for the 6 cases mediastinal tumor in our hospital between
March and July 2010.
Results: Tumor dissection was performed by two specialists in thoracic
surgery who were certificated using the da Vinci® surgical system and one
another specialist for assistant. Mean of the total operation time was 1.85
hours, mean of the da Vinci working time was 50.6 min. and a mean of the
total bleeding was 25.8 ml in our 6 cases operation. We experienced
differences between robotic surgery and standard thoracotomy include the
advantages of the 12-fold enlarged operation field of robotic surgery, and the
ability to access difficult-to-reach areas like the mediastinum.
Conclusion: Robotic surgery is an effective surgical method for the treat-
ment of a various type of mediastinal tumor in clinical.
P-069
Feasibility of Mediastinal Lymph Node Dissection Based on
Sentinel Lymph Node during Pulmonary Metastasectomy
Hyun Koo Kim1, Sungeun Kim2, Young Ho Choi1 1Department of Thoracic
and Cardiovascular Surgery, College of Medicine, Korea University Guro
Hospital, Republic of Korea, 2Department of Nuclear Medicine, College of
Medicine, Korea University Guro Hospital, Republic of Korea
Introduction: The role of mediastinal lymph node dissection during pulmo-
nary metastasectomy has not been established because its prognostic signif-
icance is controversial. In this study, we aimed to evaluate the feasibility of
mediastinal lymph node dissection based on sentinel lymph node in meta-
static lung cancer.
Methods: Thirteen patients (10 men, 3 women; mean age 60.87.48 years)
who were candidates for pulmonary metastasectomy for metastatic lung
cancer were enrolled. None of the preoperative CT and PET reported
suspicion of malignant involvement of hilar and mediastinal lymph nodes in
all patients. 99mTc- MSA was administered at the peri-tumoral region under
the chest CT guidance 2 hours before surgeryin. During operation, the
radioactivity of the lymph nodes was counted with a handheld gamma probe.
All harvested lymph nodes were examined histologically.
Results: Primary lesions of metastatic lung cancer were rectum (adenocar-
cinoma) in 4 patients, colon (adenocarcinoma) in 3, kidney (renal cell
carcinoma) in 3, skin (malignant granular cell tumor) in 2, and thigh
(sarcoma) in 1. Lobectomy was performed in 11 patients, segmentectomy in
1, and wedge resection in 1. The number of dissected lymph nodes was
17.310.89 (544) per patients. Sentinel lymph nodes could be identified in
all patients, and the number of sentinel lymph nodes was 2.01.22 stations
(range, 15) per patient. Only one of the 13 patients (7.7%) had metastases
in sentinel lymph node (false negative rate; 0%).
Conclusion: Sentinel lymph node identification may be a good tool to decide
whether mediastinal lymph node dissection should be performed or not
during pulmonary metastasectomy.
P-070
High Grade Occult Pleural Micro-Metastasis Detected with
Touch Print Cytology Method during Surgery Has Bad Survival
than Low Grade
Doosang Kim1, Youngwoo Park1, Yunjung Kim2 1Department of Thoracic
and Cardio-Vascular Surgery, Seoul Veterans Hospital, Republic of Korea,
2Department of Pathology, Seoul Veterans Hospital, Republic of Korea
Introduction: Peritoneal micrometastasis is important staging factor in
gastric and ovarian cancer. In NSCLCa, malignant pleural effusion is
classified as T4. However, occult pleural micrometastasis is not classified
yet, because it is difficult to detect using pleural lavage cytology during
surgery due to its low sensitivity range of 4-14%. Touch print cytology is
used to detect occult pleural micrometastasis easily with higher sensitivity.
The impact of occult pleural micrometastasis is remained to be elucidated.
Methods: To detect pleural micrometastasis, we underwent touch print
cytology (TPC) test using glass slides. Just after thoracotomy, touch print
was carried with 2 pieces of glass slide from the visceral pleural surface of
tumor mass of patients. The glass slides were examined and graded as
negative TPC (group I), positive low grade (grade 1, 2) TPC (group II)
and positive high grade (grade 3, 4) TPC (group III) for confirming
pleural micrometastasis of cancer cells. From March 1998 to May 2010, 249
tumor masses of lung cancer patients have been subjected. Among them,
Group I, II and III are 82, 146 and 21 cases respectively.
Results: TPC was found positive in 67.1% (167/249), while pleural lavage
cytology in 8.0% (20/249) of pre-resection and in 1.6% (4/249) of post-
resection. Low grade TPC and high grade TPC was 58.6% (146/249) and
8.4% (21/249) respectively. 5YSR of each group are 41.7%, 52.3% and
28.8%. There is significant difference between group I and II (p.0236).
Conclusion: Occult pleural micrometastasis detected using touch print
cytology method during surgery shows survival impact in NSCLCa patients.
P-071
New Surgical Strategy for Primary Lung Cancer in Which
Video-Assisted Thoracic Surgery (VATS) Plays the Leading
Role - Assessments for Post-Operative Morbidity and Mortality
Michihiko Tajiri, Takahiro Oomori, Ko Takahashi, Joji Samejima Depart-
ment of General Thoracic Surgery, Kanagawa Cardiovascular and Respi-
ratory Center, Japan
Introduction: We constructed the new strategy for the surgical resection of
primary lung cancer. The complete video-assisted thoracic surgery (c-VATS)
is the standard surgery for this new strategy. When c-VATS is too difficult
to be conducted, we switch to Hybrid VATS or the anterolateral thoracotomy
(AT). When we need to perform an extensive operation, we perform the
regular thoracotomy (RT) using a posterolateral or a median incision. We
named this strategy CHART.
Methods: 238 patients underwent the surgical resection under CHART at
our institute between April 2007 and March 2010. As a control group, we
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also studied 231 cases in which we performed surgeries via conventional
open thoracotomy (COT) from January 2004 to March 2007. We use 4
access-ports and monitoring vision only when performing c-VATS. We
elongate the incision to 6 or 8 cm when performing Hybrid VATS and use
a small rib-opener to allow for occasional direct vision. We further elongate
the incision to 10 or 15 cm on the anterolateral side of the trunk when
performing AT.
Results: Under CHART, We performed c-VATS on 187 patients (78.6%),
Hybrid VATS on 31 patients (13.0%), AT on 13 patients (5.5%), and RT on
7 patients (2.9%). Blood loss was lower with CHART (18.030.0 ml) than
with COT (243.0257.0ml). The rates of post-operative complications were
less with CHART (8.6%) than with COT (29.8%). Surgery-related death was
found with 7 cases with COT, but none were found with CHART.
Conclusion: Our results suggest that CHART is superior to COT in post-
operative morbidity and mortality.
P-072
Peripheral Lung Adenoid Cystic Carcinoma
Young Jo Sa, Sung Bo Sim, Sun Hee Lee Department of Thoracic and
Cardiovascular Surgery, Yeouido St. Mary’s Hodpital, The Catholic Uni-
versity of Korea, Republic of Korea
Introduction: Adenoid cystic carcinoma (ACC) is a distinctive malignant
neoplasm that usually arises in salivary glands. However, this type of tumor
can also occur in the breast, skin, uterine cervix, upper digestive tract and
lung. Primary lung ACC is relatively rare, accounting for 0.090.2% of all
primary lung cancers. Peripheral lung ACC is very rare and represents
approximately 10% of primary lung ACC. We described adenoid cystic
carcinoma that developed in the periphery of right lower lobe of a 52-year-
old woman.
Methods: 52-year-old female patient was referred with solitary pulmonary
nodule found accidentally from health checkup. On the chest CT scan, a
solitary lung mass that measured less than 3cm was detected at the right
lower lobe (RLL) but not involved right upper lobe. The mass was located
near the major fissure and well circumscribed, white colored and hard. The
result of intraoperative frozen section was malignancy. So, we performed the
right lower lobe lobectomy with lymph node dissection.
Results: The pathologic diagnosis was “Adenoid cystic carcinoma”. The
tumor was measured 2.5 x 1.8 cm and invaded the visceral pleura but lymph
node metastasis was not examined. On the PET-CT to exclude the possibility
of metastatic lung carcinoma from other sites, we confirmed the primary lung
adenoid cystic carcinoma. The result of immunohistochemistry was EGFR
positive (1), P53 negative, Ki-67 index 4% and COX-2 negative.
Conclusion: We presented a patient with relatively rare primary peripheral
adenoid cystic carcinoma of the lung with literature comparison.
P-073
Repeated Pulmonary Metastasectomy for Patients with Osteo-
sarcoma
Hae Won Lee, Jin Wook Hwang, Hee Jong Baek, Jong Ho Park Department
of Thoracic Surgery, Korea Institute of Radiological and Medical Science,
Republic of Korea
Introduction: Metstasectomy has been recommended for pulmonary met-
stasis of osteosarcoma if surgery is feasible. However, clinical analysis of
repeated pulmonary metastasectomy is not well reported. So, we analyzed
clinical results of repeated pulmonary metastasectomy for osteosarcoma in a
single cancer center.
Methods: We reviewed clinical variables of 109 patients who underwent
pulmonary metastasectomy for osteosarcoma from 1993 to 2008 in Korea
Cancer Center Hospital. Clinical factors including size of primary tumor,
tumor differentiation, response rate to chemotherapy, disease free survival
after primary site treatment, recurrence, overall survival were analyzed using
Cox proportional hazard model.
Results: The number of surgical resection was 156 for 109 patients. Mean
follow-up duration was 50 months (24102 months). Five-year survival rate
after first metastasectomy was 47.6% when complete resection was done
(101/109). Second metastasectomy was done in 38 patients, third in 8
patients, and forth in 1 patient. Average number of metastatic nodules was
11.4. Number of metastatic nodules, size of primary tumor and resection
margin of primary treatment were significant prognostic factors (p0.05).
But size of metastatic nodules, repetition of metastasectomy and bilaterality
did not affect prognosis significantly. After second metastasectomy, 5 year
survival rate was 36%, and it was 20% after operation for third metastasis.
Conclusion: From this study, repeated pulmonary resection can be recom-
mended when complete resection is possible, regardless of size, number of
metastatic nodules and bilaterality.
P-074
Result of Surgical Resection for Pulmonary Metastasis from
Urothelial Carcinoma
Jae Min Park, Yong Soo Choi, Hong Kwan Kim, Jhingook Kim, Young Mog
Shim, Kwhanmien Kim Department of Cardiovascular and Thoracic Sur-
gery, Samsung Medical Center, Republic of Korea
Introduction: The role of surgical resection has not been established for
pulmonary metastasis from urothelial carcinoma. The aim of our study is to
assess the outcome of pulmonary metastasectomy from urothelial carcinoma.
Methods: This is a retrospective review of pulmonary metastasectomy for
urothelial carcinoma at single institution between 1998 and 2009. Overall 14
patients underwent 18 pulmonary metastasectomies.
Results: Primary urothelial carcinomas consisted of adenocarcinoma (n3),
and papillary urothelial carcinoma (n11). Treatment for primary urothelial
carcinomas included transurethral resection (TUR), nephroureterectomy, and
cystectomy. Five patients received repeated TUR for loco-regional recurrence.
All patients received cisplantin-based palliative chemotherapy before pulmonary
resection. Pulmonary resection was performed by wedge resection (n10),
segmentectomy (n2), lobectomy (n7), and pneumonectomy (n1). Three
patients received repeated pulmonary resection for recurrent pulmonary metas-
tasis. Eleven patients received cisplantin-based adjuvant chemotherapy after
pulmonary metastasectomy. Mean number of tumors was 1.33, and mean
hospital stay was 5.1 days. There was no postoperative complication or mortal-
ity. Overall five-year survival was 60.0%. Three patients with papillary urothe-
lial carcinoma survive without tumor recurrence over 6 years.
Conclusion: In selected patients with pulmonary metastasis from urothelial
carcinoma, surgical treatment is feasible and could contribute to long-term
survival.
P-075
Results of Surgical Treatment for Clinical T4 Non-Small Cell
Lung Cancer
Jae Min Park, Hong Kwan Kim, Kwhanmien Kim, Jhingook Kim, Young
Mog Shim, Yong Soo Choi Department of Cardiovascular and Thoracic
Surgery, Samsung Medical Center, Republic of Korea
Introduction: Surgical treatment of T4 non-small cell lung cancer (NSCLC)
is debatable. The objective of this study was to assess the result of surgery
for clinical T4 NSCLC.
Methods: Retrospective review of medical records was performed for
consecutive cases of presumably resectable clinical T4 (AJCC 6th staging)
NSCLC between 2001 and 2008.
Results: All 85 clinical T4 NSCLC patients (71 men and 14 women) were
referred for surgical treatment. The reasons for T4 were as followings: heart
or great vessel invasion (n32), vertebral body invasion (n5), suspicious
malignant pleural effusion (n10), carina invasion (n7), and satellite
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nodule in the same lobe of primary tumor (n31). Lobectomy was per-
formed in 57 cases, bilobectomy or pneumonectomy in 23 cases, and carinal
sleeve pneumonectomy in 6 cases. R0 resection was achieved in 69 cases
(81.2%). Pathologic staging was T4 (pT4) in 37 patients (43.5%), earlier than
T4 in 46 patients (53%), and M1 in 3 patients. In-hospital mortality was 5.8%
and causes of death were pneumonia (n2) and postoperative ARDS (n3).
Median and overall 5-year survival were 24 months and 37.4 % in pT4
patients compared to 51 months and 43.9 % in the earlier stages than pT4
(p0.087). Among the pT4 patients, pN2 was found in 6 patients (16.2%)
and their 5-year survival was 0% compared to 42.6% in pN0-1 (p0.47).
Conclusion: Clinical staging for T4 NSCLC was relatively inaccurate and
over-staged compared to their pathological staging in our study. Some of
clinical T4 NSCLC patients could get a chance for better prognosis by
complete resection.
P-076
Surgical Outcome in Small Cell Lung Cancer
Minho Ju, Hyeong Ryul Kim, Do Kyun Kang, Yong Hee Kim, Dong Kwan
Kim, Seung-Il Park Department of Thoracic and Cardiovascular Surgery,
Seoul Asan Medical Center, Republic of Korea
Introduction: Institutional experiences of surgery for small cell lung cancer
were reviewed to evaluate surgical outcomes and prognosis.
Methods: From April 1999 to Dec. 2009, thirty four patients (28 male)
underwent major pulmonary resection and lymph nodes dissection. Lobectomy
was performed in 24 patients, bilobectomy in 1, pneumonectomy in 8 and
segmentectomy in 1. Operative complication, mortality, disease-free survival
(DFS) rate and survival rate were analyzed retrospectively.
Results: The mean follow-up period was 53 months (range, 4-241 months)
and there was one operative mortality (2.9%). Six (17.6%) patients experi-
enced recurrence, which were all systemic. Eight patients died during
follow-up. Four patients died of disease progression and the other four died
of pneumonia or non-cancerous cause. Three-year DFS rate was 79.22.6%
and overall survival rate was 66.410.5%. Recurrence or death were
significantly prevalent in patients with lymph node metastasis (p0.001) or
without adjuvant chemotherapy (p0.008). Three-year survival rate was
significantly better in patients with pathologic stage I / II than patients with
stage III/IV (84% vs 13%, p0.001).
Conclusion: Major pulmonary resection for small cell lung cancer was
feasible. Patients with pathologic stage I or II showed excellent survival rate
after surgery. Prospective randomized studies are needed to establish the
surgical role in early stage small cell lung cancer.
P-077
The Effect of Neoadjuvant Chemotherapy for N2() Stage IIIA
Korean Lung Cancer Patients
Hae Won Lee, Jin Wook Hwang, Hee Jong Baek, Jong Ho Park Department
of Thoracic Surgery, Korea Institute of Radiological and Medical Science,
Republic of Korea
Introduction: According to several clinical guidelines, neoadjuvant chemo-
therapy is recommended for stage IIIA, N2() NSCLC. However, there was
no definite prospective study reporting benefit of neoadjuvant chemotherapy
for N2() stage IIIA Asian lung cancer patients. So we did retrospective
study about effect of neoadjuvant chemotherapy in a single cancer center.
Methods: We reviewed clinical data of 73 N2() stage IIIA NSCLC patients
who received neoadjuvant chemotherapy from 1998 to 2007 in Korea Cancer
Center Hospital. During this period, another 381 pathologic N2() stage IIIA
patients underwent surgery without preoperative chemotherapy. Among them,
43 patients, who had definite clinical N2() disease, were selected as a control
group. Several clinical parameters were analyzed to evaluate the effect of
neoadjuvant chemotherapy for N2() stage IIIA NSCLC.
Results: In the neoadjuvant group, 45 patients (61.6%) underwent surgery
(5 YSR: 37.1%, MS : 36.2 months). Remaining 28 patients could not have
surgery (5 YSR : 14.4%, MS : 11.9 months). Refusal of operation and
disease progression were the main causes. There was no significant
difference of survival between neoadjuvant group and control group
(31.5% and 23.4 months, and 29.9% and 24.4 months respectively
p0.86). And even when neoadjuvantsurgery group was compared to
control group, survival benefit was no significant difference in survival
(p0.43). Only the enrollment of surgery within neoadjuvant group was
a prognostic factor (p.05).
Conclusion: In contrast to western reports, we could not find definite benefit
of neoadjuvant chemotherapy for N2() stage IIIA NSCLC. We would like
to recommend a large randomized prospective study for Asian patients.
P-078
The Prognostic Factors of Resected Non-Small Cell Lung Can-
cer with Chest Wall Invasion
Chang Young Lee, Jin Gu Lee, In Kyu Park, Dae Joon Kim, Kyung Young
Chung Department of Thoracic and Cardiovascular Surgery, Yonsei Uni-
versity College of Medicine, Republic of Korea
Introduction: We retrospectively reviewed the clinical features and surgical
outcomes of patients with a surgically resected NSCLC invading chest wall
in order to identify prognostic factors that impact long term survival and to
suggest the optimal treatment strategy.
Methods: Between January 1990 and December 2009, 107 patients who
underwent surgical resection for chest wall invading NSCLC were reviewed.
Results: There were 91 men and 16 women; median age was 64 years (range
30 to 80 years). . Operative mortality was 5% (n5). Pathologic stages were
T3N0 in 64 (60%) cases, T3N1 in 19 (18%) cases and T3N2 in 24 (22%)
cases. Overall 5 year survival rate was 26.3%. The univariate prognostic
factors for survival included gender, extent of resection (pneumonectomy vs
lobectomy), tumor size(5cm vs 5cm), nodal status (N0 or N1 vs N2),
completeness of resection (complete vs incomplete) and completeness of
adjuvant chemotherapy. At multivariate analysis, five independent prognos-
tic factors were shown; depth of invasion (superficial vs deep), tumor size,
nodal status, completeness of resection, and completeness of adjuvant che-
motherapy. In patients with completely resected T3N0 NSCLC, completion
of chemotherapy is the only prognostic factor for long term survival. (5 year
overall survival 21.8% vs. 45.8%, p0.001).
Conclusion: Completeness of resection, nodal status, depth of invasion,
tumor size, and adjuvant chemotherapy were prognostic factors for long-term
survival in NSCLC patients with chest wall invasion. Strategic approach
towards selected patients should be considered based on the prognostic
factors and patients with completely resected stage T3N0 tumor should
undoubtedly receive adjuvant chemotherapy.
P-079
The Role of Surgery for Elderly Patients of Non-Small Cell
Lung Cancer
Byung Su Yoo, Chang Hyun Kang, Young Tae Kim, Joo Hyun Kim
Department of Thoracic and Cardiovascular Surgery, Seoul National Uni-
versity Hospital, Republic of Korea
Introduction: In lung cancer, surgery is the treatment of choice but, many
elderly patients do not receive surgery because their age. The risk of
operation of elderly patients is more higher than that of young patients. But
operation offers good survival rate in selected patients. This study was
undertaken to reveal the prognostic factors of operation of the elderly
patients of non-small cell lung cancer (NSCLC).
Methods: Forty-four patients who 80years old or older diagnosed lung
cancer and treated operation in Seoul National University Hospital between
January 2001 and July 2010 were selected. They were received operations
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more than wedge resections. There were 31 males and 13 females. The mean age
was 81.91.9 (Range: 80-87)years. The mean FEV1(%) was 107.924.6%.
The most common pathologic type were adenocarcinoma 24 (54.5%). The most
common pathologic stage were Ia 13 (29.5%) and Ib 21 (47.7%).
Results: The overall survival was 51% at 5 years and one clinical variables,
female (p0.038) was analyzed as prognostic factors for longterm survival
in multivariable analysis. Recurrence occurred in 8(18.2%) patients. The
operation mortality was 4.5%. The 5years disease free survival rates was
48%. Only gender (p0.009) was analyzed as prognostic factors for disease
free survival in univariable analysis.
Conclusion: In lung cancer operation for the patients who 80 years old or older,
gender was prognosis factor recurrence and survival. Even their mortality and
morbidity were higher than that of young patients, prognosis was favorable.
Even elderly patients, surgeon have operation possibility in mind. However
carefully selects patients because of the increased operative risk.
P-080
Unplanned Conversion into Thoracotomy during VATS Lobec-
tomy Does Not Compromise the Outcomes of Surgery
Joon Suk Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Young
Mog Shim, Kwhanmien Kim Department of Thoracic Surgery, Samsung
Medical Center, Republic of Korea
Introduction: Technical and oncological safety related with unplanned
thoracotomy during VATS lobectomy is not fully defined. We tried to
analyze the early and late outcomes of patients with thoracotomy conversion
from VATS, and evaluate the safety of unplanned conversion from VATS
lobectomy.
Methods: From Dec. 2003 to Dec. 2008, we experienced 34 unplanned
conversions into open-thoracotomy. Patients’ characteristics, operative data,
cause of conversion, early postoperative outcomes and follow-up informa-
tions were retrospectively analyzed.
Results: 26 patients underwent operation for lung cancer, and 8 for benign
diseases. The conversion rate was 4.91%. Cause of conversion was as
follows. First one was problems related with anthracofibrosis of lymph nodes
in 14 patients. Second was intraoperative injury of vessel or bronchus in 11.
Third was fused interlobar fissure in 4. Fourth was oncologic problem such
as lymph node metastasis in 2. Last included 3 related with vascular
anomaly. There was one operative death due to postoperative pneumonia.
Two more patients suffered from postoperative pneumonia, one required
therapeutic mechanical ventilation. Median follow-up period was 3011.47
months, and there were 3 recurrences among the patients with lung cancer,
all of them were found to have pathologically stage III disease, but no
cancer-related death was observed. Survival and recurrence of these patients
were not significantly different from those of patients with successful VATS
lobectomy.
Conclusion: VATS lobectomy can be safely performed with acceptable
conversion rate. Unplanned conversion into open-thoracotomy does not
compromise patients’ prognosis. However it might be avoided by careful
preoperative evaluation of patient.
ENDOSCOPY AND INTERVENTION
BRONCHOSCOPY
P-081
Endbronchial Ultrasound-Transbronchial Fine Needle Aspira-
tion (EBUS-TBNA) as a Modern Gold Standard for Clinical N2
(c-N2) Lung Cancer Patients
Masaki Hashimto1, Teruhisa Takuwa1, Yoshitomo Okumura1, Hayato Orui1,
Kazu Shiomi1, Seiji Matsumoto1, Nobuyuki Kondo1, Fumihiro Tanaka1,
Noriaki Tsubota2, Kazuya Fukuoka3, Takashi Nakano3, Seiki Hasegawa1
1Department of Thoracic Surgery, Hyogo College of Medicine, Japan,
2Department of Thoracic Oncology, Hyogo College of Medicine, Japan,
3Department of Internal Medicine, Division of Respiratory Medicine, Hyogo
College of Medicine, Japan
Introduction: Definite diagnosis of mediastinal lymph nodes (LNs) is
essential to predict the prognosis of lung cancer patients. Mediastinoscopy
(MS) is the “gold standard” methodology for clinical N2 (c-N2) lung cancer
patients. However, endbronchial ultrasound transbronchial fine needle aspi-
ration (EBUS-TBNA) is taking place of MS because of less invasiveness and
cost benefit.
Methods: All the cases where EBUS-TBNA was performed on c-N2 lung
cancer patients from November 2005 to July 2010 in our hospital were
retrospectively analyzed. In case where EBUS-TBNA failed to prove ma-
lignant cells, MS and/or thoracotomy were performed for definite diagnosis.
Results: A total of 142 patients underwent EBUS-TBNA without serious
complications from November 2005 to July 2010. One hundred and three of
142 (72.5%) were for patients with lung cancer. In 77 of 103 patients,
definite pathological diagnosis for mediastinal LNs was established through
either of EBUS-TBNA, MS, or thoracotomy. Malignant cell was detected in
53 of 77 (68.8%) EBUS-TBNA. Of 24 EBUS-TBNA-negative patients, true
negative and false negative were 11 and 13, respectively. Sensitivity, spec-
ificity, and accuracy of EBUS-TBNA were 78.6%, 100%, and 83.1%,
respectively.
Conclusion: EBUS-TBNA is a safe and reliable diagnostic tool for medi-
astinal LNs. By virtue of EBUS-TBNA , neither MS nor thoracotomy were
required in 68.8% of cN2 patients.
P-082
Management of Multiple Primary Lung Cancer Patients with
Centrally Located Early Cancer Lesions
Jitsuo Usuda, Shuji Ichinose, Keishi Ohtani, Tatsuya Inoue, Hisashi Saji,
Masahiko Kakihana, Naohiro Kajiwara, Osamu Uchida, Tatsuo Ohira, Nori-
hiko Ikeda Department of Surgery, Tokyo Medical University, Japan
Introduction: Patients with centrally located early lung cancer (CLELC) are
often heavy smokers with a considerably high risk of multiple lung cancer
lesions (MPLC); treatment strategies for such patients must preserve the
cardiopulmonary function.
Methods: Between June 2004 and June 2008, patients with CLELC under-
went PDT using NPe6, second-generation photosensitizer at Tokyo Medical
University Hospital. Among these patients, we retrospectively analyzed
MPLC which were treated by surgery plus PDT or PDT alone, and examined
the effectiveness of PDT and we propose a treatment strategy for patients
with MPLC.
Results: A total of 64 patients with CLECL received NPe6-PDT, and
MPLCs were observed in 22 patients (34.4%). Among the patients with
MPLC, 10 patients underwent surgery (9 lobectomies and 1 pneumonec-
tomy) for primary lung cancer and then underwent NPe6-PDT for the
treatment of secondary primary CLELC. In 8 of these 10 patients, CLELC
was found as metachronous lesions using sputum cytology and a broncho-
scopical examination using autofluorescence bronchoscopy. In 11 of the 22
patients, all 28 lesions were CLELC and identified by autofluorescence
bronchoscopy and were performed PDT alone. Among the 22 patients with
MPLC including peripheral type lung cancres which were resected by
surgery, all 39 CLELC lesions exhibited a complete response after PDT, and
all patients were alive.
Conclusion: For lung cancer patients with a long-term history of smoking,
careful follow-up examinations after surgical resection are needed consider-
ing the incidence of metachronous primary lung cancers. PDT can play an
important role for the treatment strategy for MPLC.
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P-083
The Evaluation of EGFR and KRAS Mutations in the Biopsy
Specimens Obtained by Bronchoscopy and EBUS-TBNA
Yeh Rim Kang1, Sang-Won Um1, Kyeongman Jeon1, Won-Jung Koh1, Gee
Yeoung Suh1, Man Pyo Chung1, Hojoong Kim1, O Jung Kwon1, Yoon-La
Choi2, Jungho Han2 1Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Republic of Korea, 2Depart-
ment of Pathology, Samsung Medical Center, Sungkyunkwan University
School of Medicine, Republic of Korea
Introduction: The procurement of tumor tissue is mandatory for the test of
mutation which is requisite for the use of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors. The purpose of this study was to evaluate
the usefulness of bronchoscopic biopsy and endobronchial ultrasound-trans-
bronchial needle aspiration (EBUS-TBNA) for the detection of EGFR and
KRAS mutations.
Methods: Tumor DNA was extracted from formalin-fixed paraffin-embed-
ded tissues, and amplifications of exons 18 through 21 of EGFR and exons
2 and 3 of KRAS were performed by polymerase chain reaction (PCR). PCR
products were subjected to direct sequencing in both directions.
Results: Between November 2009 and June 2010, 205 patients underwent
bronchoscopic biopsy or EBUS-TBNA for diagnosis and staging of NSCLC.
Among 145 patients who were requested for the analyses of EGFR or KRAS
mutations, the evaluation of mutations was feasible in 137 patients (94.5%).
EGFR and KRAS mutations were detected in 19.1 % (25/131) and 9.0%
(12/133), respectively. EGFR mutation was more frequently detected in
EBUS-TBNA sample compared with bronchoscopic biopsy sample (24.5 %
vs. 15.4 %). Detection rate of KRAS mutation was similar between EBUS-
TBNA and bronchoscopic biopsy (7.8% vs. 9.8 %). Among the patients with
adenocarcinoma (N71), the frequencies of EGFR and KRAS mutations
were 33.8 % and 15.5%, respectively.
Conclusion: The small tissue samples obtained by bronchoscopic biopsy and
EBUS-TBNA are sufficient for the detection of EGFR and KRAS mutations
in most cases. Detection rate of EGFR or KRAS mutation was 49.3 % in
patients with adenocarcinomas.
P-084
The Role of Narrow Band Imaging Videobronchoscopy in Lung
Cancer
Jinkyeong Park1, Youngju Jung1, Sejin Jang2, Youngsoo Park2, Yeonmok
Oh1, Taesun Shim1, Woosung Kim1, Changmin Choi1 1Department of
Pulmonary and Critical Care Medicine, University of Ulsan, College of
Medicine, Asan Medical Center, Republic of Korea, 2Department of Pathol-
ogy, University of Ulsan, College of Medicine, Asan Medical Center,
Republic of Korea
Introduction: Narrow band imaging (NBI) videobronchoscopy is an optical
technique in which filtered light enhances superficial neoplasm based on their
neoangiogenic pattern. The objectives of this study investigate its sensitivity
and specificity in the assessment of lung cancer.
Methods: 101 patients with suspected lung cancer were prospectively
conducted between July 2009 and June 2010. Inspection with high resolution
endoscopy was followed by NBI. Detected lesions were biopsied. We were
applied the system of shibuya et al. to analyze and classify vascular patterns
by NBI into four categories.
Results: We examined 134 endobroncheal lesions – 44 squamous carci-
noma, 17 adenocarcinoma, 17 small cell lung cancer, 1 calcinoid tumor, 1
sarcomatoid carcinoma, 2 squamous dysplasia, 52 other benign lesion. Spiral
and screw pattern was seen in 50 lesions (sensitivity 61%, specificity 100%,
accuracy 76.1%, negative predictive value 61.9%, positive predictive value
100%), dotted pattern was 21( 22%, 94.2%, 50%, 43.4%, 85.7%), tortuous
pattern was 41 (12.2%, 40.4%, 23.1%, 22.6%, 24.4%), and avascular pattern
was 30 ( 20.7%, 75.0%, 41.8%, 37.5%, 56.7%) in NBI. Unexpectedly,
additional early cancer lesions were detected in five patients. All of these
lesion(3 dotted ,1 tortuous, 1 spiral and screw pattern) were squamous
carcinoma.
Conclusion: In our study, all of NBI abnormal areas were spiral and screw,
dotted, spiral, and avascular pattern. It can be concluded that NBI is useful
and predictable in revealing malignant lesions in such spiral and screw
pattern. This technology could aid not only early-stage lung cancer diagnosis
but also more accurate local staging of lung cancer.
P-085
Lung Cancer in HIV-Positive Patients
Aruna Alahari Dhir, Sheela Prashant Sawant, Rajesh C Mistry, Purvish P
Parikh, Jaiprakash P Agarwal, Nirmala Ajit Jhambekar Department of
Medicine, Tata Memorial Hospital, India
Introduction: Lung cancer is known to occur in a higher incidence among
HIV positive patients. Presently there is not much data from India in this
setting.We studied the clinical profile of HIV positive patients with lung
cancer at Tata Memorial Cancer Hospital.
Methods: HIV positive patients with pathologically proven lung cancer
between the year 2000-2005 were reviewed. Proportional incidence ratio
(PIR) was calculated using the gender and age-specific proportions of lung
cancer of the year 2002 recorded in the Hospital Cancer Registry.
Results: There were 16 patients who were HIV positive and diagnosed LC
during the study period. Proportional Incidence Ratio was not increased for
lung cancer. Median age was 50yrs, 87.5% were males.81.3% consumed
tobacco.81.3% patients presented with advanced stage. 50% patients had
adenocarcinoma, 43.8% were non-small cell carcinoma,6.3% were small cell
carcinoma.62.5% patients received cancer directed treatment. 37.5% patients
received HAART.50% patients of the study group had a previously diag-
nosed seropositive status. 75% patients had a CD4 count200/cumm. 8
patients were lost to follow up, 8 patients expired with median survival of 4.5
months, No opportunistic infections were detected in either of these patients.
Conclusion: Male predominance and median age of incidence [50 yrs] for
lung cancer are similar to those in non HIV patients. Adenocarcinoma is the
commonest histopathology in these patients. Smoking is related to the
incidence of lung cancer as in non HIV patients. LC presents at an advanced
stage in HIV positive patients. The prognosis and survival is poor. Significant
immunosuppression was not seen. Smoking cessation must be strongly
emphasized for prevention of lung cancer among HIV positive patients.
P-086
The Incidence of Cytotoxic Chemotherapy-Related Exacerba-
tion of Interstitial Lung Disease with Lung Cancer
Hirotsugu Kenmotsu1, Tateaki Naito1, Akira Ono1, Yukiko Nakamura1,
Asuka Tsuya1, Kyoichi Kaira1, Haruyasu Murakami1, Toshiaki Takahashi1,
Masahiro Endo2, Nobuyuki Yamamoto1 1Department of Thoracic Oncol-
ogy, Shizuoka Cancer Center Hospital, Japan, 2Department of Diagnostic
Radiology, Shizuoka Cancer Center Hospital, Japan
Introduction: Lung cancer is known to frequently occur in patients with
interstitial lung disease (ILD). It is important to establish treatment strategies
for lung cancer with ILD.
Methods: To identify the risk of acute exacerbation of ILD, we retrospec-
tively reviewed 109 lung cancer patients with ILD treated with cytotoxic
chemotherapy at Shizuoka Cancer Center Hospital between August 2002 and
April 2010.
Results: On pretreatment computed tomography of the chest, sixty-nine
patients (63%) were identified with clinical idiopathic pulmonary fibrosis
(IPF), and forty patients (37%) had non-IPF. Patient characteristics (IPF
group/non-IPF group) were as follows: median age (range) 70 (55-84)/69
(54-80); male 97/90%; smokers 100/100%; PS0-1 90/80%; adenocarcinoma
32/35%, squamous cell carcinoma 30/28%, small cell lung cancer (SCLC)
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29/33%; stage IV 45/65%; recurrence after surgical resection 6/10%. Patients
with IPF developed cytotoxic chemotherapy-related exacerbation of ILD
more frequently than those with non-IPF (38 vs. 8%, p0.01). The inci-
dences of exacerbation of ILD by treatment regimens (IPF group/non-IPF
group) were as follows; paclitaxel 6/0%; docetaxel 28/8%; etoposide 24/0%;
vinorelbine 15/0%. In SCLC, overall survival (OS) from the start of first-line
chemotherapy was significantly shorter in IPF group than non-IPF group
(median OS: 9 vs. 16 months, p0.0475), while there was no significant
difference in non-small cell lung cancer patients (median OS: 12 vs. 9
months, p0.2529).
Conclusion: In lung cancer with IPF, the incidence of exacerbation of ILD
was significantly higher than in lung cancer with non-IPF. In SCLC with IPF,
the prognosis was also significantly poor.
RADIOTHERAPY
P-087
Comparison of Dose Coverage of Lung Tumor Volume in
Three- and Four-Dimensional Robotic Radiotherapy Treatment
Planning
Young Kyung Lim Department of Radiation Oncology, Gyeongsang Na-
tional University Hospital, Republic of Korea
Introduction: Four-dimensional treatment planning should be required for
accurate dose calculation in moving and deforming lung cancers. We
compared three- and four dimensional treatment plans calculated with Ray
Tracing or Monte Carlo algorithm, and showed the necessity of Monte Carlo
calculation for lung heterogeneity correction in lung cancers.
Methods: Four-dimensional computed tomographies (4D CTs) in six
patients were obtained in Brilliance CT 64-Channel scanner (Philips
Medical Systems, Best, Netherlands) with a respiratory bellows gating
device. After 4D treatment planning with Ray Tracing algorithm in
Multiplan 3.5.1 (Accuray Inc., Sunnyvale, CA), 3D Ray Tracing, 3D and
4D Monte Carlo dose calculations were performed under the same beam
conditions (same number, directions, monitor units of beams). 3D plan
was done in a primary CT image set corresponding to a middle phase of
expiration (50%). Relative dose coverage of GTV or PTV was compared
each other.
Results: Dose coverage of GTVs and PTVs in 3D plans using the same
calculation algorithm matched well with that of 4D plans within 5% of dose
even though the tumor was located in lower lobe of lung. The tumor motion
and deformation did not affect seriously to the reduction of dose coverage.
However, the heterogeneity correction of low lung density had a large
influence on the reduction of dose coverage. The mean dose reduction was
more than 10%.
Conclusion: While 4D treatment planning is necessary only for large tumor
motion and deformation, Monte Carlo calculation is always necessary, not
depending on the tumor location in the lung.
P-088
Concurrent Chemo-Radiation Therapy in Locally Advanced
Non-Small Cell Lung Cancer
Jin Hee Kim1, Ok Bae Kim1, Sang Jun Byun1, Seung Gyu Park1, Young Kee
Oh1, Tae Jin Choi3, Young June Jeon2 1Department of Radiation Oncology,
Keimyung University, School of Medicine, Republic of Korea, 2Department
of Internal Medicine, Keimyung University, School of Medicine, Republic of
Korea, 3Department of Medical Engineering, Keimyung University, School
of Medicine, Republic of Korea
Introduction: To evaluate effectiveness of concurrent chemo-radiation ther-
apy (CCRT) in non-small cell lung cancer (NSCLC).
Methods: From April 2000 to December 2008, 57 patients with NSCLC
were treated with CCRT at Keimyung University Dongsan Medical Center.
Twelve patients whose total treatment dose was below 45Gy were excluded,
and 45 patients were analyzed. There were 42 male and 3 female patients.
The range of age was from 37 to 80(median 63). According to the AJCC
TNM stage, there were 12 patients (26.7%) with stage IIIA, and 33 patients
(73.3%) with stage IIIB. Total dose 45-70Gy was irradiated (median 63)
through 5 days per week, 1.8-2.0Gy once a day with paclitaxel or cisplatin
containing regimen. The range of follow-up periods was from 3 to 59 months
(median 15).
Results: Local control was observed in one patient with complete re-
sponse and 22 patients with partial response. The 3-year overall survival
rate was 14.2%. One-year disease-specific survival rate was 63.9%,
2-year rate 32.2%, 3 year-rate 16.7%. Median survival time was 16
months. On univariate analysis for survival time, the age (63 vs.63)
was statistically significant (p0.017). There was no statistical signifi-
cance on sex, morphology, AJCC stage and tumor diameter, nodal status,
use of 3D-conformal technique, hemoglobin level and neoadjuvant che-
motherapy. On correlation analysis, there was correlation between dose
and survival time after CCRT, with higher dose to longer survival time
(Pearson correlation factor0.309).
Conclusion: We thought CCRT in NSCLC is an effective treatment option
in view of survival rate, especially for younger age. It is more effective using
higher radiation dose to accomplish better outcome.
P-089
Involved Field Radiation Therapy as a Salvage Treatment for
Loco-Regional Recurrence after Complete Resection of Non-
Small Cell Lung Cancer
Sun Hyun Bae1, Yong Chan Ahn1, Hee Chul Park1, Do Hoon Lim1, Young
Mog Shim2, Jhingook Kim2, Kwhanmien Kim2, Yong Soo Choi2, Keunchil
Park3, Myung-Ju Ahn3, Jin Seok Ahn3 1Department of Radiation Oncology,
Samsung Medical Center, Sungkyunkwan University School of Medicine,
Republic of Korea, 2Department of Thoracic Surgery, Samsung Medical
Center, Sungkyunkwan University School of Medicine, Republic of Korea,
3Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Republic of Korea
Introduction: This retrospective study is to report the outcomes by involved
field radiation therapy (RT) as a salvage treatment for loco-regional recur-
rence (LRR) after complete resection of non-small cell lung cancer
(NSCLC).
Methods: Between 1994 and 2007, 64 patients with LRR without distant
metastasis after complete resection of NSCLC were treated by RT alone
(78%) or with concurrent chemotherapy (CCRT, 22%) at Samsung Medical
Center. The median time to recurrence from the date of surgery was 10
months. The sites of LRR were local at the bronchial stump or the chest wall
in 29 patients (45%), regional at the mediastinum in 26 (41%) and combined
in nine (14%). The median RT dose was 54 (4066) Gy. The radiation target
included the recurrent lesion with a 1-2cm margin and no attention was given
to the regional lymphatics electively.
Results: The median follow-up time was 15.5 months. The rates of in-field
failure free survival, intrathoracic failure free survival, and extrathoracic
failure free survival at 2 years were 52.3%, 33.9%, and 59.4%, respectively.
The median survival after RT was 18.5 months and the 2-year overall
survival rate (OS) was 47.9%. On multivariate analysis, the longer time
interval till postoperative recurrence and the use of CCRT were significantly
favorable prognostic factors for OS.
Conclusion: The current study, including the largest number of patients,
showed superior outcomes compared to other studies, and involved field RT
with concurrent chemotherapy seems an effective salvage treatment for LRR
after complete resection of NSCLC.
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P-090
Prophylactic Cranial Irradiation in Small Cell Lung Carcinoma
Yoshiro Nakahara1, Yukio Hosomi1, Yusuke Okuma1, Yusuke Takagi1, Mari
Iguchi1, Tatsuru Okamura1, Naoko Maezawa2, Nobuteru Kubo2, Gencho
Kuga2, Ta-Chen Chang2, Katsuyuki Karasawa2, Masahiko Shibuya1 1De-
partment of Respiratory Medicine, Tokyo Metropolitan Cancer and Infec-
tious Diseases Center Komagome Hospital, Japan, 2Department of Radiol-
ogy, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome
Hospital, Japan
Introduction: Prophylactic cranial irradiation (PCI) has been established as
standard therapy for small cell lung carcinoma. However, this treatment is
associated with late adverse effects, such as dementia and progressive
multifocal leukoencephalopathy. We herein discuss the safety and efficacy of
PCI.
Methods: We retrospectively analyzed 14 small cell lung carcinoma cases
treated at our hospital with PCI between 2004 and 2010.
Results: Twelve patients were male, and 2 patients were female. Median age
was 67 years (range: 52-78 years). Thirteen patients had limited disease
(LD), and 1 patient had extensive disease (ED). Nine patients were initially
treated with concurrent chemoradiotherapy, 4 were treated with sequential
chemoradiotherapy and 1 was treated with chemotherapy. Eight patients
showed complete response (CR), while 6 showed partial response (PR). PCI
was delivered at 2-3 Gy/day for a total dose of 10-36 Gy. Recurrence was
seen in 6 cases, and brain metastasis was seen in 3 cases. Median survival
time was 22 months (range: 5-68 months). Dementia occurred in 5 cases, and
progressive multifocal leukoencephalopathy occurred in 1 case.
Conclusion: Treatment outcomes with PCI in small cell lung carcinoma
were relatively good, although late adverse effects need to be considered
before starting therapy.
P-091
Radiation-induced Pulmonary Fibrosis Volume and Pulmonary
Function Loss in Post-operative Radiotherapy for Non-Small-
Cell Lung Cancer
O Kyu Noh1, Hyunsoo Jang1, Young-Taek Oh1, Kyung Joo Park2, Kwang
Joo Park3, Mi Hwa Kim1, Mison Chun1 1Department of Radiation Oncol-
ogy, Ajou University School of Medicine, Republic of Korea, 2Department of
Radiology, Ajou University School of Medicine, Republic of Korea, 3Depart-
ment of Pulmonology and Critical Care Medicine, Ajou University School of
Medicine, Republic of Korea
Introduction: To evaluate radiation-induced pulmonary function loss in
post-operative radiotherapy (PORT) for non-small cell lung cancer (NSCLC)
using the volume of radiation-induced pulmonary fibrosis.
Methods: Patients with NSCLC who were treated with PORT were enrolled
in this investigation. Pulmonary function tests (PFTs) were determined
pre-operatively, pre-PORT, and  6 months after PORT. Pre-PORT PFTs
were also estimated from pre-operative PFTs using a quantitative CT
method. The volume of radiation-induced pulmonary fibrosis (Vf) was
evaluated on chest CT scan  6 months after the completion of PORT. The
correlations among the dosimetric parameters of the lung, Vf, and radiation-
induced pulmonary function loss were analyzed.
Results: Between January 2003 and January 2007, 48 patients were treated
with conformal radiotherapy. The mean values of FEV1 were 2.16 L
pre-operatively, 1.65 L pre-PORT; 1.61 L estimated pre-operatively, and
1.59 L during follow-up PFTs. PORT showed no additional decline in FEV1
(estimated pre-PORT FEV1 vs. follow-up FEV1 [1.63 L vs. 1.59 L];
P0.48). The radiation-induced pulmonary function loss was well-correlated
with the dosimetric parameters (V25; r-0.734; P.01), as well as the Vf
(r-0.695; P.01).
Conclusion: The degree of radiation-induced pulmonary function loss is
well-correlated with the volume of radiation-induced pulmonary fibrosis in
patients with NSCLC who underwent surgical resection followed by PORT.
Radiation-induced fibrosis volume should be investigated as a quantitative
imaging marker in assessment of radiation-induced pulmonary injury.
P-092
Stereotactic Radiotherapy (SRT) as Comprehensive Terapy for
Non-Small Cell Lung Cancer in Local Community Hospital
Yo-Hei Futamura1, Toshiyuki Sawa1, Tsutomu Yoshida1, Takashi Ishiguro1,
Akane Horiba1, Takayoshi Iida2, Takashi Watanabe2 1Department of Respi-
ratory Medicine and Oncology, Gifu Municipal Hospital, Japan, 2Depart-
ment of Radiology, Gifu Municipal Hospital, Japan
Introduction: Stereotactic radiotherapy (SRT) has recently been used for the
treatment of early stage or small lung malignant tumors while standard
method has not been established. We retrospectively evaluated the efficacy
and safety of SRT for non-small cell lung cancer (NSCLC) treated in our
hospital which is popular local community core hospital for cancer treatment.
Methods: Between October 2007 and December 2009, 31 tumors of 29
patients were treated by SRT (mean age, 75 years: stage IA, n13; stage IB,
n5; stage IIIA, n1; stage IIIB, n1; recurrence, n11 ). Most of patients
were considered medically inoperable, and 2 cases of patients declined
surgery. Risk-adapted SRT schemes were used with the two total dose of 48
grays in 26 site and 52 grays in 5 site by 4 fractions, depending on the
patient’s risk for toxicity.
Results: All of the patients completed the treatment. In one patient who had
radiation pneumonitis before SRT, progression of pulmonary fibrosis was
observed, and treated with steroid therapy. In evaluable 29 tumors of 27
patients, the recurrence rates are 11/29(37.9%). Median progression free
survival time was 8 months. The recurrence rate and median progression free
survival time of stage IA and IB subgroups was 4/17(23.5%) and 12 months
respectively.
Conclusion: SRT is thought to be a safe and effective treatment for stage I
NSCLC. For patients with stage I NSCLC, SRT can be comprehensive
therapy for surgical resection even in local community hospital.
SMALL CELL LUNG CANCER
P-093
Bi-Weekly Paclitaxel – Gemcitabine in Small Cell Lung Cancer
Patients Pretreated with Platinum-Etoposide Chemotherapy
Sergio Carrera Revilla, Guillermo Lopez Vivanco, Alberto Mun˜oz Llarena,
Itziar Rubio Etxebarria, Aintzane Sancho Gutierrez, Ines Marrodan Ciordia,
Juan Manuel Man˜e, Abigail Ruiz De Lobera, David Ballesteros, Eddy
Gutierrez Department of Medical Oncology, Cruces Hospital Baracaldo,
Spain
Introduction: The primary objective of the study was to determine the
efficacy and the toxicity profile of a biweekly regimen of paclitaxel plus
gemcitabine in patients with small cell lung cancer previously treated with
etoposide and platinum based chemotherapy (sensitive and refractory/resis-
tant).
Methods: A total of 40 patients were evaluated: median age 57.5 years
(range 39-77), male 34 (85%)/female 6 (15%), ECOG 0/1/2: 4(10%)/
25(62.5%)/11(27.5%). Four patients (10%) were platinum-sensible, 31
(77.5%) were platinum-resistant (progression within 3 months since the last
course) and 5 (12.5%) were platinum-refractory (progression during the first
line with platinum-etoposide based chemotherapy). Treatment consisted of
paclitaxel (80 mg/m2) and gemcitabine (1250 mg/m2) on days 1 and 15 of
a 4 week cycle.
Results: Patients received a median of 2 cycles (range 1-6). Tumor control
was reported in 13 patients (32.5%) with 6 partial responses (15%) and 7
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stable diseases (17.5%). Median progression free survival was 8 weeks (95%
CI 5.67 – 10.32) and median overall survival 13 weeks (95% CI 0.00 –
27.35). Those patients with ECOG 2 had a significant shorter overall survival
compared with ECOG 0 and 1 (5 weeks versus 28 and 19 weeks, p0.035).
Toxicity profile was mild: neurotoxicity grade 2 (20%) and grade 3 (2.5%),
thrombocytopenia grade 3 (2.5%) and grade 4 (10%) and one febrile
neutropenia.
Conclusion: Paclitaxel plus gemcitabine given on days 1 and 15 of a 4 week
cycle is a well tolerated and an active combination regimen in pretreated
patients with small-cell lung cancer and good performance status.
P-094
High-Dose Involved Field Radiotherapy and Concurrent Che-
motherapy for Limited-Disease Small-Cell Lung Cancer
Na Young Jang1, Jong-Seok Lee2, Chang Hoon Song3, Jae-Sung Kim1
1Department of Radiation Oncology, Seoul National University Bundang
Hospital, Republic of Korea, 2Department of Internal Medicine, Seoul
National University Bundang Hospital, Republic of Korea, 3Department of
Radiation Oncology, Seoul National University Hospital, Republic of Korea
Introduction: To evaluate the treatment outcome of high dose involved field
radiotherapy and concurrent chemotherapy in patients with limited disease of
small-cell lung cancer.
Methods: Medical records of 37 patients with limited stage of small cell lung
cancer were reviewed. All patients were treated with induction chemotherapy
followed by definitive radiotherapy and concurrent chemotherapy. The radiation
dose was 60 Gy for 31 patients and 50 - 58 Gy for 6 patients with once-daily 2
Gy per fractions. Elective nodal irradiation was not performed. The chemother-
apy regimen was either combinations of etoposide and cisplatin or irinotecan and
cisplatin. Prophylactic cranial irradiation of 25 Gy in 2.5 Gy per fraction was
administered to the patients who had a complete or near complete response. The
median follow-up period was 17 months (range 5-57).
Results: The 2-year overall survival and locoregional control rates were
55%. Complete response was achieved in 17 patients (46%), partial response
in 19 patients (51%) and progressive disease in 1 patient (3%). Seven
patients experienced a tumor recurrence within the radiation field and four of
those recurrences were isolated local recurrences. There was only one
isolated regional recurrence outside radiation field. Grade 3 treatment-related
esophageal toxicity occurred in 2 patients. Two patients died of treatment-
related pulmonary complication.
Conclusion: Involved field radiotherapy of 60 Gy could achieve favorable
survival and low rate of isolated nodal failure outside radiation field.
However, considerable number of patients still experienced in-field failure.
Further studies to establish optimal radiation dose and fractionation for
improving locoregional control are needed.
P-095
Irinotecan Plus Cisplatin Induction Followed by Concurrent
Thoracic Irradiation with Irinotecan Plus Cisplatin Chemother-
apy for Limited-Disease Small-Cell Lung Cancer: A Retrospec-
tive Analysis of NCC Korean Experience
Jae-Heon Jeong1, Ji Hyun Sung2, Hong Ryull Pyo3, Kwan Ho Cho3, Heung
Tae Kim2, Ji-Youn Han2, Tak Yun2, Hyae Young Kim2, Geon Kook Lee4,
Jin Soo Lee2 1Department of Clinical Trial, National Cancer Center,
Republic of Korea, 2Department of Lung Cancer, National Cancer Center,
Republic of Korea, 3Department of Proton Therapy Center, National Cancer
Center, Republic of Korea, 4Department of Pathology, National Cancer
Center, Republic of Korea
Introduction: Etoposide plus cisplatin (EP) concurrent chemoradiotherapy
(CCRT) in limited-disease small cell lung cancer (LD-SCLC) showed
unsatisfactory effeciay and the toxicity concern has always existed. So we
evaluated the efficacy and toxicity of irinotecan plus cisplatin (IP) induction
chemotherapy followed by IP CCRT.
Methods: Thirty patients with LD-SCLC received IP chemotherapy. Twen-
ty-nine patients were male, and 29 (97%) had an Eastern Cooperative
Oncology Group performance status of 0 or 1. The median age was 60 years.
Treatment consisted of one to six cycles of 21-day cycles of irinotecan
65mg/m2 and cisplatin 30mg/m2 intravenously (IV) on days 1 and 8 followed
by two 21-day cycles of irinotecan 60mg/m2 IV and cisplatin 30mg/m2, with
concurrent thoracic adiotherapy.
Results: The objective response was observed in 30 (100%, partial response
[PR], 30) of 30 patients after induction chemotherapy and also 28 (100%,
complete response [CR], 5; PR, 23) of 28 patients who got CCRT. The
estimated median survival was 34.2 months (95% CI, 21.9 – 46.5). Median
progression-free survival (PFS) was 11.3 months. The most common toxic-
ities were grade 3 or 4 neutropenia noted in 30% of patients during induction
chemotherapy and 15% during CCRT. Febrile neutropenia occurred in 7 %
of patients during induction chemotherapy and 7% during CCRT. There was
neither grade 3 or 4 esophagitis and radiation pneumonitis nor grade 2
alopecia.
Conclusion: IP induction chemotherapy followed by IP CCRT in LD-SCLC
showed a promising activity with favorable 1- and 2-year survival rates, and
favorable toxicity. Further studies is warranted for using IP during CCRT.
P-096
Phase II Study of Belotecan and Cisplatin as First-Line Chemo-
therapy for Extensive Disease of Small Cell Lung Cancer:
Preliminary Results
Junshik Hong, Sun Young Kyung, Sang Pyo Lee, Jeong Woong Park, Sung
Hwan Jung, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae
Hoon Lee Department of Internal Medicine, Gachon University Gil Hospital,
Gachon Graduate School of Medicine, Incheon, Republic Of Korea
Introduction: The aim of this study is to evaluate the efficacy and safety of
belotecan with cisplatin (BP) as first-line chemotherapy for extensive disease
small cell lung cancer (ED SCLC).
Methods: Patients with histologically or cytologically confirmed ED SCLC
were eligible if they were; age18 years, with measurable lesion, chemo-
therapy naive, an ECOG Performance Status 0-2, and adequate organ
function. Each cycle consisted of belotecan 0.5mg/m2 IV on days 1-4 and
cisplatin 60mg/m2 IV on day 1. The cycle was repeated every 3 weeks up to
6th cycle or disease progression or intolerable toxicity.
Results: Thirty-five patients (median age, 68 years) were enrolled. Median
number of cycles delivered was 5.0 (range 1-6). Relative median dose
intensity was 70.1% for belotecan and 83.0% for cisplatin, respectively. Of
29 evaluable patients, 24 patients for PR, 2 for SD, and 3 for PD were
reported. Objective response rate was 68.6% [95% confidence interval (CI)
52.4-84.8] by intent to treat principle (82.8% by per protocol analysis).
During median follow up duration of 13.2 months, median PFS was 5.0
months (95% CI 2.4-7.7) and median OS was 9.7 months (95% CI 7.7-11.7),
respectively. Frequently reported grade 3 or 4 toxicities included neutropenia
in 24 patients (68.6%), thrombocytopenia in 10 (28.6%), and anemia in 7
(20.0%). Grade 4 neutropenia was reported in 19 (54.3%) and 8 patients
(22.9%) experienced neutropenic fever. There were two cases (5.7%) of
treatment related mortality due to neutropenic sepsis.
Conclusion: BP combination therapy showed significant efficacy in ED
SCLC. Neutropenia was the most frequent toxicity.
P-097
The Efficacy of Amrubicin on CNS Metastases from Small-Cell
Lung Cancer
Satoru Miura1, Kyoichi Kaira1, Rieko Kaira1, Asuka Tsuya1, Hirotsugu
Kenmotsu1, Tateaki Naito1, Haruyasu Murakami1, Toshiaki Takahashi1,
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Masahiro Endo2, Nobuyuki Yamamoto1 1Department of Thoracic Oncol-
ogy, Shizuoka Cancer Center, Japan, 2Department of Diagnostic Radiology,
Shizuoka Cancer Center, Japan
Introduction: Central nerve system (CNS) metastases due to small-cell lung
cancer (SCLC) is a dismal situation with poor outcome. CNS metastases
from SCLC are usually treated with chemotherapy or radiotherapy, however
it is unclear whether chemotherapy is sensitive to CNS metastases from
SCLC. Amrubicin is a promising agent for relapsed SCLC, but it is unknown
whether the agent is effective for CNS metastases due to SCLC.
Methods: Between April 2002 and December 2009, 278 SCLC patients were
treated at Shizuoka Cancer Center. Of these patients, we retrospectively
reviewed 16 patients with CNS from relapsed SCLC treated by amrubicin.
Results: Patient’s characteristics is as follows: median age 65 (range, 46-79
yr); male/female, 13/3; PS 0/1/2, 7/8/1. Of 16 patients, 4 patients were
sensitive relapse and 12 refractory relapse. Nine patients were treated by
amrubicin 40mg/m2 and 7 patients 35mg/m2. Eight patients received amru-
bicin alone, and the other patients palliative irradiation followed by amru-
bicin. Amrubicin yielded a response rate of 30%, and median survival time
from amrubicin administration was 4.9 months. In all patients, CNS response
rate revealed 43.7% (sensitive relapse 75% and refractory relapse 33%). In
8 patients treated by amrubicin alone whereas, CNS response rate revealed
50% (sensitive 100% and relapse 33%) with a disease control rate of 87.5%.
Conclusion: The results of this study suggest that amrubicin is active for
patients with CNS metastases secondary to SCLC.
MESOTHELIOMA, THYMOMA & OTHERS
P-098
Comparative Analysis of Thymectomy for Myasthenia Gravis
Performed by Thoracoscopic versus Transsternal Approach
Kyoung Min Ryu, Pil Won Seo, Seongsik Park, Jae-Wook Ryu Department
of Thoracic and Cardiovascular Surgery, Dankook University, Republic of
Korea
Introduction: Both transsternal and Video-assisted thoracoscopic surgery
(VATS) approaches are used for thymectomy in Myasthenia Gravis(MG).
Recently, VATS may allow a minimally invasive alternative to the transter-
nal approach. We compared outcomes of VATS and transsternal thymec-
tomy in patients with MG.
Methods: January 1996 and December 2008, 74 thymectomies were per-
formed for MG.; 31 by VATS and 43 by transsternal apporoach. During
VATS thymectomy, all patients were placed in 30 degree left lateral
decubitus position under double-lumen intubated anesthesia. Usually three-
port approach were used. Preoperative Osserman’s classification and post-
operative disease status were compared between the groups.
Results: Mean age was 38.414.3(VATS) versus 36.913.7 years(transs-
teranl). Preoperative duration of MG was 1321 versus 1127 months,
respectively. Preoperative Osserman’s classification revealed the following:
class I; 7(23%), 8(19%), IIA; 11(36%), 18(42%), IIB; 9(29%), 13(30%), III;
4(12%), 3(7%), IV; 0(0%), 1(2%), respectively. The operative time, the need
for postoperative ventilator, The amount of chest tube were not difference
between both group. The mean length of stay and the use of analgesics were
better results in VATS group(p0.05). Thymoma were found in 11.6% of
the VATS and 13.6% of transsternal group(p0.29). There were no surgical
mortality cases. The mean follow up period was 3.94.3years(VATS) and
5.84.6years(transsternal). Complete remission without any medication af-
ter surgery was 18% and 19%; Partial remission after surgery was 45% and
49%.
Conclusion: Thymectomy is an effective treatment in patients with MG with
equivalent clinical outcomes obtained by either approach. However VATS
has several advantages over transsternal open approach; shortens hospital
stay and gives better cosmetic results.
P-099
Epidemiologic and Clinicopathologic Analysis of Malignant Me-
sothelioma in Korea during Past Four Years (from 2006 to 2009)
Soon-Hee Jung1, Minseob Eom1, Hyoung-Ryoul Kim2, Sang-Baek Koh3,
Suk-Joong Yong4, Myoung Ja Chung5, Chang Hun Lee6, Ji Sun Song7
1Department of Pathology, Yonsei University Wonju College of Medicine,
Republic of Korea, 2Department of Preventive Medicine and Industrial
Medical Center, Catholic University College of Medicine, Republic of
Korea, 3Department of Preventive Medicine, Yonsei University Wonju Col-
lege of Medicine, Republic of Korea, 4Department of Pulmonology, Yonsei
University Wonju College of Medicine, Republic of Korea, 5Department of
Pathology, Chonbuk National University Medical School, Republic of Korea,
6Department of Pathology, Pusan National University College of Medicine,
Republic of Korea, 7Department of Pathology, Kwandong University College
of Medicine, Republic of Korea
Introduction: This study estimated the magnitude of malignant mesotheli-
oma in Korea and its clinicopathologic features. We collected 244 cases
through the Korea malignant mesothelioma surveillance system (KMMS)
from 2006 to 2009.
Methods: Using the clinical information, epidemiologic survey and patho-
logical evaluation collected by the members of the cardiopulmonary study
group of the Korean Society of Pathologists, the patients’ age, sex, occupa-
tion history, tumor sites, specimen type with diagnostic method, and his-
topathologic subtype during past four years were analyzed and compared
with previous 5 year results.
Results: Patients were 159 men (65%) and 85 women (35%). Among 70
cases with available occupational history, 31 (44%) were related with
asbestos exposure occupation. The distribution of sites was pleura (71%),
peritoneum (27%), and pericardium (3%). The pathologic subtypes were
epithelioid (69%), biphasic (16%), sarcomatous (10%), and desmoplastic
(3%), and variants (1%) in order. The epidemiologic and clinicopathologic
data of past four years were not so different with that of previous 5 years
data. However, we could estimate the accuracy rate (68%) of reporting cases
of malignant mesothelioma after comparing the data of Health Insurance
Institute. According to this rate, about 100 cases of malignant mesothelioma
could be occurred every year in Korea.
Conclusion: The number of malignant mesothelioma patients and the rela-
tion rate with occupational asbestos exposure were relatively low. The
surveillance system of malignant mesothelioma in Korea supplemented by an
active surveillance system by the government support could be helpful to
understand the more exact status of malignant mesothelioma of Korea.
P-117
Factors Associated with Prognosis of Atypical Carcinoid Tu-
mors in Lung and Thymus
Boram Han, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keun-Chil Park
Division of Hemato-oncology, Department of Internal Medicine, Samsung
Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Introduction: Carcinoid tumor in the chest is rare entity accounting for less
than five percent of all thoracic neoplasms. Atypical histologic features
including number of mitotic counts of tumor cells and necrosis are diagnostic
findings of atypical carcinoid tumors and are associated with unfavorable
clinical outcomes. We evaluated clinical features predicting prognosis of
atypical carcinoid tumors of lung and thymus.
Methods: We analyzed the association of clinical and pathologic features
with the relapse free survival (RFS) and overall survival (OS) in patients with
atypical carcinoid tumor of lung or thymus diagnosed between December
2003 and April 2010.
Results: Of the 15 patients, ten had tumors in lung and five in thymus. The
RFS was significantly shorter in carcinoid with more mitotic tumor cells
(5-10 mitoses/10HPF) than that with fewer mitoses (5 mitoses/10HPF)
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(59.6 months vs 25 months, p0.049) but other clinical (age, sex, smoking)
and histological features (necrosis, invasiveness to blood or lymphatic
vessels) had no significant differences in RFS and OS. Especially pathologic
staging and postoperative adjuvant treatments (chemotherapy or radiation
therapy) made no significant impact on survival benefit, but in our study,
adjuvant treatments were administered for significantly fewer patients with
early stages (I or II) and for all with advanced stages (33% vs 100%,
p0.01). Taken together, these suggested that postoperative adjuvant treat-
ments may overcome shorter RFS and OS with advanced staged tumor.
Conclusion: Number of mitoses was a prognostic factor and adjuvant
treatments might be necessary for improvement of prognosis in patients with
atypical carcinoid tumor especially in advanced stages.
BASIC SCIENCE
P-100
Amphiregulin Contributes to Tumor Progression in Lung Ade-
nocarcinoma
Mian Xie1, Toshihiro Nukiwa2, Noriko Nukiwa2, Li Zhang3 1Department of
Medical Oncology, The First Affiliated Hospital of Guangzhou Medical
University, China, 2Department of Respiratory Medicine, Tohoku University
Graduate School of Medicine, Japan, 3Department of Medical Oncology,
Sun Yat-Sen University Cancer Center, China
Introduction: Amphiregulin (AREG) , a ligand of epidermal growth factor
receptor(EGFR), is associated with shortened survival of patients with lung
cancer and poor prognosis. However, the ability of AREG to mediate distinct
function in lung metastasis remains unknown.
Methods: PC9 cells (lung adenocarcinoma cell line harboring EGFR exon 19
deletion) were stably transfected with empty vector or pcDNA3.1/ AREG.
Anoikis was induced with the use of poly-HEMA. Apoptosis assay was per-
formed by TUNEL assay. The cells were cultured in soft agar to evaluate
anchorage-independent colony formation. In vitro assay was conducted to assess
the effect of recombinant AREG on capillary tube formation. Lung metastasis
was evaluated 4 weeks after tail vein injection of control or AREG-overexpress-
ing PC9 cells. Immunohistochemistry for COX-2, CD31, VEGF-D, MMP-1,
P21WAF1/Cipl was performed on lung cancer tissues. Vessel number and vessel
size were quantified with the computer program ImageJ.
Results: Greater anoikis resistance was associated with higher level of
AREG expression. PC9 cells overexpressing AREG resulted in larger and
more colonies in colony formation assay. In vitro angiogenesis was signif-
icantly induced by AREG. There was significant difference of lung metas-
tasis between control and AREG overexpressing xenograft tumors. The
expressions of CD31, VEGF-D, MMP-1, P21WAF1/Cipl were increased in
AREG transfected lung cancer tissues. Not only the tumour size was
increased, but also the vessel density and the vessel size were increased.
Conclusion: AREG may contribute to lung cancer metastasis and angiogen-
esis, providing a possible explanation for the aggressive nature of lung
cancer that overexpress AREG.
P-101
EpCAM in Lung Adenocarcinoma Proliferation and Progres-
sion
Youngwook Kim1, Jooyoung Cha1, Keunchil Park2, Myung-Ju Ahn2 1De-
partment of Medical Nano-Element Development, Samsung Biomedical Re-
search Institute, Republic of Korea, 2Department of Hematology and On-
cology, Samsung Medical Center, Republic of Korea
Introduction: Epithelial cell adhesion molecule (EpCAM) is a type I
transmembrane glycoprotein involved in intercellular adhesion. EpCAM was
found to be over-expressed in various human epithelial carcinoma. This
study was conducted to investigate the role of EpCAM in non-small cell lung
cancer (NSCLC) to evaluate the functional significance of EpCAM expres-
sion in NSCLC.
Methods: EpCAM expression level was measured in several human NSCLC
cells, as well as in 95 NSCLC tissue samples. To assess the funciional
significance of EpCAM expression in NSCLC, doxycycline inducible Ep-
CAM shRNA system was established in a NSCLC (PC9) cell line.
Results: EpCAM overexpression was detected in 40 of 95 surgically re-
sected NSCLC tissue (42.1%). EpCAM depletion by inducible shRNA
revealed that EpCAM suppression delayed cell cycle progression. The
marked influence of EpCAM on cell cycle progression was also seen in
transcriptome analysis of EpCAM depleted cells. This effect was further
confirmed in animal xenograft model study.
Conclusion: Although the prognostic value of EpCAM expression in NSCLC
still remains controversial, a high frequency of EpCAM overexpression in
NSCLC tissue and its effect on cell cycle in model system studies indicate that
it may play a role in the carcinogenesis and /or tumor progression.
P-102
FoxO1a Transcriptional Regulation of Prx1 Enhances the Che-
mosensitivity of Lung Cancer toward Docetaxel
Euntaik Jeong, Hwijung Kim, Kieun Hwang, Soyoung Kim, Seihoon Yang,
Hakryul Kim Department of Internal Medicine, Wonkwang University Hos-
pital, Republic of Korea
Introduction: Prx1 is a major 2-Cys peroxiredoxin family member and this
seems to confer increased treatment resistance. The precise mechanism of
chemoresistance is not clearly known. We investigated the role of Prx1 in
docetaxel-induced apoptosis of A549 lung cancer.
Methods: We generated shRNA targeting Prx1 in A549 cells to test the
sensitivity to docetaxel treatment. The change of expression of Prx1, PARP,
Akt, and FoxO1a was examined by Western blotting. A549 scramble and
knock-down cells were pretreated with or without LY294002, and then
treated with docetaxel. In vivo, athymic nude mice were xenografted sub-
cutaneously using control- and shPrx1-sublines. Mice were divided into four
groups. Group 1 and 3 animals received normal saline and were designed as
controls of Prx1 scramble and knock-down. Group 2 and 4 animals received
docetaxel treatment at a dose of 20mg/kg, given I.P. These were also divided
two subgroups, molecular and tumor growth measurement subgroup.
Results: Inhibition of Prx1 by shRNA increased apoptotic potential through
activation of caspase cascade and suppressed the phosphorylation of Akt and
FoxO1a, a substrate of Akt, by docetaxel treatment in A549 cells. Further-
more, PI3K inhibitor LY294002 inhibited the phosphorylation of FoxO1a
and increased the cytotoxicity of docetaxel in A549 cells. Consistent with in
vitro results, phosphorylated Akt was shown in group 1 and 2, and phos-
phorylated FoxO1a was shown in group2. On the other hands, Prx1 knock-
down completely suppressed Akt-FoxO axis. Next, group 4 increased mRNA
level of TRAIL, but not FasL.
Conclusion: Prx1 provides resistance to docetaxel-induced apoptosis in lung
cancer via Akt-FoxO1a axis.
P-103
Safety and Pharmacokinetics of Intrathecal Administration of
Pemetrexed in the Rat
Jong-Mu Sun1, Duk Joo Lee1, Myung-Ju Ahn1, Jin Seok Ahn1, Jae Yong
Chung1, Keunchil Park2, Soo-Youn Lee3, Yeon-Lim Suh4 1Department of
Medicine, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Republic of Korea, 2Department of Pharmacology and Clinical
Pharmacology, Severance Hospital, Yonsei University College of Medicine,
Republic of Korea, 3Department of Laboratory Medicine and Genetics,
Samsung Medical Center, Sungkyunkwan University School of Medicine,
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Republic of Korea, 4Department of Pathology, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Republic of Korea
Introduction: Leptomeningeal carcinomatosis represents a devastating com-
plication. Therefore a search for new agents is urgently needed. Pefmetrexed
is an antifolate antimetabolite used for treatment of non-small-cell lung
cancer. We evaluated safety and pharmacokinetics of intrathecally adminis-
tered pemetrexed to the rat.
Methods: Three levels of pemetrexed (0.3mg/kg, 1mg/kg, and 3mg/kg) were
administered into 15 rats per each level through specifically designed
indwelling subarachnoid catheters twice a week for two weeks. Clinical and
pathological evidence of neurotoxicity were observed at each pemetrexed
level. For the pharmacokinetic study, independent cohorts of 30 rats were
administered with 1mg/kg of pemetrexed. The pemetrexed concentration in
cerebrospinal fluid (CSF) and blood were measured using UPLC/MS/MS at
each defined time point.
Results: There was no clinical or pathologic neurotoxicity after intrathecal
administrations of pemetrexed at the levels of 0.3mg/kg and 1mg/kg. However,
five of 15 rats died at 3mg/kg of pemetrexed. The distribution/elimination of
pemetrexed in CSF was best described by a 2-compartment model, with the
initial and terminal half-lives were 0.43 hours and 1.43 hours, respectively. The
Cmax in CSF was 588 M and the concentration sustained at high levels for a
long time. The area of under the curve and volume of distribution at steady state
were 560 M●h and 1.14 ml, respectively.
Conclusion: The no observed adverse effect level of intrathecal administra-
tion of pemetrexed was 1mg/kg in the rat. At this level, therapeutically high
and durable pemetrexed concentration was achieved. Based on these results,
further researches on intrathecal pemetrexed in humans or non-human
primates should be considered.
TRANSLATIONAL RESEARCH
P-104
Enhanced Antitumor Effect of Novel Dual-Targeted Paclitaxel
Liposomes
Shuyan Meng, Bo Su, Wei Li, Yongmei Ding, Liang Tang, Wei Zhou, Ying
Song, Heyan Li, Caicun Zhou Department of Oncology, Shanghai Pulmo-
nary Hospital, Tongji University School of Medicine, China
Introduction: Recently, there is considerable interest in the development of
active liposomal antitumor drugs by attaching specific ligands or antibodies
on the liposomes surface. Lots of molecules have been reported to be
effective tumor targets. However, no unique molecule with satisfying selec-
tivity and sensitivity to tumors has been identified yet. Thus, we hypothe-
sized that targeting two receptors or antigens might be a new strategy that can
enhance the drug delivery efficiency.
Methods: A novel dual-targeted peptide containing an alpha V integrins
specific ligand and a neupilin-1 specific motif was designed and then
incorporated to the liposomes. Fluorescent assays were used to evaluate the
binding affinity of this peptide and active dual-targeted liposomes to cells.
Paclitaxel was then entrapped in this carrier and targeting efficiency was
evaluated in vitro and in vivo.
Results: Compared to single-targeted peptides (containing just alpha V integrins
specific ligand or neupilin-1 specific motif), dual-targeted peptide had the
highest binding activity. Dual-ligand fluorescent liposomes maintained best
binding property than single-targeted formulations. The improved targeting
effects can be explained by a synergistic action of these two peptides. Cytotox-
icity assay and in vivo uptake study both confirmed that dual-targeted paclitaxel
liposomes enabled an increased internalization of paclitaxel than single-targeted
paclitaxel liposomes and Taxol. When treated xenograft models with dual-
targeted paclitaxel liposomes, tumor growth rate was greatly reduced.
Conclusion: Dual-targeted liposomes prepared in present study might be a
novel approach that can improve the selectivity of drug-loaded nanocarriers.
P-105
GOLPH3 Protein Expression in Cancer Tissue May Predict the
Efficacy of mTOR Inhibitor, RAD001, in Patients with Ad-
vanced NSCLC Who Had Received Multi-Line Chemotherapy
Jin-Ji Yang, Hai-Yu Zhou, Xu-Chao Zhang, Zhi-Hong Chen, Xue-Ning Yang,
Qing Zhou, Yi-Long Wu Department of Pulmonary Oncology, Guangdong
General Hospital & Guangdong Academy of Medical Sciences, China
Introduction: GOLPH3 links the Golgi network to mTOR signaling and
may act as an oncogene in human cancer by amplification in the genome. The
potentially predictive role of GOLPH3 for mTOR inhibitor in advanced
non-small cell lung cancer (NSCLC) has not yet been determined in clinical
setting.
Methods: Data of RAD001 treatment for 8 cases of NSCLC, 1 large cell
carcinoma, 1 squamous cell carcinoma and 6 adonocarcinomas, who had
received multi-line chemotherapy were collected. GOLPH2/3, mTOR, p-
mTOR, PI3K, p-AKT were detected by immunohistochemistry. Expressions
of tumor GOLPH2/3 were also tested at mRNA level. Data were prelimi-
narily analyzed for the relationship between the molecular characteristics and
anti-tumor effects of mTOR inhibitor, RAD001.
Results: Tumor response was as PR for 1 (12.5%), PD for 3 (37.5%), and SD
for 3 patients (37.5%) with a range of 6 to 22 weeks of PFS. If focusing on
the primary tumor lesions in the lung, after the treatment of RAD001, six out
of seven evaluable cases (86%, 6/7) were observed with obvious volume
shrinkage in these primary tumor lesions (P0.05). GOLPH3 protein, along
with AKT and p-mTOR, significantly increased in the two cases that showed
more than 30% shrinkage (47.8% and 34.3%) of the primary pulmonary
lesions. Expressions of GOLPH2/3 at mRNA level did not correlate to the
shrinkage of primary lesions in the lung.
Conclusion: High expression of GOLPH3 protein in cancer tissues may
predict the sensitivity of primary target tumor lesions to mTOR inhibition. A
large sample size study is warranted in the future.
P-106
Growth Inhibition of Non-Small Cell Lung Cancer Cells by
Blockade of AP-1 and Phosphatidylinositol 3-Kinase Pathway
Yasushi Shimizu1, Ichiro Kinoshita1, Junko Kikuchi2, Masaharu Nishimura2,
Michael J Birrer3, Hirotoshi Dosaka-Akita1 1Department of Medical Oncol-
ogy, Hokkaido University Graduate School of Medicine, Japan, 2Department
of Internal Medicine, Hokkaido University School of Medicine, Japan,
3Department of Cell and Cancer Biology, National Cancer Institute, United
States of America
Introduction: CJun is frequently overexpressed in non-small cell lung
cancers (NSCLCs). Moreover, the phosphatidylinositol 3-kinase (PI3K)/Akt
signal transduction pathway is important in proliferation, survival and
metastasis of NSCLC cells. The purpose of this study is to determine the
effects of AP-1 and PI3K blockade on the growth of NSCLC cells.
Methods: Transient transfection of a cJun dominant-negative mutant,
TAM67, was performed in NSCLC cell lines, H1299, A549 and H520. We
examined whether TAM67 affected colony forming efficiency in these cell
lines. We next established H1299 clones that expressed TAM67 under the
control of doxycycline-inducible promoter. Using these clones and a PI3K
inhibitor, LY294002, we investigated anchorage-dependent growth by MTT
assay and anchorage-independent growth by soft agar assay. Furthermore,
we performed the flow cytometric analysis to examine the effect on the cell
cycle, and measured the expression of cell-cycle regulatory proteins by
Western blot analysis. We also investigated whether TAM67 could inhibit
tumor growth of H1299 in vivo.
Results: TAM67 inhibited AP-1 activity. The colony-forming efficiency of
H1299 and A549 was reduced by TAM67. In the TAM67-inducible H1299
clone cells, TAM67 inhibited anchorage-dependent growth by promoting G1
cell-cycle block, which was enhanced by LY294002. TAM67 and LY294002
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decreased the expression of cyclin A and increased that of p27Kip1. TAM67
and LY294002 inhibited anchorage-independent growth at least additively.
TAM67 reduced growth of established xenograft tumors.
Conclusion: These results suggest that AP-1 and PI3K/Akt pathways play an
essential role in the growth of some of NSCLC cells and would be potential
therapeutic targets.
P-107
MAGEA3 Gene Expression Associated with Histology and Gen-
der in Chinese Non-small Cell Lung Cancer
Xue-Ning Yang, Ling Huang, Zhi-Yong Chen, Xu-Chao Zhang, Wei Meng,
Jin-Ji Yang, Qing Zhou, Yi-Long Wu Department of Cancer Center, Guang-
dong Lung Cancer Institute, Guangdong Academy of Medical Sciences and
Guangdong General Hospital, China
Introduction: MAGEA3 is a promising target for biotherapy in NSCLC.
However, MAGEA3 expression was found differentially expressed between
ethnicity and histology. This study is to explore the MAGE3 expression in
Chinese NSCLCs.
Methods: Real time qRT-PCR was used to quantify the MAGEA3 expres-
sion at mRNA level in specimens of 114 cases of Chinese NSCLCs. ACTB
gene expression assay was performed at the same experiments as internal
controls. One sample kindly donated by GSK (Gerl) was used as positive
sample. Delta Ct values of 1% dilution of Gerl was taken as cut-off value. All
delta Ct values were analyzed for the possible association with clinical
factors.
Results: 12.3% (14/114) samples were detected positive for MAGEA3
expression at mRNA level. Positivity of MAGEA3 expression in adenocar-
cinoma (4/59, 6.8%) was significantly lower than those in squamous cell
carcinoma (6/39, 15.4%) and large cell carcinoma (4/8, 50%). MAGEA3
expression was also significantly different between male and female patients
(P0.05). By bivariate correlation test, MAGEA3 was primarily found to
reversely correlate to age and smoking packyears.
Conclusion: Positivity of MAGEA3 expression at mRNA level in Chinese
NSCLC patients is about 12.3% with different distribution in histology and
gender. The low positive expression rate needs further investigation to clarify
if it is due to MAGEA3 gene polymorphism and/or gene methylation.
P-108
Notch 1 and Notch 3 for Prognosis of Resected Non-Small Cell
Lung Cancer
Eun Kyung Cho1, Seung Yeon Ha2, Sanghui Park2, Junshick Hong1, Sun Jin
Sym1, Jinny Park1, Jae-Ik Lee3, Dong Bok Shin1, Jae Hoon Lee1 1Depart-
ment of Internal Medicine, Gachon University , Gil Hospital, Incheon,
Republic of Korea, 2Department of Pathology, Gachon University, Gil
Hospital, Incheon, Republic of Korea, 3Department of Thoracic Surgery,
Gachon University, Gil Hospital, Incheon, Republic of Korea
Introduction: Notch can variously serve as an oncogene or a tumor sup-
pressor and a repressor or inducer of terminal differentiation. We examined
Notch 1 and 3 to study the correlation of Notch expression and prognosis for
non-small cell lung cancer.
Methods: We analyzed Notch 1 and 3 by immunohistochemical stain on
surgical tumor specimens.
Results: One hundred fifty-nine of 185 resected tissues for lung cancer
(median age 62 years) were available for immunohistochemical stain. Notch
1 and 3 receptors were detected in 119 (74.8%) and 130 (81.7%) of total 159
(M:F114:45) tumor tissues, respectively. Notch 1 receptors showed higher
expressions on squamous cell carcinoma than non-squamous cell carcinoma
(58.8% vs. 37.8%, p0.03). However, it was not correlated with sex,
smoking status or advanced stages. Three year-overall survival (OS) and
relapse free survival (RFS) were 66 % and 52 % in all patients, respectively.
Patients with any expression of Notch1 or 3 have correlated with neither RFS
nor OS. Both of their expressions were detected in 106 of 159 (66.7%) tumor
tissues. Sixteen (10 %) had negative expressions in both of them. The
patients with both positive expressions had the tendency of longer OS than
all negative patients. Their 3 year OS were 66.5 % vs. 47.1% (p0.071) and
3 year RFS were 63.5% vs. 43.8 % (p0.237).
Conclusion: Notch 1 showed higher expression on squamous cell carci-
noma. Neither Notch 1 nor 3 have correlated with RFS or OS, but patients
with both expressions had the tendency of longer overall survival.
P-109
The EGFR T790M Mutation in Acquired Resistance to an
Irreversible Second-Generation EGFR Inhibitor
Youngwook Kim1, Jeonghun Ko1, Zhengyun Cui1, Amir Abolhoda3, Jeeyun
Lee2, Jinseok Ahn2, Sai-Hong Ou3, Myung-Ju Ahn2, Keunchil Park2 1De-
partment of Medical Nano-Element Development Center, Samsung Biomed-
ical Research Institute, Republic of Korea, 2Department of Hematology and
Oncology, Samsung Medical Center, Republic of Korea, 3Department of
Medicine-Hematology/Oncology, Chao Family Comprehensive Cancer Cen-
ter, University of California Irvine Medical Center, United States of America
Introduction: Currently, molecular targeted therapies in NSCLC patients
with gefitinib or erlotinib ultimately fail due to acquired resistance to these
target drugs. Clinical trials employing second-generation EGFR-TKIs are
currently underway, and it is imperative to understand the nature of the
responses to the second-generation drugs in order to predict the therapeutic
potentials and limitations.
Methods: An NSCLC cell line, PC9, with an EGFR-activating mutation of
exon 19 in frame deletion was grown in the presence of a second generation
EGFR-TKI, BIBW2992. Independent clones that acquired resistance to the
drug in vitro were analyzed at the molecular level.
Results: Molecular analysis of obtained clones revealed two different
classes of acquired resistance. One group of cells remained EGFR
dependent with the emergence of T790M- containing EGFR allele. The
degree of acquired resistance was dose-dependent with the copy number
of the T790M-containing allele. The other group of resistant cells
acquired the resistance phenotype by escaping EGFR dependence. We
also confirmed a clinical case, in which a patient harboring activating
EGFR gene mutation treated with BIBW2992 developed T790M mutation
when resistance occurred.
Conclusion: These results suggest that the kinetic mode of blocking EGFR
by currently available second-generation EGFR-TKI may not be sufficient
for mechanistically blocking the emergence of cells that are still dependent
on EGFR signaling.
P-110
The High Expression of GLI3 Protein Associated with Poorly
Overall Survival in Lung Adenocarcinoma
Yilong Wu, Xiaoyan Bai, Jiaying Lin, Xuchao Zhang, Zhi Xie Department
of Lung Cancer, Guangdong Academy of Medical Science, Guangdong
General Hospital, Guangdong Lung Cancer Institute, China
Introduction: The hedgehog (HH) pathway is involved in embryogenesis
and organogenesis and closely correlated to various types of malignancies.
GLI3 is one of the zinc-finger transcription factors in hedgehog signaling
pathway, which exist in both activator and repressor forms. our purpose is to
investigate whether GLI3 expression might be involved in lung carcinogen-
esis, and the potential relationship with clinicopathological factors and
survival outcome of lung cancer patients.
Methods: 418 lung cancer specimens were used to establish tissue microar-
ray, along with other 16 cases of paired paraffin-embedded tissue sections of
lung cancer and adjacent non-neoplastic tissues, were subjected to immuno-
histochemical analysis with the GLI3 polyclonal antibodies. Correlations of
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expression of GLI3 with clinicopathological parameters and survival out-
come were further evaluated.
Results: Compared with matched adjacent non-neoplastic lung tissues, the
GLI3 expression was clearly higher in 16 lung cancer samples (P0.005). High
expression of GLI3, was closely related with lymph node metastasis (P0.018).
The high expression of GLI3 was significantly related with poorly overall
survival (P0.021), and further analysis in different pathological type showed
this difference mainly existed in the adenocarcinoma, but not in squamous-cell
carcinoma or other pathological types. In the adenocarcinoma, over-expression
of GLI3 had the significant relationship with unfavorable overall survival
(26.2months VS 40.8months, P0.016, Log-rank test).
Conclusion: Elevated level of GLI3 protein in lung cancer, especially in
adenocarcinoma, is associated with poor prognosis. GLI3 protein expression
may have a prognostic implication in lung cancer. Hedgehog pathway may
be activated in some lung cancers and the detailed function of GLI3
warranted further investigation.
IMMUNOLOGY
P-111
A Phase II Study of Personalized Peptide Vaccines (PPV) for
Refractory Non-Small Cell Lung Cancer (NSCLC)
Koichi Yoshiyama1, Shinzo Takamori1, Yasuhiro Terazaki1, Akira Yamada2,
Masanori Noguchi2, Kazuo Shirouzu1, Kyogo Itoh3 1Department of Surgery,
Kurume University, Japan, 2Department of Innovative Cancer Therapy,
Kurume University, Japan, 3Department of Immunology and Immunother-
apy, Kurume University, Japan
Introduction: This study is to evaluate the anti-tumor immunologic effect
and safety of PPV for patients (pts) with refractory NSCLC.
Methods: All patients had histological confirmed NSCLC with measurable
metastatic sites and their HLA-A molecules should be each of HLA-A2, A3,
A11, A24, A26, A31 or A33. Pre-vaccination plasma was measured for their
IgG levels reactive to each of the previously reported 31 candidate peptides
followed by subcutaneous administration of the four peptides at maximum
showing higher levels of IgG. PPV was administered on 6 times for 6 weeks,
6 times for 12 weeks, and 12 times for 48 weeks. Whenever six times of PPV
was administered, IgG levels in the pts were measured. Concurrent conven-
tional chemotherapy or target-based therapy was available for the combina-
tion of PPV. The primary endpoint was anti-tumor immunologic effect and
safety.
Results: A total of 35 pts were enrolled. Significant adverse events were not
noted. Grade 1 or 2 erythema and pain at the injection site were the most
common adverse events. After 6 times of vaccination, 16 (61.5%) of 26 pts
had the elevation of the IgG level. After 12 times of vaccination, 11 (100%)
of 11 pts had the elevation of the IgG level. Median time was not reached,
26 (74.3%) out of 35 pts were still alive ranging 2 to 20 months follow-up
periods.
Conclusion: PPV induced a good immune response without severe adverse
events in pts with refractory NSCLC.
P-112
Role of Centrocyte/Centroblast Marker 1 on A549 Lung Cancer
Cell Line
Hyun-Kyung Lee1, Young Min Lee1, Seung Heon Lee1, Dae Young Hur2
1Department of Internal Medicine, Busan Paik Hospital, College of Medi-
cine, Inje University, Republic of Korea, 2Department of Anatomy, College
of Medicine, Inje University, Republic of Korea
Introduction: Centrocyte/centroblast marker 1(CM1) is a novel germinal
center marker and was defined by a monoclonal antibody developed against
concanavalin-A-activated peripheral blood mononuclear cells (PBMCs).
CM1 expression and its induction of apoptosis in some Burkitt lymphoma
cell lines were reported previously. So we investigated whether A549 lung
cancer cells express CM1. And if these cells express CM1, we would like to
investigate the role of CM1 expression on A549 cells using anti-CM1
antibodies.
Methods: To evaluate expression of CM1 A549 lung cancer cells, flowcy-
tometric analysis and confocal microscopy were used. To investigate the
function of CM1, CM1 molecules were stimulated using immobilized anti-
CM1 antibodies. Flowcytometric analysis was performed to identify the
mechanism of apoptosis, disruption of mitochondrial membrane potential,
and production of reactive oxygen species by stimulation of CM1.
Results: CM1 stimulus with anti-CM1 mAb enhanced apoptosis, disruption
of mitochondrial membrane potential, and ROS production on A549 lung
cancer cells. And CM1 ligation induced the expression of FasL, death
receptor ligand, in theses cells. Furthermore, anti-Fas blocking antibody,
ZB4, effectively blocked the CM1-mediated apoptosis of A549 cells.
Caspase inhibitor, z-VAD-fmk effectively blocked CM1-induced cell death.
Both Bax and Bad mRNA expression was up-regulated, however, Bcl-2
mRNA expression was down-regulated by CM1 stimulus.
Conclusion: CM1-mediated apoptosis was induced through FasL expres-
sion, caspase pathway, and mitochondira-dependent pathway on A549 cells.
These findings suggest that CM1 can be developed as an effective therapeutic
target for lung cancer and provide a new approach to the modulation of
cancer cells expressing Fas.
IMAGING
P-113
Targeted Therapy-Related Interstitial Lung Disease: A Case-
Based Review
Ji Hye Min1, Ho Yun Lee1, Kyung Soo Lee1, Hoyeong Lim2, Keunchil
Park2, Myung-Ju Ahn2, Tae Sung Kim1, Chin A Yi1, Myung Jin Chung1
1Department of Radiology, Samsung Medical Center, Sungkyunkwan Uni-
versity School of Medicine, Republic of Korea, 2Department of Medicine,
Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan
University School of Medicine, Republic of Korea
Introduction: Molecular-targeted drugs have emerged as an important
agents for the treatment of NSCLC. Previous reports about drug-induced
interstitial lung disease (ILD) caused by targeted agents have focused on the
significance of fatal cases being encountered in the acute or subacute phase.
However, pulmonary toxicity in the chronic phase has also been described.
Moreover, sequential imaging changes over time, long-term effect of the
toxicity on lung function, or the interrelationship between toxicity and
pre-existing ILD has not been well known. The purpose of this exhibit is to
describe the gamut of clinical, imaging, and pathologic findings of ILDs
caused by diverse targeted drugs.
Results: CONTENT ORGANIZATION 1. To tabulate various kinds of
targeted agents that may result in short- and long-term pulmonary toxicity 2.
To note epidemiology focused on racial difference in drug susceptibility 3.
To represent clinical manifestations 4. To elaborate predisposing/risk factors
5. To discuss on pathogenetic mechanism and pathologic subtypes 6. To
notice inter-relationship between the toxicity and pre-existing ILD 7. To
demonstrate the spectrum of radiologic findings and sequential imaging
changes 8. To describe management, clinical course, and prognosis.
Conclusion: The major teaching points of this exhibit are as follows: 1. To
be aware of various kinds of targeted agents causing pulmonary toxicity 2.
To review the spectrum of radiologic findings of pulmonary complications
which radiologist should be familiar with 3. To recognize factors affecting
long term patient prognosis, such as, pre-existing ILD
Abstracts Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 5, December 2010
Copyright © 2010 by the International Association for the Study of Lung CancerS422
P-114
“Are Those Really the Same Stage?” - Persistent Dilemmas and
Controversies of the Revised TNM Staging of Non-Small Cell
Lung Cancer and Answers Based on Tertiary Hospital Experi-
ence
Yi Kyung Kim1, Ho Yun Lee1, Kyung Soo Lee1, O Jung Kwon2, Hojoong
Kim2, Myung-Ju Ahn2, Keunchil Park2, Chin A Yi1, Myung Jin Chung1, Tae
Sung Kim1 1Department of Radiology, Samsung Medical Center, Republic
of Korea, 2Department of Internal Medicine, Samsung Medical Center,
Republic of Korea
Introduction: The purpose of this exhibit is to propose the major contro-
versies and dilemmas of the newly revised TNM system of Non-Small Cell
Lung Cancer (NSCLC). We will focus particularly on the issues in the
diseases that belong to and are classified into the same stages, but show
different prognosis or need other management than the same-staged tumors.
Results: -Same size but different tumor component -Multifocal adenoca.
with BAC components vs. lung-to-lung metastasis -Same nodal staging but
different nodal burden -Localized lymphangitic meta. vs. diffuse lym-
phangitic meta. -Dry pleural seeding vs. malig. pleural effusion -Meta. to a
single organ vs. meta. to multiple organs -Extra-thoracic meta. vs intratho-
racic spread plus extrathoracic meta. -Cancers showing the same stage on the
initial staging workup and on the restaging after neoadjuvant tx.
Conclusion: The major teaching points of this exhibit are: 1. To propose current
controversies and dilemmas encountered when applying the new edition of
TNM classification to clinical staging 2. To review the issues in the diseases that
belong to and are classified into the same stages, but show different prognosis or
need other management than the same-staged tumors 3. To recognize problems
and suggest better approach for each elaborated issue.
HEALTH SERVICES RESOURCES
P-115
Influence of Psychosocial Consultation with Comprehensive
Psychosocial Assessment (CPA) on Identifying Their Difficulties
in Lung Cancer Patients
Jae Jin Lee1, Gyu Seon Lee2, Sang Ouk Chin1, Sul Ra Lee1, Yeo Jung Kim1,
In Jung Choi1, Jee-Hong Yoo3, Cheon Woong Choi3, Yee Hyung Kim3,
Young-Tae Kwak4, Dae-Hyun Kim4 1Department of Medical Oncology and
Hematology, Kangdong Kyung Hee University Hospital, Republic of Korea,
2Department of Social Healthcare, Kangdong Kyung Hee University Hospi-
tal, Republic of Korea, 3Department of Respiratory and Critical Care,
Kangdong Kyung Hee University Hospital, Republic of Korea, 4Department
of Thoracic and Cardiovascular Surgery, Kangdong Kyung Hee University
Hospital, Republic of Korea
Introduction: Cancer patient’s psychosocial difficulty is considered as the
sixth vital sign with increasing overall survival and drugs cost. We evaluated
the contributory factors to determine the referral to the social worker.
Methods: We prospectively conducted the study in single institute. We
investigated patient’s characteristics and performed a questionnaire including
seven questions and overall need.
Results: 35 patients were enrolled and had an interview with a social worker.
The median age was 67 years. Male was 77% , stage IIIB/IV 83%, PS ECOG
1-2 80%, pain VAS 0-3 63%, high education 49%, having got married 89%,
and keeping job was 17%. The most common needs were to know the social
system (86%), to solve the financial (74%), and personal care problem
(71%). 66% of interviewees wanted to consult with social worker. 2 or more
of total count (7 points) was significantly correlated with their overall need
(R0.497, p0.002). With the referral, 51%, 37%, and 23% of patients
benefit from support in terms of the benefit of social system, psychosocial
and financial problem, respectively. The benefit from social system was
given to the patients with lower education, living alone, psychological
support to higher education, financial support to Buddhists, treatment for
curative intent, living alone, and that from personal care support to more than
65 years, Medicare, PS ECOG 3, 4 or more of VAS. Overall, 80% of patients
benefited from CPA.
Conclusion: The assessment of the psychosocial difficulty should be eval-
uated in cancer patients for improving the quality of life as the sixth vital
sign.
P-116
Japanese Current Perceptions of Lung Cancer - Analysis from
International Survey by Global Lung Cancer Coalition (GLCC)
Toshiyuki Sawa1, Matthew Peters2, Jesme Fox2, Carolyn Aldige2, Jim
Gowing2, Yasuo Iwamoto2, Kenji Eguchi2, Hiroshi Semba3, Yukito Ichi-
nose3, Kazuhiko Nakagawa3, Youichi Nakanishi3 1Department of Respira-
tory Medicine and Oncology, Gifu Municipal Hospital, Japan, 2Department
of Patient Advocacy, Global Lung Cancer Coalition, United Kingdom,
3Department of Education and Official Relations, West Japan Oncology
Group, Japan
Introduction: West Japan oncology group had carried out several activities
for patient advocacy to improve affiliation rate for lung cancer in this decade.
To evaluate the outcome of our mission, we have analyzed Japanese
perceptions of lung cancer using an international quantitative survey.
Methods: This survey was commissioned to understand the following
among adults, 1) perceptions of which cancers kill the greatest number of
people, 2) attitude towards lung cancer. Nationally representative quota
sample of 1,272 adults across Japan was interviewed. Also, interviews were
conducted in other 14 countries.
Results: 1) In Japan, unlike most other countries where this survey took
place, lung cancer is tied with bowel or colon cancer as the cancer that adults
perceive to kill the most people (65% and 67%). 2) Despite this, along with
Norway, Japan is the country with the greatest proportion of adults who think
lung cancer is the biggest killer (both 65%). 3) In Japan, unlike most other
countries, many people are unable to say whether they have less sympathy
for people with lung cancer, given its link to smoking (44%). Of those who
do give an opinion one way or the other, 32% say they do not have less
sympathy but 20% do, which is about average compared to other countries.
Conclusion: It was shown that Japanese has a high interest in lung cancer,
while there is a little sympathy for people with lung cancer. It was thought
that a new strategy should be planned to improve sympathy for patients with
lung cancer.
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